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Abstract 
Valproic acid (VPA) is a commonly used drug for the treatment of epilepsy, bipolar 
disorder and migraine, yet its mechanisms of action are unknown. The neuroprotective 
effect of VPA has been hypothesized to be secondary to inhibition of the cAMP/protein 
kinase A (PKA) pathway. Here, the result show that VPA (1mM) inhibited mossy fibre 
long-term potentiation induced (LTP) by application of high frequency stimulation in 
dentate gyrus. Furthermore, VPA (1mM) inhibited enhancement of mossy fibre 
responses induced by application of forskolin (50 μM), consistent with an effect on the 
PKA pathway. Using biochemical assays, it was further demonstrated that this was not 
due to a direct effect on PKA, but resulted from inhibition of adenylyl cyclase. The 
results further show using in vitro seizure models (Pentylenetetrazole model and low-
Mg
2+ model) that this mechanism cannot fully explain VPA’s anti-seizure effect, but 
rather, by modifying synaptic plasticity, it may be more important for VPA’s 
antiepileptogenic and neuroprotective action. VPA therefore has distinct mechanisms of 
action that contribute to its diverse biological activity. In hippocampi from epileptic rats 
(following pilocarpine-induced status epilepticus), but not in control tissue, VPA affects 
short-term plasticity, indicating that VPA may have specific effects in epileptic rather 
than control animals.   
 
Using in vitro seizure models (Pentylenetetrazole model and low-Mg
2+ model) and an in 
vivo status epilepticus model (the perforant pathway stimulation model), 4-
methyloctanoic acid is further established that it is a more potent antiepileptic drug than 
VPA and provides neuroprotective effects which are similar to VPA. Furthermore, 4-
methyloctanoic acid (1mM) inhibited enhancement of mossy fibre responses induced by 
application of forskolin (50 μM), indicating that 4-methyloctanoic acid shares the same 
effect as VPA on modulation of PKA.    
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ED-cAMP  Enzyme donor –labelled cAMP 
EEG Electroencephalography 
EFC Enzyme  fragment  complementation 
EDTA  Ethylene glycol tetraacetic acid 
eNOS Endothelial  NO  synthase 
ER Endoplasmic  reticulum 
ERK  Extracellular signal regulated kinase   
ERK1/2 Extracellular  signal  regulated kinase 1 and 2 
ERK5  Extracellular signal regulated kinase 5 
fEPSP  Field excitatory postsynaptic potentials 
GABA Gamma-aminobutyric  acid 
GSK  Glycogen synthase kinase 
HAT Histone  acetyltransferases 
HDAC  Histone deacetylase enzymes 
HFS High-frequency  stimulation 
iNOS  Inducible NO synthase 
IBMX Isobutylmethyl  xanthine 
IPSP Inhibitory  postsynaptic  potentials 
ip Intraperitoneal  administration 
IP3 Inositol  1,4,5-triphosphate 
IP3R IP3  Receptor 
LDH Lactate  dehydrogenase  
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LTP Long-term  potentiation 
LWDAQ Long-Wire  Data  Acquisition 
MAPK Mitogen-activated protein kinase 
MARCKS Myristoylated  alanine-rich C kinase substrate 
MEK1  Extracellular signal-regulated kinase activator 
kinases 
MF Mossy  fibre 
MOPS  3-(N-morpholino) propanesulfonic acid 
NGF  Nerve growth factor 
NMDA N-methyl-D-aspartate 
NTDs Neural  tube  defects 
NO Nitric  oxide 
nNOS  Constitutive neuronal NO synthase 
PEBP  Polyomavirus enhancer-binding protein 
PED Phosphodiesterase 
pEPSP  Population excitatory post-synaptic potential 
PLC Phospholipase-C 
PI3K Phosphatidyloinositol-3-kinase 
PIP3 Phosphatidylinositol  3,4,5-Trisphosphate 
PKA Protein  kinase  A 
PKB  Protein kinase B 
PKC  Protein kinase C 
PS Population  spikes 
PTP Post-tetanic  potentiation 
PTZ Pentylenetetrazole 
RSK1  Phospho-ribosomal protein S6 kinase-1 
SC Schaffer/collaterals  pathway 
SE Status  epilepticus 
SD Sprague  Dawley 
SRS Spontaneous  recurrent  seizures 
SSSE Self-sustained-status epilepticus 
STP  Short term plasticity 
TLE  Temporal lobe epilepsy 
TrkB  Tyrosine kinase B 
VPA Valproate 
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1.1 Epilepsy 
Epilepsy is the commonest serious neurological condition, affecting 0.5-1 % of the 
population, of which 30% have epilepsy that is not adequately treated with our present 
antiepileptic drugs (AED). These patients have a high mortality and morbidity. The term 
epilepsy refers to a diverse family of common chronic disorders of the central nervous 
system (CNS). An epileptic syndrome is defined as recurrent provoked seizures that can 
arise either in a generalized fashion or from specific brain regions; moreover, the 
epilepsies are associated with psychosocial disability such as depression and decreased 
cognitive abilities.   
 
Epilepsy syndromes can be broadly divided into two categories: generalized epilepsy 
and partial epilepsy. Each can be further subdivided by aetiology: (1) idiopathic, which 
is mainly genetically determined, (2) symptomatic, and (3) cryptogenic (or probable 
symptomatic) in which there is an assumed symptomatic cause. Most generalized 
epilepsies are idiopathic (e.g. Absence epilepsy, and Juvenile Myoclonic Epilepsy). 
Most partial epilepsies are symptomatic or cryptogenic, and often result from a brain 
insult such as head trauma or prolonged seizures (Johnson and Sander, 2001;Chang, 
2003).  
 
The mechanisms by which seizures occur have not been fully elucidated, but there 
appear to be certain key factors associated with epilepsy: changes in intrinsic properties 
of neurons, such as decreased potassium conductances or increased calcium 
conductances; changes in network inhibition in particular GABA(A) receptor-mediated 
inhibition, and enhancement of excitatory transmission, through “sprouting” of 
excitatory fibres and changes in glutamate receptors. 
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Our present pharmacotherapy of epilepsy prevents the symptom (seizures), but has not 
been shown to alter the course of the disease. There are several strategies by which 
AEDs suppress seizures: limiting sustained repetitive firing; increasing GABA-
mediated inhibition; attenuating activity of voltage-sensitive Ca
2+ channels; decreasing 
glutamate-mediated excitation (Perucca, 2001)(Table 1). 
 
Table 1.1: Mechanism of AEDs and neuroprotective compounds 
  Effect 
GABA 
system 
Effect 
Calcium 
channels 
 
Effect glutamate-
mediated 
excitation. 
 
Effect voltage-
dependent Sodium 
channels 
Old AEDs         
  Benzodiazepines  +       
  Carbamazepine  +  +    + 
  Ethosuximide    +     
  Phenobarbital  +  +     
  Phenytoin        + 
  Valproic acid  +  +     
         
New AEDs         
  Felbamate  +  +  +   
  Gabapentin  +  +     
  Lacosamide        + 
  Lamotrigine  +  +    + 
  Levetiracetam  +  +     
  Oxcarbazepine    +     
  Pregabalin  +  +     
  Tiagabine  +       
  Topiramate  +  +  +  + 
  Vigabatrin  +       
  Zonisamide    +    + 
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1.1.1 Temporal lobe epilepsy 
The seizures associated with temporal lobe epilepsy (TLE) consist of simple partial 
seizures without loss of awareness and complex partial seizures. Further spread can 
result in secondary generalized seizures. Patients with temporal lobe epilepsy are 
predisposed to behavioural changes and deep emotionality. Furthermore, patients with 
TLE often respond poorly to AEDs (Sutula, 1990).   
 
TLE can be subdivided into those in which the seizure onset zone involves the mesial 
temporal lobe and those involving the lateral temporal lobe. Mesial temporal lobe 
seizures can be localised to the limbic system, particularly the hippocampus, entorhinal 
cortex and amygdala (Bartolomei et al., 2005). 
  
Mesial temporal lobe epilepsy is associated with hippocampal sclerosis and comprises 
the majority of the cases of epilepsy refractory to pharmacotherapy. Mesial temporal 
lobe seizures usually begin in late childhood or early adolescence (French et al., 1993). 
Generally, TLE is thought to be initiated by an “initial precipitating injury” such as 
status epilepticus, infection, febrile convulsions, traumatic brain injury etc. There is a 
seizure-free time interval which is known as the “latent period” followed by the 
appearance of spontaneous seizures. Hippocampal sclerosis is characterised by cell loss 
and gliosis in specific subfields of the Cornu Ammonis - CA1 ,CA3 and the dentate 
hilus, while the CA2 region is relatively spared (Sutula, 1990). Other, changes in the 
hippocampal formation changes are also observed, including mossy fibre sprouting, 
interneuron loss and granule cell dispersion in the dentate gyrus (Curia et al., 2008). 
 
Lateral temporal lobe epilepsy (also known as neocortical temporal lobe seizures) is less 
common. Less than 10% of patients with TLE have seizures originating in the lateral  
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temporal neocortex (Walczak, 1995). There are various causes including genetic causes, 
such as Autosomal Dominant Lateral Temporal Lobe Epilepsy which is rare family 
epilepsy characterized by partial seizures with auditory disturbances. 
 
1.2 Hippocampus formation 
Human TLE is often accompanied by sclerosis in the hippocampus, also known as 
Ammon’s horn sclerosis, with neuronal degeneration and dentate gyrus granule cell 
dispersion. The sclerotic hippocampus removed by surgery often improves this epileptic 
condition. Seizure-induced remodelling of hippocampus during the process of epilepsy 
contributes to its low seizure threshold leads spontaneous recurrent seizure. It has been 
suggested that the alteration in epileptic hippocampus includes mossy fibre sprouting 
and recurrent innervations of granule cells forming a feedback loop promoting 
synchronization of spike activity and deteriorating inhibitory network in strict 
correlation to epileptogenesis (Pitkänen and Sutula, 2002).   
  
The hippocampus is a part of the brain located in the medial temporal lobe and adjacent 
to amygdala. The shape of hippocampus is like horseshoe. It forms a part of the limbic 
system and plays a part in memory, navigation, emotions and spatial orientation. 
 
The hippocampus can be divided into two major U-shaped areas. One sector is called 
the fascia dentate, including area dentata, dentate gyrus. Another sector is called the 
hippocampus proper, cornu ammoni. The hippocampus proper can be further divided 
into four fields, CA1, CA2, CA3, and CA4. CA4, now, is frequently called the hilus and 
considered part of the dentate gyrus. 
The fascia dentata comprises three layers: the granule cell layer which is the location of  
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the densely packed bodies of cell granule cells; the molecular layer which is formed by 
the apical dendrites of the granule cells and their afferents; and the polymorph layer in 
the hilus of the fascia dentata which merges with the CA4 field and contains the initial 
segments and axons of the granule-cell, forming the mossy fibre bundle. Also, it 
contains non-granule cells, such as basket cell.   
 
The hippocampus proper is divided into several layers, defined by a particular feature of 
the large pyramidal cells or their afferents: The alveus containing the axons of the 
pyramidal cells towards the fimbria or subiculum; the stratum oriens which is the layer 
between alveus and the pyramidal cell bodies contains the basal dendrites of the 
pyramidal cells ; stratum pyramidale, or pyramidal cell layer is the location of the 
pyramidal cell bodies; the stratum radiatum and the stratum lacunosum/moleculare are 
formed by the proximal and distal segments of the apical dendritic tree; stratum lucidum 
which is between the CA3 pyramidal cell bodies and the stratum radiatum receives the 
mossy-fibre input from the dentate granule cells. 
 
There are several sources of input to the cells in the hippocampus: intrinsic input from 
cells in same sector; intrinsic input from other sectors; commissural afferents from the 
opposite hippocampus; extrinsic afferents from outside the hippocampus (Summary in 
Figure 1.1). 
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Figure 1.1: Summary of hippocampal formation. The entorhinal cortex (EC) projects to 
dentate gyrus (DG) via perforant pathway fibers. DG granule cells output mossy fibers 
(MF) to CA3. CA3 pyramidal cells send axons recurrently to CA1 through the 
Schaffer/collaterals (SC) pathway. CA1 pyramidal cells project back to EC.   
 
 
1.2.1 Intrinsic input from cells in same sector 
In the same CA field, the interactions between pyramidal cells fall into two types:   
direct excitatory and indirect inhibitory. The indirect inhibitory effect is mediated via 
interneurons, such as the basket cells. The axons of the basket cells synapse in the 
pyramidal region and make contact with numerous adjacent pyramidal cells. However 
the basket cell receives input from these same pyramidal cells. This feedback loop could 
form the basis for a Renshaw-type inhibitory circuit. There are also direct monosynaptic 
excitatory connections between pyramidal cells of the CA3 field (Lopes da Silva et al., 
1990;Skrede and Westgaard, 1971).   
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1.2.2 Intrinsic input from other sectors 
As described by Cajal, unmyelinated axons of the dentate granule cells gather together 
in the polymorph layer in the hilus and afferent out of the hilus. There are two different 
pathways, one is run above the pyramids of CA3 in the stratum lucidum as the mossy 
fibres, and one is run below the pyramids in the stratum oriens. The lower bundle stops 
in CA3 region (between CA3b and CA3c). Mossy fibre synapses on CA neurons are 
large aggregations of termini, with multiple transmitter release sites and post-synaptic 
densities. 
 
Three pathways have been described as collaterals for the axons of both the giant CA3 
pyramidal neurons and the pyramids of CA4, with one branch entering the fimbria and 
going to the septum: the Schaffer collateral pathway arises from the CA4, CA3 
pyramidal cells and projects to the stratum radiatum of CA1 with excitatory synapses en 
passage; a pathway of collaterals of CA4 and CA3 around the fascia dentata runs 
parallel to the long axis of the hippocampus making contact with the proximal dendrites 
of the dentate granule cells; longitudinal and associational pathway arising in the CA2 
and CA3 fields which is a collateral of the Schaffer collateral pathway or a collateral of 
the pathway project to the fimbria, connecting cells within the same sector (O'Keefe and 
Nadel, 1978). 
 
There are input pathways from outside the hippocampus, including (a) entorhinal 
cortex; (b) brain-stem; (c) medial septal area.   
 
The entorhinal afferents provide one of the main extrinsic inputs and consist of the 
perforant path, alvear path and crossed temporo-ammonic tract.   
The perforant pathway is the major avenue of entorhinal afferents to hippocampus.    
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The axons of the perforant path arise from layer II and III of entorhinal cortex and 
project to the dentate gyrus and to the pyramidal cells of the CA1 and the subiculum as 
the lateral perforant path. Axons of perforant path also arise from layer IV and V of 
entorhinal cortex and project to the granule cells of the dentate gyrus (DG) and 
pyramidal cells of the CA3 region as the medial pathway. Glutamate is the main 
neurotransmitter in this pathway. 
 
1.2.3 Brain-stem afferent 
There are several brain-stem projections to the hippocampus, such as median raphe 
nucleus and particularly the nucleus centralis superior. This projection courses primarily 
through the fimbria, fornix, and cingulum, terminating mostly in stratum lacunosum or 
moleculare of CA1 and CA3, and in some specific hilar areas. The locus coeruleus also 
projects to the hippocampus. The pathway arises from locus coeruleus through the 
medial forebrain bundle and septum, entering hippocampus via restroplenial cortex. 
Fibres terminate in the stratum lacunosum/moleculare of CA1 and CA3, the hilus of the 
fascia dentata, and the stratum lucidum of CA3. 
 
Septal afferents arise from septal area and project sparsely to all ipsilateral fields of the 
hippocampus, stratum oriens and stratum radiatum of the hippocampus and to the 
polymorph zone of the fascia dentata. There is a small projection to the molecular layer 
of CA4 and fascia dentata. These fibres travel in the fimbria to CA3-CA4, or travel in 
the dorsal fornix and alveus to CA1. The major termination zones are just above and 
below the main cell bodies, indicating the target cell might be interneurones.   
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Other afferents include an input from the fastigial nucleus of the cerebellum to CA2, 
CA3, and CA4 and to the fascia dentata, terminating in stratum oriens, stratum radiatum 
and stratum lacunosum in the hippocampus proper, and the polymorph layer in the 
fascia dentata. This pathway approaches the hippocampus through cingulate and 
uncinate, entering either through the alvear or perforant paths (Lopes da Silva et al., 
1990). 
 
1.2.4 Efferents from the hippocampal   
The hippocampal efferents project to: (1) the lateral preoptic (2)medial and lateral 
hypothalamic areas, (3) the septal region, (4) the thalamus, (5) the mammillary bodies, 
(6) the rostral mid-brain, and (7) caudally to the subiculum and the entorhinal cortex. 
 
1.3 Long term potentiation (LTP) 
The mechanisms of memory which depends on formation of long-term potentiation 
(LTP) are similar to those mechanism underlying epileptogenesis by kindling. The 
stimulus parameters which best induce kindling are similar to LTP, such as high 
frequencies stimulation, resulting in structural synaptic changes through modulation of 
synaptic facilitation and protein synthesis (Meador, 2007). Additionally, in vitro 
experiment, LTP can be induced by spontaneous epileptiform activity, suggesting that 
LTP could be involved in the generation of seizure foci (Morgan and Teyler, 2001). 
Seizures can also reduce the ability to induce LTP, resulting in the impaired spatial 
learning in animals in repeated electroconvulsive seizures and kindling model (Reid and 
Stewart, 1997;Leung and Wu, 2003). LTP is markedly reduced in the hippocampal 
seizure focus in humans with temporal lobe epilepsy, resulting in deficient declarative 
memory (Beck et al., 2000).  
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The definition of LTP is an increase in strength of a chemical synapse in specific brain 
pathways that lasts from minutes to several days. In in vitro and in vivo experiments, 
applying high-frequency electric stimuli or excitatory chemical agents to a synapse can 
induce the LTP on the synapse for minutes to hours. 
 
LTP contributes to plasticity in synaptic connections and formation of learning and 
memory. LTP can be divided into in three phases: Short-term potentiation, early phase 
and late phase (Andersen et al., 2007). 
·  Short-term potentiation is NMDA receptor  independent  without  involving    
         p r o t e i n   s y n t h e s i s and protein kinase activity.   
·  Early phase which usually happened in the first hour, involves increased   
      sensitivity  of  the  synapse  without  any new gene transcription or mRNA           
      translation  occurring.  There  are  several protein involve in early phase,   
      including  calcium/calmodulin-dependent  protein  kinase  II  (CaMKII)  
      (Lledo  et  al.,  1995),  protein  kinase C (PKC) (Otmakhova et al., 2000),   
      protein  kinase  A  (PKA),  mitogen-activated protein kinase   
      (MAPK)  (English  and  Sweatt, 1997;Sweatt, 2001) and tyrosine   
      Kinases  (Huang  and  Hsu,  1999).  
·  Late phase usually persist for many hours and even many days, requiring new   
      gene  transcription,  mRNA  translation (Frey et al., 1996) and protein   
         synthesis  in  the  postsynaptic  cell.  AMPA  receptors  expression  increases  and  
         formation  of  entirely  synapses  changes  (Lynch,  2004).  
Hippocampal LTP plays a crucial role in memory formation and learning, such as spatial  
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learning, recognition memory, working memory (Lynch, 2004).   
 
In the hippocampus, LTP can be classified by different mechanisms into NMDA 
receptor mediated LTP and non-NMDA receptor mediated LTP. LTP in CA1 and dentate 
regions in hippocampus requires NMDA receptor activation and postsynaptic 
depolarization. In CA3 region of hippocampus, pyramidal cells receive two different 
synaptic inputs, an associational-commissural input and mossy fibre inputs. NMDA 
receptor antagonists are able to block the LTP induced in associational-commissural 
pathway, but not mossy fibre LTP. Paired-pulse facilitation, an index of increase 
transmitter release was reduced during mossy fibre LTP, indicating that the early and 
later phases of LTP in mossy fibres is expressed presynaptically (Zalutsky and Nicoll, 
1990).  
 
1.3.1 NMDA receptor mediated LTP 
The influx of calcium through NMDA receptors contributes to a cascade of events 
which ultimately leads to an increase in synaptic efficacy. Such LTP is associational as it 
requires glutamate release and coincidental post-synaptic depolarisation to relieve the 
magnesium block of the NMDA receptors (Bliss and Collingridge, 1993). 
 
The influx of Ca
2+ into the neuron through NMDA receptors activates calcium-
calmodulin-dependent kinase II (CaMKII) which phosphorylates critical proteins. For 
example, CaMKII phosphorylates AMPA receptors, increasing their permeability to 
sodium ions (Na
+). The activation of NMDA receptors varies with stimulation 
frequency. Activation dependent synaptic modifications depend on stimulation 
frequency. With high-frequency stimulation, the cellular responses result in LTP. With  
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low-frequency stimulation, the cell responses initiate long term depression. Moreover, 
sustained stimulation of NMDA receptors trigger the process of apoptosis (Popescu, 
2005) 
 
NMDA receptors have been shown to be a key factor for spatial memory function. NR1 
knockout mice had poor performance in water maze task compared to the normal mice, 
indicating that their spatial memory was disrupted. Furthermore, these mice had 
impaired LTP in CA1 region (Tsien et al., 1996).       
 
1.3.2 Non-NMDA receptor mediated LTP 
The LTP at mossy fibre to CA3 pyramidal neuron synapses demonstrate NMDA 
receptor independent LTP (Zalutsky and Nicoll, 1990;Harris and Cotman, 1986). This 
LTP is similarly induced by tetanic stimulation and is expressed pre-synaptically 
(Summary in Figure 1.2). 
 
Mossy fibre LTP has been proposed to be independent of postsynaptic calcium (Mellor 
and Nicoll, 2001;Castillo et al., 1994) and postsynaptic membrane potential (Zalutsky 
and Nicoll, 1990). However, there are some conflicting reports that claim that induction 
of mossy fibre LTP requires postsynaptic calcium entry and depolarization.  
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Figure 1.2: cAMP contributes to the long term potentiation in mossy fibre synapse to 
CA3 region. Stimulation synaptic activity results in the entry of presynaptic Ca
2+. The 
increase the level of Ca
2+activates adenylyl cyclase, a Ca
2+-sensitive kinase, leading to 
activate cAMP-dependent protein kinase A (PKA) via increase of cAMP level. This 
results in a long-lasting increase in glutamate release. 
 
 
There is considerable evidence that the expression of mossy fibre LTP requires the 
involvement of cyclic adenosine monophosphate (cAMP). Application of adenylyl 
cyclase activator, forskolin, or membrane-permanent analogues of cAMP cause a long 
lasting presynaptic enhancement of mossy fibre responses which occlude mossy fibre 
LTP (Huang et al., 1994;Nicoll and Malenka, 1995;Tzounopoulos et al., 
1998;Weisskopf et al., 1994). Giving the PKA antagonist, not only the antagonist of  
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catalytic but also regulatory sites, reverses mossy fibre enhancement after application of 
forskolin (Weisskopf et al., 1994). Also, applying high-frequency tetanic stimulation 
induces LTP at mossy fibre synapses. It has been suggested that high-frequency tetanic 
stimulation activates a calcium/calmodulin-dependent adenylyl cyclase via rising 
presynaptic calcium. This results in an increase in presynaptic cAMP levels and 
activation of the cAMP-dependent protein kinase. The activation of PKA increases 
neurotransmitter release (Nicoll and Malenka, 1995). 
 
A recent study suggests that presynaptic hyperpolarization-activated cation channel (Ih) 
contributes to the LTP in mossy fibre and is modulated by cAMP (Mellor et al., 2002). 
However, the involvement of Ih in the expression of LTP in mossy fibre has been 
challenged (Chevaleyre and Castillo, 2002). 
 
 
1.4 Epileptogenesis 
Epileptogenesis is the process by which the brain develops the capability of generating 
spontaneous, recurrent seizures. It may take months to years to develop epilepsy. During 
this period an area of brain injury undergoes morphologic and biologic changes 
(Herman, 2002). The epileptogenic process can be divided into three phases. First, there 
is an initiating injury produced by events such as head trauma, stroke, infection or status 
epilepticus. Second, a latent phase follows which can last for weeks to years without 
seizure occurrence. In this phase, alterations in molecular, cellular and network 
properties occur. Finally, spontaneous epileptic seizures occur. Once seizures occur, the 
epileptic disease state probably continues to progress, as seizures may induce additional 
neuronal alterations, further lowering seizure threshold (Figure 1.3). 
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Figure 1.3: The process of development of epilepsy. The epileptogenic process can be 
divided into three phases: an initiating injury produced by events such as head trauma, 
stroke, infection or status epilepticus, a latent phase follows which can last for weeks to 
years without seizure occurrence, and chronic epileptic phase which spontaneous 
epileptic seizures occur. 
 
 
1.5 Animal models of epileptogenesis 
By development and characterization of insult- and age-specific animal models of 
epileptogenesis, there has been significant progress in our understanding of the factors 
that contribute to human epileptogenesis in recent years. To study the epilepsy in animal 
model allows us to elucidated the mechanism of epileptogenesis, and to develop the 
therapy to prevent the epileptogenic process (White, 2002). 
 
1.5.1 Animal models of temporal lobe epilepsy 
Several animal models have been developed to investigate epilepsy and epileptogenic 
process (Table 1.2). In addition, there are models based upon spontaneous genetic 
mutations in diverse animal species, or induced mutations in mice. The two most 
common models for studying epileptogenesis of TLE are the kindling and the post-
status epilepticus models. These chronic animal models are used not only to investigate 
the mechanism of epilepsy, but also to evaluate the effect of AEDs to prevent 
epileptogenesis. Both types of model provide a reliable method to study the progression 
of epilepsy.  
36 
 
Table 1.2: A summary of animal model to investigate epilepsy and epileptogenesis 
 
Acute seizure model 
  Cell culture 
    Low magnesium model  (Rose et al., 1990) 
       
  Acutely isolated hippocampus slices 
    mGlu agonist model  (Thuault et al., 2002) 
       
  Combined hippocampal-parahippocampal slices   
    Schaffer collateral model  (Rafiq et al., 1995) 
       
  Acutely combined entorhinal cortex-hippocampus slices 
    Pentylenetetrazole model  (Armand et al., 1998) 
    Low magnesium model  (Armand et al., 1998) 
       
  Interconnected intact hippocampal formation 
    Three-chamber model  (Khalilov et al., 2003) 
       
Electroshock model  (Jones, 1991) 
Chronic spontaneous seizure model 
  Model of acquired epilepsy 
    Kindling model  (Goddard, 1967) 
    Pilocarpine model  (Hamilton et al., 1997) 
    Kainic acid model  (Sperk, 1994) 
    Electrical stimulation model  (Walker et al.,, 1999) 
    Hypoxic seizure model  (Jensen, 1995) 
    Undercut cortex model  (Li and Prince, 2002) 
    Post-traumatic epilepsy model  (Kharatishvili et al., 2006)
       
  Model of genetic epilepsy 
    Spontaneous mutations in diverse   
animal species 
(Frankel et al., 1994) 
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1.5.2 The kindling model 
The kindling phenomenon was first described by Goddard (Goddard, 1967). It became 
one of the most common animal models for the study of temporal lobe epilepsy. In the 
kindling model, repeated exposure to an initial sub-convulsive stimulus eventually 
results in evoked seizures. Initially, electrical kindling stimuli only elicit short-duration 
after discharges which are produced by synchronous neuronal discharges from the 
stimulated region. Additional kindling stimulations induce longer afterdischarges and 
increase the area of brain involved. The seizures become more and more complex and 
longer with repeated stimuli. This increase in sensitivity to previously sub-convulsant 
stimuli may take a number of days or weeks. The kindling induced reduction in seizure 
threshold is permanent. 
 
There are many advantages of the kindling model for research into the epileptogenic 
process, such as: the precise activation of defined brain regions; the development of 
epilepsy is easy to observe; the pattern of seizure propagation and generalisation can be 
readily monitored; inter-ictal, ictal and postictal periods are easily manipulated, and the 
pharmacology of kindled seizures are very similar to the clinical condition. 
 
However, the kindling model rarely results in the development of spontaneous seizures 
unless a very large number of kindling stimulations are applied (the “over-kindling” 
model). Kindling can, however, cause some cell loss and sprouting of axonal collaterals 
(Morimoto et al., 2004).   
 
1.5.3 The status epilepticus models 
Status epilepticus (SE) is defined as prolonged seizure activity. Experimental SE can be 
induced by acute systemic exposure to convulsant agents, such as drugs which block  
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GABAergic inhibition or increase glutamatergic transmission. Kainic acid, a glutamate 
receptor agonist, and pilocarpine, a cholinergic agonist, are the most commonly used 
methods for chemical induction of SE. In addition, electrical stimulation of the 
hippocampus, amygdala or perforant pathway can induce SE. Usually, spontaneous 
seizures first occur after a latent period of about 3–4 weeks after the episode of SE in 
rats. Generally speaking, the development of epilepsy after SE can be classified into 
four stages: (1) the acute phase (2) the active phase (3) the latent phase and (4) the 
chronic phase (Morimoto, 2004)   
 
The advantages of the SE model are that the neuronal alterations are similar to those 
seen in people with epilepsy. SE induces cell loss in specific neuronal populations in 
multiple brain regions, such as hippocampus, amygdala and entorhinal cortex. Other 
cells can undergo delayed cell death after seizure termination. Surviving brain cells 
transform their morphology, including axon sprouting and altered density of dendritic 
spines. Furthermore, SE also affects non-neuronal brain cells, changing the number and 
morphology of astrocytes and microglia. Therefore, SE can be used not only to help us 
understand the epileptogenic process, but also to test the antiepileptogenic properties of 
drugs by administering the drugs following SE and examining the effects on neuronal 
pathology and the expression of spontaneous seizures. However, the disadvantages of 
the SE model are that the SE can be unpredictable and difficult to control, and there 
may be considerable neuronal damage. 
 
1.5.3.1 Pilocarpine model 
Pilocarpine is a non-selective muscarinic receptor agonist. M1 receptor knockout mice 
are resistant to the development of seizure activity in the pilocarpine model (Hamilton  
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et al., 1997), indicating that the M1 receptor is required for the initiation of epileptic 
seizures. Furthermore, pretreatment with atropine, the muscarinic antagonist, blocks 
pilocarpine-induced seizure activity (Clifford et al., 1987;Priel and Albuquerque, 2002). 
In cultured hippocampal neurons, application of pilocarpine caused an increase of 
excitation through modulation of muscarinic receptors, resulting in generation of seizure 
activity (Priel and Albuquerque, 2002). 
 
Injection of pilocarpine induces limbic and tonic–clonic seizures. The animal has oro-
facial movements, salivation, eye-blinking, twitching of vibrissae, and yawning 5-15 
minutes after administration of pilocarpine. This activity persists for up to 45 minutes. 
Discontinuous seizures are observed 30 minutes after injection and last up to 90–150 
min. Finally, the seizure activity develops into limbic motor seizures with intense 
salivation, rearing, forearm clonus, and falling. After pilocarpine injection, around 60% 
of the rats have been described to develop SE (Curia et al., 2008) Several hours after 
SE, the seizure activity in pilocarpine-treated animals ceases spontaneously and the 
animals enter a seizure-free period. 14-15 days after SE, pilocarpine-treated animals 
have spontaneous recurrent seizures and enter a chronic epilepsy stage.     
 
Animals with several hours of SE have lesions and histopathological alterations in many 
brain areas, such as olfactory cortex, amygdala, thalamus, hippocampal formation, and 
neocortex. The hilus, area CA1 and area CA3 of the hippocampus are most affected 
(Lemos and Cavalheiro, 1995). There is also extensive network reorganization, which 
may result from neuronal loss. There is not only mossy fibre sprouting, but also 
sprouting of CA1 axons into area CA3 increased connectivity between CA1 neurons 
and sprouting of subicular neurons into area CA1 (Lehmann et al., 2001). These  
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structural alterations result in enhanced excitatory feedback loops within and between 
hippocampal regions, resulting in increased synchronization of pathological discharges 
in  the  hippocampus.     
 
1.5.3.2 Kainic acid model 
Kainic acid is a natural marine acid which is a specific agonist for the kainate receptor, 
an ionotropic glutamate receptor subtype. Kainic acid given locally into the brain or 
systemically has been used as experimental models of temporal lobe epilepsy, because 
the clinical signs and pathology are similar to those seen in patients with temporal lobe 
epilepsy. 
 
Rat behaviour during kainic-acid induced status epilepsy can be divided into several 
stages: Stage 1, staring and movement arrest is observed 5-6 min after administration; 
Stage 2, masticatory movements, head nodding, myoclonic twitches of the head, face 
and fore limbs, and ‘wet dog’ shakes are observed after 5 minutes of administration and 
last for 30 minutes; stage 3, about 1 hours after injection kainic acid, the rats have 
recurrent generalised tonic-clonic seizures, rearing, loss of postural control and 
increased salivation, production of foam at the mouth often mixed with blood. Once the 
recurrent generalised tonic-clonic seizures develop, they continue for 4-5 hours and 
remit spontaneously. Approximately 60-80 % of animal develop the full seizure 
syndrome after systemic kainic acid administration, via the subcutaneous or 
intraperitoneal route. In addition to the involvement of entorhinal cortex and 
hippocampus, the epileptic activity recruits other limbic structures, including the 
median thalamic complex, and medial frontal cortex (Sperk, 1994). Kainic acid 
preferentially induces seizures in limbic structures, perhaps secondary to the high  
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density of kainate receptors in the CA3 region of the hippocampus, increasing the 
release of the endogenous excitatory amino acids, glutamate and aspartate and further 
activating all types of glutamate receptors (Oprica et al., 2003;Ferkany et al., 1982).     
 
Administration of kainic acid into rats not only induces ongoing convulsions, but also 
causes degeneration of neurons and hyperexcitability of surviving neurons. Kainic acid 
can directly induce cell death because of its excitotoxic properties, increasing 
intraneuronal calcium levels and the activation of calcium-dependent proteases. In 
addition, kainic acid also results in neuronal death through the induction of seizure 
activity (Ben-Ari et al., 1979). 
 
1.5.3.3 Electrical stimulation model 
Sustained electrical stimulation of the perforant pathway (the angular bundle i.e. the 
pathway from entorhinal cortex to hippocampus) evokes hippocampal granule cell 
population spikes and epileptiform discharges (Sloviter, 1983). By using biphasic 
electrical stimulation with continuous low frequency, 20Hz to 50 Hz, of the perforant 
path in awaken animals; it is possible to evoke self-sustaining SE (Walker et al., 1999; 
Martín and Pozo,, 2006;Prasad et al., 2002).   
 
During stimulation, the rats first have ‘wet dog shakes’ and progress to limbic seizure 
consisting of chewing, head nodding, forelimb clonus and few tonic seizures. The 
seizure activity remits spontaneously over a period of hours. The seizure may reappear 
in few weeks after stimulation procedure.   
 
Even though perforant path stimulation is unilateral, it evokes bilateral granule cell  
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discharges and causes bilateral hippocampal damage. In this model, the hilar 
somatostatin-containing cells of the dentate gyrus are the most susceptible, followed by 
the pyramidal cells of CA1 and CA3. The CA2 pyramidal cells and the dentate gyrus 
granule cells appear to be most resistant (Sloviter, 1983;Kelsey et al., 2000).   
 
The effects of perforant path induced SE extend beyond hippocampal neuronal loss, and 
include impairment of learning and memory (Rogers et al., 1989;Kelsey et al., 2000). 
The learning and memory deficits are associated with hippocampal cell loss, the 
frequency of inter-ictal spikes and the age of seizure onset (Ylinen et al., 1991;Thurber 
et al., 1992).     
 
1.6 Mechanisms of epileptogenesis 
The mechanisms of epileptogenesis are still unclear. However, different initiating events 
may lead to a similar sequence, including acute and delayed excitotoxicity, resulting in 
the death of specific, susceptible neuronal populations. Long-term alterations which are 
evoked by inducing gene activity expression or compensatory responses to cell damage 
and death appear to produce effects on neuronal circuitry, dendritic plasticity, 
neurogenesis and molecular reorganization of membranes and extracellular space (Jutila 
et al., 2002). 
 
1.6.1 Excitatory systems in epileptogenesis 
A number of studies have pointed out that increased activity in the excitatory system 
may play an important role in epileptogenesis. Enhancement of excitatory activity can 
be due to increased presynaptic neurotransmitter release, increased postsynaptic 
receptor sensitivity, and changes in glutamate uptake and metabolism.  
43 
 
1.6.1.1 Glutamate receptors in epileptogenesis 
Glutamate receptors can be divided into two classes: ionotropic glutamate receptors and 
metabotropic glutamate receptors. Ionotropic glutamate receptors consist of N-methyl-
D-aspartate (NMDA) receptors, alpha-amino-3-hydroxy-5-methyl propionate (AMPA) 
receptors and kainate receptors. Metabotropic glutamate receptors are divided into three 
groups: Group one receptors, which include mGluR1 mGluR5, are coupled via Gq/11 
protein and phospholipase Cβ (PLCβ) to inositol phospholipids metabolism; Group two 
receptors, which include mGluR2 and mGluR3, and are negatively coupled by Gi to 
adenylyl cyclase; Group three receptors, which include mGluR4, mGluR6, mGluR7, 
and mGluR8 are negatively coupled by Gi to adenylyl cyclase. Both ionotropic 
receptors (especially NMDA receptors) and metabotropic glutamate receptors have been 
linked to excitotoxicity. 
 
1.6.1.2 NMDA receptor in epileptogenesis 
The NMDA receptor (NMDAR) is an ionotropic receptor, allowing flow of Na
+, K
+, and 
Ca
2+ ions. Calcium influx through NMDARs plays an important role in Hebbian 
plasticity. NMDA receptors probably consist of 5 subunits per channel. The NMDA 
receptor subunits include: NR1, NR2A, NR2B, NR2C, NR2D, and NR3. The functional 
receptor requires two NR1 and a subtype of the NR2 subunits. The NR1 subunits bind 
the co-agonist glycine and NR2 subunits bind the neurotransmitter, glutamate 
(Yamakura and Shimoji, 1999). 
 
NMDA receptors are blocked by magnesium at hyperpolarized potentials and this block 
is removed by depolarization. NMDA receptor currents lead to a prolonged 
depolarization. Over-activation of glutamate receptor causes the influx of chloride and 
water, resulting in neuronal swelling and cellular necrosis. Additionally, over-activation  
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of NMDA receptor triggers intracellular signalling and regulatory pathways, resulting in 
delayed cell degeneration (apoptosis or “programmed cell death”). This depends upon 
calcium entry through NMDA receptors. Other routes of calcium entry, such as through 
L-type voltage-sensitive Ca
2+ channels do not usually initiate apoptosis. This may be 
because the enzymes or substrates responsible for excitotoxicity co-localize with 
NMDA receptors (Arundine and Tymianski, 2003). 
 
Calcium entering through NMDA receptors during SE may initiate a cascade of cellular 
events, including activation of catabolic enzymes, impairment of energy metabolism 
and generation of reactive oxygen species and ultimately leading to cell death. NMDA 
receptor activation also leads to permanent alterations in neuronal circuits and 
excitability. 
 
Recent evidence suggests that NMDA receptor currents are increased following SE 
(Scimemi et al., 2006). This may also occur in other models of epileptogenesis. 
NMDAR1 expression is increased after Fe
3+-induced epileptogenesis (Doi et al., 2001). 
In humans, changes in NMDA receptors in TLE patients are region specific. For 
example, the expression of NR1 increases in CA3-1 stratum radiatum, while the 
expression of NR2 increases through all hippocampal subfields (Mathern et al., 1998). 
 
1.6.1.3 AMPA receptor activation in epileptogenesis 
AMPA receptors are a four subunit receptor composed of, GluR1, GluR2, GluR3, and/or 
GluR4. The AMPA receptor mediates fast glutamatergic synaptic transmission. The 
combination of GluR1 and GluR2 constitute the majority of AMPA receptor complexes 
in the neocortex and hippocampus (Wenthold et al., 1996)  
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Some researchers have suggested that AMPA receptors play a role in epileptogenesis 
and glutamate-induced neuronal death. In patients with chronic epilepsy, it has been 
reported that there was a significant increase of GluR2/3 on the dendrites of dentate 
granule cells in the hippocampus (de Lanerolle et al., 1998). In animals, a variety of 
changes in AMPA receptor subunits have been described. The expression of GluR1and 
GluR2 in the hippocampus change with epileptogenesis (Doi et al., 2001). The GluR2 
subunit is reduced in limbic forebrain and amygdala 24 hours after amygdaloid kindling 
(Prince et al., 1995). After lithium–pilocarpine induced SE, the expression of different 
AMPA receptor subunits changes (e.g. GluR2 increases and GluR3 decreases) in dentate 
granule neurons (Porter, 2006). Perhaps the most direct evidence for a role of AMPA 
receptors in epileptogenesis is provided by the observation that application of the AMPA 
receptor antagonist, YM90K, markedly retarded the evolution of kindling (Kodama et 
al., 1999). Changes of AMPA receptor subunits during epileptogenesis alter excitatory 
neurotransmission and may contribute to seizure propagation. 
 
1.6.1.4 Kainate receptor activation in epileptogenesis 
The kainate receptor is a four subunit receptor composed from subunits: GluR5, GluR6, 
GluR7, KA1 and KA2 (Dingledine et al., 1999). Kainate receptors are permeable to 
sodium and potassium ions. The kainate receptor plays a role in: modulation of 
transmitter release, including regulation of excitatory synaptic transmission (Lauri et al., 
2001b;Vignes and Collingridge, 1997); regulation of inhibitory synaptic transmission 
(Lerma, 2003); synaptic plasticity- long-term potentiation (Lauri et al., 2001a;Vissel et 
al., 2001). The CA3 area, which is considered as a pacemaker for the generation of 
synchronized activity that subsequently propagates to CA1 and other brain regions, is 
highly vulnerable to network hyperactivity and readily degenerates following recurrent  
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seizures probably because of a sustained release of glutamate leading to over-activation 
of kainate receptors (Ben-Ari and Cossart, 2000). In both humans and various animal 
species, high-affinity kainite receptors are greatly enriched at mossy fibre synapses onto 
CA3 pyramidal cells (stratum lucidum) (Monaghan and Cotman, 1982;Tremblay et al., 
1985). Activation of kainate receptor generates seizures in CA3 pyramidal neurons that 
propagate to CA1 and to other limbic structures (Robinson and Deadwyler, 1981;Fisher 
and Alger, 1984;Ben-Ari and Gho, 1988). Furthermore, long-lasting changes of synaptic 
responses result from the spontaneous synchronized discharges present during and 
shortly after the application of kainic acid (Ben-Ari and Gho, 1988).   
 
1.6.1.5 Metabotropic glutamate receptor in epileptogenesis 
Metabotropic glutamate receptors, or mGluRs, are G-protein-coupled receptors, 
activated by glutamate binding. The mGluRs are located pre- and postsynaptically in the 
brain. 
 
Metabotropic glutamate receptors play an important role in the central nervous system 
(CNS), regulating both neuronal excitability (Colwell and Levine, 1999) and 
neurotransmitter release (Cartmell and Schoepp, 2000). mGluRs may also play an 
important role in synaptic plasticity (long term potentiation and long-term depression) 
(Riedel and Reymann, 1996). Group I metabotropic glutamate receptors have been 
implicated in epileptogenesis. The group I mGluRs are comprised of two receptor 
subtypes, mGluR1 and mGluR5, both of which are present in the hippocampal CA3 
region ( Blümcke et al., 1996;Lujan et al., 1996). In vitro studies indicate that ictal-like 
discharges, which persist for hours, can be induced by transient application of the 
selective group I mGluR agonist (S)-3,5-dihydroxyphenylglycine (DHPG) (Merlin,  
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1999). Furthermore, application of group I mGluR antagonists block persistent ictal-
length discharges induced by the transient activation of group I mGluRs (Merlin and 
Wong, 1997;Merlin, 1999). By using subtype-selective antagonists to evaluate the 
separate roles of mGluR1 and mGluR5 in the induction of epileptogenesis, both 
mGluR1 and mGluR5 participate in both the induction and maintenance of mGluR-
mediated burst prolongation. However, mGluR1 activation plays a greater role in 
sustaining the expression of prolonged bursts, whereas mGluR5 activation may be a 
more critical contributor to the induction process underlying epileptogenesis (Merlin, 
2002;Wong et al., 2005). In human, expression of mGluR5 increases have been 
observed in the hippocampus in TLE patients (Notenboom et al., 2006;Wong et al., 
2005).  
 
Even though activation of group I mGluRs are proconvulsant, activation of group II and 
group III mGluRs are anticonvulsant. Activated Group II and Group III mGluRs show 
anticonvulsant efficacy in a number of models of limbic and generalized motor seizures 
(Alexander and Godwin, 2006). Application of LY379268 and LY389795, selective 
group II mGlu agonists, showed anti-epileptic effect in a variety of in vivo seizure 
models (Moldrich et al., 2001). Additionally, in fully kindled rats following daily 
electrical stimulation of the basolateral amygdale, application with DCG-4, a group II 
mGlu agonist, increased the generalized seizure threshold in these seizure susceptible 
animals and inhibited depolarization-induced release of aspartate from rat 
cerebrocortical synaptosomes, suggesting that the anticonvulsant property of group II 
mGlu receptors may be due to their modulatory action on neuronal glutamate release 
(Attwell et al., 1998). Selective activation of group III mGluRs by (R,S)-4-
phosphonophenylglycine, a select selective agonist for group III mGluRs results in  
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neuroprotection against NMDA and quinolinic acid-induced striatal lesions in rats and 
showed anticonvulsive effect in the maximal electroshock model in mice (Gasparini et 
al., 1999) 
 
1.6.2 Inhibitory systems in epileptogenesis 
1.6.2.1 GABA(A) receptors in epileptogenesis 
The neutral amino acid GABA interacts with post-synaptic GABA(A) receptors, 
resulting in fast synaptic inhibition. GABA(A) receptors are heteromeric protein 
complexes composed of five subunits that form ligand-gated anion-selective channels. 
Once GABA binds to GABA(A) receptors, the pore opens to allow chloride ion influx 
which contributes to inhibitory postsynaptic potentials (IPSP). 
 
There are numerous subunit isoforms for the GABA(A) receptor (GABAR). GABA(A) 
receptors are pentameric structures composed of 2 alphas and 2 betas and one other 
subunit. There are 6 alpha subunits, 3 beta subunits, 3 gamma subunits, and also delta, 
epsilon, pi and rho subunits. The composition of subunits determines the GABA(A) 
receptor’s properties, such as agonist affinity, opening probability and conductance 
(Barnard et al., 1998). 
 
Impaired GABA-ergic function is associated with epilepsy (De Deyn et al., 1990;Jeffrey 
and Dudek, 1991). It has been demonstrated that post-synaptic GABAR function 
undergoes long-lasting alterations in temporal lobe epilepsy (Gibbs et al., 1997;Buhl et 
al., 1996;Nusser et al., 1998;Schwarzer et al., 1997). Epilepsy-associated changes in 
GABAR function may result from altered subunit composition (Brooks-Kayal et al., 
1998;Fritschy et al., 1999).  
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Alterations of GABAR subtypes may lead to changes of the pharmacological properties 
of synaptic GABAR. Molecular reorganization of GABAR subunits significantly 
increases the blockade of GABA evoked currents by zinc in epileptic patient (Shumate 
et al., 1998) and in animal models of TLE (Buhl et al., 1996). In rats with SE induced 
by lithium–pilocarpine, there were drastic changes in GABAR-mediated inhibition 
within dentate gyrus granule cells that were sensitive to modulators such as 
benzodiazepine and neurosteroids (Leroy et al., 2004). In addition, GABAR endocytosis 
during prolonged seizures may contribute to decreased expression of specific GABAR 
subtypes (Blair et al., 2004). The change of pharmacological properties of synaptic 
GABAR may be crucial to epileptogenesis and the occurrence of seizures.     
 
1.6.2.2 GABA(B) receptors in epileptogenesis 
GABA(B) receptors are composed of two subunits GABA-R1 and GABA–R2. 
GABA(B) receptors are G protein coupled receptors which are involved in a number of 
physiological and disease processes, including epilepsy. The activation of presynaptic 
GABA(B) receptors inhibits neurotransmitter release; the activation of post-synaptic 
receptors increases potassium channel activation, resulting in prolonged synaptic 
inhibition. In addition, GABA(B) receptors alter cAMP formation via adenylyl cyclase 
(Kerr and Ong, 1995;Couve et al., 2000). 
  
A number of studies have indicated that GABA(B) receptor function is altered during 
epileptogenesis. GABAB1 subunit knockout mouse develop generalized epilepsy 
resulting in premature death (Prosser et al., 2001). In rats with kindling-induced 
epileptogenesis, the sensitivity of presynaptic GABA(B) receptors located on the nerve  
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terminals of glutamatergic afferents was reduced, leading to the enhancement of 
excitatory transmission. This alteration lasted 4-6 weeks after kindled seizure, indicating 
a long-lasting alteration (Asprodini et al., 1992). Additionally, there is evidence of 
decreased presynaptic GABA(B) receptor inhibition of excitatory transmission at mossy 
fibre during the development of epilepsy following perforant path stimulation or 
pilocarpine administration (Chandler et al., 2003). 
 
1.6.3 Non-synaptic mechanisms in epileptogenesis 
Non-synaptic mechanisms refer to those mechanisms that are independent of active 
chemical synaptic transmission, resulting in the synchronization of neuronal activity 
during seizures. These “non-synaptic” mechanisms include electronic coupling of gap 
junctions, electrical field effects and ionic interactions. All of these may be enhanced 
during epileptogenesis due to changes in the extracellular space, gliosis and the 
formation of gap junctions (Dudek et al., 1998). Blocked chemical synaptic 
transmission both pre and post-synaptically, and decreases in osmolality, which shrink 
the extracellular volume, cause or enhance epileptiform bursting, indicating the 
enhancement of synchronization among CA1 hippocampal neurons through non-
synaptic mechanisms. Increases in osmolality, which expand the extracellular volume, 
block or greatly reduce epileptiform discharges (Dudek et al., 1990). 
 
Gap junctions are intercellular channels composed of connexin proteins, which can be 
modulated by a number of intracellular and extracellular factors, allowing certain 
molecules and ions to move freely between neurons. This permits direct electrical 
transmission between cells, chemical transmission between cells via small second 
messengers, and the passage of small molecules (1000 Dalton). Gap junction channels  
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contribute to neuronal synchronization in the brain (Draguhn et al., 1998;Draguhn et al., 
1998;Traub et al., 2003). In addition, they may also play a role in hypersynchrony in 
epilepsy models (Kohling et al., 2001;Perez Velazquez and Carlen, 2000). Recent 
studies indicate that gap junctions can significantly modify the expression, duration, and 
propagation of seizures in in vitro (Gajda et al., 2003) and in in vivo (Gajda et al., 2005) 
epilepsy models. 
 
Electrical-field effects depend on neuronal orientation, polarity and the size of the 
extracellular space (Ghai et al., 2000). Tight packed neurons that are arranged in parallel 
are susceptible to the effect of activity-induced electrical fields. Electric fields can 
modulate neuronal activity in the central nervous systems. They influence a variety of 
cellular events, such as membrane differentiation, neurite growth during both 
development and structural regeneration, organization of local neuronal circuits, and 
even receptor localization (Faber and Korn, 1989). When synaptic activity is blocked in 
hippocampal slices by removing extracellular Ca
2+, recurrent spontaneous paroxysms, 
termed seizure-like events, occur in the CA1 region (Konnerth et al., 1986). 
 
Ionic interactions involve activity dependent shifts in the intracellular and extracellular 
concentration of ions. Intense electrical activity during seizures is associated with 
transmembrane ionic currents, causing K
+ and Cl
- redistribution. The increase of K
+ 
concentration in the extracellular milieu increases membrane excitability, resulting in a 
slow synchronizing effect on neuronal networks (Yaari et al., 1986;Jensen and Yaari, 
1997;Bikson et al., 1999). Additionally, extracellular chloride may also play a critical 
role in neuronal synchronization (Hochman et al., 1999;Hochman et al., 1995). 
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1.6.4 Cell loss and epileptogenesis 
Damage to the central nervous system can be modulated by excessive excitatory and 
reduced inhibitory neurotransmission. Furthermore, increased Na
+ and Ca
2+ loading, 
through impaired ion channels or alterations in the acid-base balance, contributes to 
both excitotoxic and apoptotic cell death. It has been suggested that cell loss in TLE, 
including principal neurons in CA1, CA3 and CA4 regions of the hippocampus 
(Margerison and Corsellis, 1966) may indirectly result in the later occurrence of 
recurrent limbic seizures (Meldrum, 1997).   
  
1.6.4.1 Apoptosis 
After brain injury, such as ischemic injury, stroke, or traumatic brain injury, apoptosis 
(programmed cell death) plays a critical role in neuronal death (Liou et al., 2003). 
Apoptosis is a physiological process for killing cells and is important for the normal 
development and function of multicellular organisms (Strasser et al., 2000). Apoptosis 
results from a highly ordered molecular cascade, including inflammatory/cytokine-
processing, Caspases- 1, 5, and 11 and apoptosis-regulatory caspases- 2, 3, 6, 7, 8, 9, 
and 10. Apoptosis may also involve changes in gene transcription (Henshall and Simon, 
2005). 
 
Repeated tonic-clonic seizures result in mild cell loss in the hippocampal formation, 
initially in the dentate gyrus (Cavazos and Sutula, 1990;Cavazos et al., 1994). 
Furthermore, there are small numbers of cells that die after brief seizures which exhibit 
'apoptotic' DNA fragmentation. 
 
Apoptosis after seizures may involve: extrinsic pathway activation which involves 
caspases 2 and 8; intrinsic pathway activation which relates to mitochondrial calcium  
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loading, cytochrome c release and calpain-mediated release of apoptosis-inducing factor 
(AIF); executioner caspase activation which includes caspase 3, 6 and7 (Henshall and 
Simon, 2005). 
 
More recent evidence suggests that executioner caspases-3 and -6 continue to be active 
during epileptogenesis. Increased caspase 3 expression was observed following SE and 
this was suggested to contribute to cell death occurring within the first week after SE 
(Narkilahti et al., 2003). Further, caspase 6 expression remains elevated up to 4 weeks 
after inducing SE (Narkilahti and Pitkänen, 2005). 
 
Bcl-2 family proteins are crucial for regulating apoptosis. The Bcl-2 family comprises 
pro-apoptotic and anti-apoptotic proteins, involved in the process of stimuli targeted at 
the mitochondrion (Adams and Cory, 1998). BAD, Bcl-2-associated death protein, has 
been shown to dissociate from its sequestered site with the molecular chaperone protein 
14-3-3. After calcineurin-induced dephosphorylation, BAD is released from 14-3-3 and 
dimerizes with the anti-apoptotic protein BCL-Xl and releases BAX (Bcl-2-associated 
X) from BCL-Xl (Yang et al., 1995). Thereafter, BAX translocates to the 
mitochondrion, promoting release of cytochrome c which contributes to the formation 
of the apoptosome, and activation of the caspase cascade (Li et al., 1997;Zou et al., 
1997). A recent study suggests that seizures elicit cell death and survival responses 
within neuronal populations and that the BAD cell death pathway contributes to seizure-
induced neuronal death (Henshall et al., 2002). 
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1.6.4.2 Mitochondrial dysfunction in epileptogenesis 
Mitochondria are important for cellular ATP production, ROS formation, control of 
apoptotic/necrotic cell death and fatty acid metabolism (Patel, 2002). Mitochondrial 
dysfunction can alter neuronal excitability. The inhibition of the mitochondrial 
respiratory chain enzymes, such as cytochrome c oxidase and succinate dehydrogenase, 
evokes seizures. This may be due to an intracellular decrease in ATP levels and 
alterations in neuronal calcium homeostasis (Kunz, 2002). Free radicals may “attack” 
mitochondrial, inhibit the activity of the respiratory chain and induce transient 
mitcohondrial calcium permeability. This results in ATP production decline and 
excessive release of free radicals, consequently causing cell death (Arzimanoglou et al., 
2002).  
 
1.6.5 Nitric oxide 
Nitric oxide (NO) is a free radical oxidant with relevance to pathological conditions in 
the brain, and reactive nitrogen intermediates could damage DNA. NO is an 
endothelium-derived relaxing factor (Palmer et al., 1987), a potent vasodilator that 
regulates cerebral blood flow during certain types of neuronal activation, including 
seizures (de Vasconcelos et al., 1995). 
 
NO is synthesized from L-arginine in CNS by Ca
2+ calmodulin-dependent NO synthase 
(NOS) which is activated by NMDA receptors. There are three isoforms of NOS- the 
constitutive neuronal (nNOS), endothelial (eNOS), and the inducible (iNOS). nNOS and 
eNOS are essential for certain forms of long-term potentiation. Nitrites increase 
markedly in the hippocampus of rats experiencing repetitive seizures (Murashima et al., 
2000). nNOS and iNOS increase in parallel during epileptogenesis. However, eNOS 
decreases during epileptogenesis (Murashima et al., 2000;Murashima et al., 2002).  
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1.6.6 Neural reorganization in epileptogenesis 
It is thought that functional and structural reorganization of neural networks is crucial 
for epileptogenesis. The alteration of neuronal circuits leading to recurrent seizure 
activity may result from reorganisation following neuronal death and changes in 
excitatory and inhibitory transmission. 
 
1.6.6.1 Neurogenesis in epileptigenesis 
Adult neurogenesis is a mechanism by which there is repair of tissues and replacement 
of dead cells. Neurogenesis in the hippocampus has been demonstrated in human with 
TLE and a number of animal models of TLE (Parent et al., 2002;Parent et al., 
2006a;Bengzon et al., 1997).     
 
In human specimens, granule cell somata extend into the molecular layer to varying 
extents, creating an irregular boundary between the lamina, which is related to the 
amount of cell loss in the polymorph layer of the dentate gyrus. The abnormal extension 
of granule cells could lead to changes in both the afferent and efferent connections of 
these neurons and, lead to altered circuitry (Houser, 1990;Scharfman et al., 2000). 
 
In rats with SE induced by pilocarpine, the subventricular zone neuroblast population, 
which is known to express a variety of immature neuronal markers before they enter the 
migratory pathway, expands and alters neuronal precursor migration in the adult rat 
forebrain (Parent et al., 2002). Cauda subventricular zone progenitors, which migrate 
into the corpus callosum to form oligodendrocytes or oligodendrocyte progenitors in 
normal condition, migrate to the injured hippocampus and differentiate into glial cells 
after SE (Parent et al., 2006b).   
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Prolonged seizures induced by administration of pilocarpine or by kindling induce 
aberrant neurogenesis in the adult rat dentate gyrus (Parent et al., 2006a;Parent et al., 
1998). After SE, newly generated neurons migrate from the dentate subgranular zone to 
hilus and molecular layer, and integrate abnormally, leading to abnormal network 
function (Parent et al., 2006a).   
 
The robust alteration in neurogenesis following SE may be due to neurodegeneration. 
Such neurogenesis may result in aberrant circuits, leading to hyperexcitability and an 
increased propensity for the propagation of epileptic activity (Curtis et al., 2007). 
 
1.6.6.2 Growth factors in epileptogenesis 
Growth factors regulate a variety of cellular processes. They bind to receptors on the 
cell surface, activating cellular proliferation and differentiation, contributing to altering 
the function of the hippocampal network.   
 
Growth factors are involved in the development of epilepsy. There is evidence that 
nerve growth factor (NGF) accelerates epileptogenesis in the kindling model and 
increases mossy fibre sprouting in the CA3 region and inner molecular layer (Adams et 
al., 1997). BDNF mRNA was markedly increased in hippocampus and neocortex in 
fully kindled rats (Simonato et al., 1998). In the kindling model, the expression of 
BNDF mRNA was increased in dentate granule cell layers, and was influenced by 
neurotrophin-3 (Elmer et al., 1997). There evidence also shows that synthetic peptides 
designed to prevent neurotrophin binding to their receptors significantly retard kindling 
induced epilepsy and inhibit mossy fibre sprouting (Rashid et al., 1995).   
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Tyrosine kinase B (TrkB), the primary target of BDNF, plays a vital role in 
epileptogenesis. Characteristic neuropathologic changes result from the interaction of 
BDNF with TrkB, such as neuronal loss and axonal sprouting, plastic changes in 
neuronal networks and synapses, neurogenesis, and dendritic outgrowth. Increased 
BDNF causes neuronal hyperexcitability and promotes long-term potentiation of 
excitatory synaptic transmission. Further studies suggest that BDNF is redistributed 
(e.g. to distal dendrites) during the development of epilepsy.   
 
1.6.6.3 Mossy fibre sprouting in epileptogenesis 
Hippocampal mossy fibres, which are the axons of dentate granule cells, converge in the 
dentate hilus and innervate hilar and CA3 neurones (Frotscher et al., 1994). In the 
rodent, the main mossy fibre axons leave the hilus and travel through CA3 in stratum 
lucidum, which corresponds to the apical dendrites of CA3 pyramidal cells (Henze et 
al., 2000). Mossy fibres transmit information from dentate gyrus into the hippocampus 
proper.   
 
Mossy fibre axons form synapses with excitatory and inhibitory cells of the hilus and 
area CA3. There are inhibitory presynaptic G-protein coupled receptors at mossy fibre 
synapses for a number of transmitters, such as GABA, adenosine and dynorphin. The 
release of glutamate and GABA can therefore have a depressant effect on mossy fibre 
synaptic transmission. The mossy fibre pathway predominantly synapses onto inhibitory 
interneurons, rather than excitatory hilar mossy cells and CA3 pyramidal cells. 
 
The presynaptic terminals of mossy fibbers are large, complex and completely surround 
branched dendritic spines with up to 20 independent release sites. The mossy fibre  
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synapses demonstrate strong activity-dependent plasticity, and a presynaptic form of 
LTP, which does not require NMDA receptor activation (Nicoll and Malenka, 1995). A 
CA3 pyramidal neuron receives only approximately fifty synapses from mossy fibres, 
whereas it receives about 12,000 synapses from other CA3 neurons located in the 
ipsilateral and contralateral hippocampus. Mossy fibre synapses are however very 
efficient and are able to bring CA3 pyramidal cells to firing threshold. Therefore, 
stimulating mossy fibres can lead to activation of recurrent excitatory synapses by firing 
of CA3 pyramidal neurons, resulting in epileptiform activity (Johnston et al., 1992). 
 
Mossy fibre sprouting is secondary to synaptic reorganization in the dentate gyrus; 
mossy fibres branch out of the dentate hilus and abnormally innervate the dentate inner 
and outer molecular layer (Dalby and Mody, 2001). Sprouting is seen as a response to 
the loss of neuronal targets. These alterations in TLE have been found in different 
chronic epilepsy animal models, such as kindling models (Bengzon et al., 1997;Sutula 
et al., 1988) and post-status epilepticus models (Elmer et al., 1996;Molnar and Nadler, 
1999). Mossy fibre sprouting is also found in hippocampal tissue TLE patients (Sutula 
et al., 1989;Proper et al., 2000). 
 
What role does mossy fibre sprouting play? Mossy fibres form excitatory recurrent 
circuits through collaterals synapsing onto granule cells and interneuron dendrites in the 
supragranular layer in the dentate gyrus (Proper et al., 2000). Also, mossy fibre spouting 
is found in the infrapyramidal CA3 region and CA1 pyramidal neurons (Holmes and 
Ben-Ari, 2001). Mossy fibre sprouting forms new excitatory connections between 
granule cells and may therefore lead to increased seizure susceptibility in the dentate 
gyrus (Wuarin and Dudek, 1996).    
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Mossy fibre sprouting could also serve a compensatory role. The granule cell mossy 
fibre system produces a strong activation of GABA-ergic hilar neurons. Therefore, 
activating the entorhinal cortical input to the dentate causes the interneuronal population 
to burst and will depress intrahippocampal associational pathways. Indeed, mossy fibre 
sprouting is aimed predominantly at inhibitory basket cells, possibly re-establishing 
normal levels of inhibition to the granule cells (Sloviter, 1992). Thus, it has been 
suggested that mossy fibre sprouting may not be a primary epileptogenic mechanism 
(Harvey and Sloviter, 2005;Timofeeva and Peterson, 1999). 
 
1.7 Interventions to prevent epileptogenesis 
The multiple processes of epileptogenesis provide a number of sites for potential 
interventions to prevent epilepsy. Elucidation of the epileptogenic process should 
provide significantly more effective methods of treatment. The opportunities for 
intervention can be divided into four stages: Initial insult modification, which can be 
achieved by early pharmacological intervention and neuro-surgery, neuroprotection, 
antagonism of epileptogenesis, and disease modification (Stefan et al., 2006). 
Interventions aimed at the epileptogenic cascade may prevent neuronal injury or death, 
preserving or restoring neuronal function, and neuronal recovery or regeneration 
(Walker et al., 2002). Epileptogenesis depends on different processes from those 
involved in seizure generation. Drugs can be designed to inhibit the initial damage 
which is produced by brain insults, such as excitotoxic cell death, and to prevent or 
reverse alterations in neuronal circuits that contribute to lowered seizure thresholds.   
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Figure 1.4: The interventions to modify the epileptogenic process. The multiple 
processes of epileptogenesis provide a number of sites for potential interventions to 
prevent epilepsy: initial insult modification, neuroprotection and disease modification. 
 
 
 
 
 
 
 
1.7.1 Initial insult modification 
Initial insult modifications may have an antiepileptogenic and disease-modifying effect. 
The effect of phenobarbital (80mg/kg), MK-801 (4mg/kg), or phenytoin (100mg/kg) at 
1, 2, and 4 hours after initiation of “continuous” hippocampal stimulation on the 
development of epilepsy has been investigated. Both phenobarbital and MK-801 
reduced the percentage of animals developing epilepsy (Prasad et al., 2002). The 
mechanism may have involved inhibition of the cascade of events that leads to the death 
of critical neuronal populations and cell death-induced reactive gliosis, sprouting, and  
61 
 
other types of damage-induced network reorganization underlying the development of 
spontaneous seizures (Pitkänen, 2002). 
 
1.7.2 Neuroprotection to prevent epileptogenesis 
Neuronal injury and death may play an important role in epileptogenesis. 
Pharmacological neuroprotection in epileptogenesis can be considered as primary and 
secondary. Primary neuroprotection lessens the initial insult by suppressing seizure 
activity or diminishing the associated ionic fluxes. Secondary neuroprotection refers to 
targeting later events in the chain linking ionic changes to altered brain morphology or 
function. AEDs and compounds designed to act on voltage- sensitive Na
+ and Ca
2+ 
channels or on glutamate receptors are considered primary neuroprotection. Secondary 
neuroprotection refers to interventions that act on the cascade leading to necrosis or 
apoptosis (Artemowicz and Sobaniec, 2005). 
 
1.7.2.1 Neuronal survival signalling pathways  
There are several signalling pathways which are involved in neuronal survival, such as 
phosphatidyloinositol-3-kinase (PI3K), extracellular signal regulated kinase 1/2 
(ERK1/2) and extracellular signal regulated kinase 5 (ERK5). The activation of 
neuronal survival signalling pathways to protect neurodegeneration after SE may 
provide novel methods of the prevention of neuronal death and the regulation of 
epileptogenesis. 
 
ERK1/2 is a member of mitogen activated protein kinases. ERK 1/2 can be activated by 
various growth factors and cAMP-signalling pathway (Vossler et al., 1997;Hetman and 
Gozdz, 2004). ERK1/2 contributes to the regulation of proliferation, differentiation,  
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actin cytoskeleton reorganization and cell migration (Wada and Penninger, 2004). The 
targets of ERK1/2 include transcription factors, cytoskeletal proteins, protein kinases 
and Ca
2+ / cAMP response element-binding protein (CREB)/CRE.   
 
It has been suggested that ERK1/2 activation protects against neuronal damage (Hetman 
and Gozdz, 2004;Impey et al., 1999;Xia et al., 1995;Hetman et al., 1999) and generates 
LTP (English and Sweatt, 1997;Impey et al., 1999). Stimulation of the ERK1/2-
signaling pathway promotes neuronal survival. ERK2 phosphorylates pro–caspase-9 at 
the Ser 125 site, which inhibits caspase-9 processing and subsequently prevents 
caspase-3 activation (Allan et al., 2003;Cheung and Slack, 2004). ERK1/2 activity 
increases in neuronal cultures after induction of NMDA-mediated excitotoxicity, 
seizure-like activity, exposure to okadaic acid, or after oxidative stress (Irving and 
Bamford, 2002;Chu et al., 2004), possibly indicating an endogenous neuroprotective 
mechanism following neuronal activity.   
 
ERK activation dramatically decreases mortality during seizures in the pilocarpine 
model of SE (Berkeley et al., 2002) suggesting that a neuroprotective role for ERK1/2. 
However, recent studies suggest that ERK1/2 can also be epileptogenic. Activation of 
ERK1/2 through a tyrosine kinase-dependent process by group I mGluRs is necessary 
for the induction of prolonged epileptiform discharges in the hippocampus (Zhao et al., 
2004). ERK1/2 phosphorylation increases by up to 80% about 20 minutes after 
treatment with 4-AP, which induces epileptiform activity in CA3 region in hippocampus 
slices. Application of the ERK pathway inhibitors U0126 or PD98059 which inhibit 
phosphorylation of ERK1/2 reduce 4AP-induced epileptiform discharges in the CA3 
area (Merlo et al., 2004). Additionally, a constitutively active form of MEK1  
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(caMEK1), resulting in ERK activation, induces spontaneous epileptic seizures, 
possibly due to stimulation of NMDA receptor activity (Nateri et al., 2007).   
 
The complex role of ERK1/2 in SE may be due to its dual roles in neuroprotection and 
neurodegeneration. It has been suggested that ERK1/2 activation can promote neuronal 
death. Inhibiting the activation of ERK1/2 can lead to reduced neuronal injury and loss 
of function in animals (Chu et al., 2004). Inhibition of ERK1/2 activity significantly 
reduced neurological deficits in ischemic brain injury in mice (Wang et al., 2003) and 
led to neuroprotection from brain injury resulting from occlusion of the middle cerebral 
artery (Alessandrini et al., 1999). The mechanism of the opposing roles for ERK1/2, 
prosurvival and cell-death-promoting activity, has been suggested to be through effects 
on glutathione metabolism to limit oxidative stress, and serving as a necessary signal to 
trigger cell death when cellular defence against oxidative stress is exhausted (Luo and 
DeFranco, 2006). 
 
Akt or protein kinase B has three isoform in mammals, termed Akt1, Akt2 and Akt 3. 
All three Akt/PKB isoforms contains an amino terminal pleckstrin homology domain, a 
central kinase domain and a carboxyl-terminal regulatory domain that contains the 
hydrophobic motif. All Akt isoforms possess two regulatory phosphorylation sites, 
Thr308 in the activation loop within the kinase domain and Ser473 in the C-terminal 
regulatory domain. The PH domain of Akt binds to PIP3, produced by activated PI3K; 
this alters its conformation to allow subsequent phosphorylation by the 
phosphoinositide-dependent kinase-1, phosphorylation of Thr308 and phosphorylation 
of Ser473. Akt is thus activated in a PI3-kinase-independent manner. The Akt signalling 
pathway is important for regulating cell survival. Akt promotes cell survival by  
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mediating growth factors both directly and indirectly (Song et al., 2005). Akt (protein 
kinase B) is able to modulate BAD (Bcl-2-associated X protein) activity by 
phosphorylating BAD at the Ser136 residue that is critical for sequestration to 14-3-3 
(Masters et al., 2001). Akt activity is regulated by phosphorylation via 
phosphatidylinositol 3 kinase (Burgering and Coffer, 1995;Datta et al., 1997;Dudek et 
al., 1997). 
 
Recent research indicates that the activation of Akt protects cells in animal models of 
SE. Seizures, induced by microinjection of kainic acid into the amygdale, induced the 
dissociation of BAD from 14-3-3 and the subsequent dimerization of BAD with BCL-
Xl, resulting in cell damage in hippocampus, whereas undamaged cortex exhibited Akt 
phosphorylation. Blocking the activation of Akt exacerbated the damage (Henshall et 
al., 2002). Furthermore, in rats with seizures induced by administration of kainic acid, 
inhibition of Akt activity resulted in an increase in apoptotic cell death (Côté et al., 
2005). 
 
1.7.2.2 Antiepileptic drugs provide neuroprotective effects during epileptogenesis 
Treatment with AEDs during or after brain injury in chronic epilepsy models, such as 
status epilepticus and kindling, can reduce cell loss and neuronal death. Such 
neuroprotection could contribute to modification of or delay in the development of 
epilepsy. Antiepileptic drugs are aimed at preventing and suppressing seizure activity. 
Some may ameliorate necrotic and apoptotic neuronal death. Injection of dizocilpine 
(MK-801) and retigabine after kainate-induced SE prevented neurodegeneration and 
expression of markers of apoptosis in limbic brain regions and significantly reduced the 
damage in limbic regions (Ebert et al., 2002;Brandt et al., 2003a). In the lithium- 
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pilocarpine model, topiramate decreased cell death in CA1 and CA3 in hippocampus 
(Rigoulot et al., 2004). Valproate has a powerful neuroprotective effect in the 
hippocampal formation and the dentate hilus in SE models (Brandt et al., 2006). 
Vigabatrin protected the hippocampus from brain damage efficiently in Ammon's horn, 
and to a lesser extent in the hilus following pilocarpine-induced SE (Andre et al., 2001). 
Carbamazepine reduced damage of the hippocampal formation in pilocarpine-induced 
SE model (Capella and Lemos, 2002). Treatment with atipamezole started 1 week after 
the induction of SE and continued for 9 weeks reduced hilar cell damage and mossy 
fibre sprouting (Pitkänen et al., 2004). The severity of hippocampal cell loss was milder 
after diazepam treatment in amygdala-kindled rats (Pitkänen et al., 2005). 
 
However, it is still questionable whether neuroprotection during or after brain injury 
will be able to prevent the process of epileptogenesis. Indeed, a number of studies have 
concluded that preventing neurodegeneration or neuronal cell loss does not always 
prevent epileptogenesis (Ebert et al., 2002;Rigoulot et al., 2004).   
 
1.8 Antiepileptogenesis   
The definition of an antiepileptogenic compound is one that prevents or modulates the 
process
 of developing epilepsy. Several experimental studies have aimed at preventing 
epileptogenesis
 in animal models, including status epilepticus and kindling models, by 
administering antiepileptic drugs. (Table 1.3) 
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1.9 Valproic acid  
Valproate (VPA, valproic acid), also referred as di-n-propylacetic acid, is an eight-
carbon branched-chain fatty acid with anti-convulsant properties (Figure. 1.5). VPA or 
more usually its sodium salt is widely used to treat epilepsy, bipolar disorders and 
migraine.  
 
 
 
Figure 1.5: The structure of Valproic acid (C8H16O2). Valproic is a short chain fatty acid 
with anti-convulsant properties. 
 
 
VPA, first synthesized by Burton in 1882, was not used clinically for over 80 years. The 
anti-convulsive action was first described by Pierre Eymard in 1962. In 1967, VPA was 
first marketed as ‘‘Depakine’’ in France. There are now more than 100 countries in 
which VPA is used for treating epilepsy, and VPA has established itself as one of the 
foremost antiepileptic drugs, especially for generalized epilepsies. 
 
VPA also exerts powerful neuroprotective effects and prevents part of the behavioural 
alterations in in vivo and in vitro epilepsy models. The effect of VPA on epileptogenesis 
is still controversial. Chronic treatment with VPA after kainate-induced SE (VPA 600 
mg/kg twice daily after kainic acid induced SE and lasted for 40 day, follow by 300 
mg/kg twice daily for 10 days) prevented spontaneous recurrent seizures (during the 
treatment period), deficits in learning in the Morris water maze test, and reduced 
histological lesions in the hippocampus (Bolanos et al., 1998). Administration of VPA  
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(400mg/kg) immediately after SE followed by three times daily administration of 200 
mg/kg for 4 weeks, however did not prevent the later occurrence of spontaneous 
seizures but did prevent locomotor hyperactivity and reduced neuronal damage in the 
hippocampal formation (Brandt et al., 2006). VPA reduced the incidence and intensity 
of convulsions and prolonged the duration of the latency period. However, VPA (100 
mg/kg) did not eliminate epileptiform activity which was induced by metaphit, a 
proposed phencyclidine receptor activator (Stanojlovic' et al., 2007).   
 
In contrast, there is evidence that VPA has a neuroprotective effect in in vivo and in vitro 
models. VPA significantly reduces cell death in hippocampal slices exposed to cytotoxic 
levels of extracellular ATP (Wilot et al., 2007). VPA (0.07–1.4 mM) prevented apoptotic 
morphological and biochemical changes, such as cell shrinkage, mitochondria damage, 
increase of lactate dehydrogenase (LDH) activity, and caspase-3 protein expression, in a 
model of potassium efflux-induced neuronal death in SH-SY5Y human neuroblastoma 
cells (Li and El-Mallahk, 2000). VPA (1-2 mM) promoted survival against low-K
+-
induced apoptosis in primary cultures of cerebellar granule cells (Mora et al., 1999). 
VPA (300 mg/kg immediately after ischemia followed by repeated injections every 12 
hours) also markedly decreased brain infarct volumes and ischemia-induced 
neurological deficit scores following cerebral ischemia and suppressed ischemia-
induced caspase-3 activation (Ren et al., 2004). 
 
1.9.1 Mechanisms of action 
It has been suggested that the acute actions of anti-anticonvulsant effects of VPA 
involve interference with the GABA system and sodium-channels. VPA (30-100 nM) 
increases levels of GABA, and enhances GABAergic inhibition (Balding and Geller,  
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1981). This may result from the inhibition of succinic semialdehyde dehydrogenase (the 
enzyme responsible for degradation of succinic semialdehyde to succinic acid) and 
GABA transaminase (the enzyme which catalyses the degradation of GABA to succinic 
semialdehyde). The inhibition of succinic semialdehyde dehydrogenase increases the 
level of succinic semialdehyde, which inhibits GABA transaminase and so prevents 
GABA catabolism (Johannessen, 2000; Löscher, 1999). VPA also modulates voltage-
gated sodium channels and voltage dependence of sodium current steady-state 
inactivation, resulting in reducing cellular excitability and suppressing high-frequency 
firing of neurons (McLean and Macdonald, 1986;Vreugdenhil and Wadman, 1999;Van 
den Berg et al., 1993). Moreover, chronic treatment with VPA (0.6 mM) up-regulates 
cell surface expression of sodium channels via transcription/translation-dependent 
mechanisms (Yamamoto et al., 1997).   
 
GABA enhancement in brain and in synaptic may only be a secondary action of 
valproate and the Na
+ channel inhibition is controversial; it has been proposed that other 
actions form the primary basis for the antiepileptic activity of valproate (Perucca, 2005). 
Moreover, it is unclear whether these theoretical mechanisms of action contribute to 
VPA’s neuroprotective or antiepileptogenic effect. 
 
1.9.1.2 The action of VPA on cAMP/PKA signalling system 
The effects of VPA on AMPA receptors and other work (see below) indicate that PKA-
cAMP is a major target for VPA. cAMP, a cyclic nucleotide, serves as a second 
messenger which is important for diverse physiological effects via cascades of 
intracellular messengers. The intracellular cAMP level is regulated by the balance 
between the activities of Adenylyl Cyclase and the cyclic nucleotide Phosphodiesterase.  
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VPA inhibits forskolin-stimulated cAMP accumulation in intact cells in a concentration-
dependent manner. The valproate (1 mM and 2mM) induced inhibition of cAMP 
accumulation was partially reversed by the phosphodiesterase (PDE) inhibitor 
isobutylmethyl xanthine (IBMX). This result suggested that the inhibition of forskolin-
stimulated cAMP accumulation by VPA was not a direct effect by inhibition of adenylyl 
cyclase activity, but an effect on cAMP metabolism (Gallagher et al., 2004). Other 
studies have demonstrated that prolonged exposure of C6 glioma to VPA (0.5 mM) 
influenced multiple components of the beta-adrenergic receptor-coupled cyclic 
adenosine monophosphate (cAMP) generating system, including receptor complement, 
cAMP production, 3H forskolin binding sites, and G protein activation. Chronic 
treatment with VPA (0.5 mM) significantly attenuated receptor- and postreceptor-
stimulated cAMP production. The basal levels of cAMP in cells were reduced by 
approximately 20% in intact cells and by 35% in cell membranes after prolong 
incubation in VPA. Also, chronic VPA incubation decreased forskolin- stimulated cAMP 
production in intact cells by 60% (Chen et al., 1996). This result is supported by further 
studies. Cortical neurons treated with VPA had decreased cAMP level induced by 
stimulation of adenylyl cyclase with forskolin and stimulation of β-adrenergic receptors 
which are linked to activation of adenylyl cyclase with isoproterenol compared to 
control neurons. An in vivo study, using microdialysis to measure extracellular levels of 
cAMP in the prefrontal cortex of freely moving animals, demonstrated that forskolin-
induced cAMP rises were significantly attenuated by VPA treatment. Furthermore, 
chronic administration of VPA (0.5 mM) decreased the density of β-adrenoreceptors 
which was reflected by a decrease in isopreterenol-evoked, receptor-mediated cAMP 
production in the rat prefrontal cortex (Montezinho et al., 2006;Montezinho et al., 
2007).   
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1.9.1.3 VPA’s effect on PKA-cAMP can also influence the extracellular signal-
regulated kinase (ERK) pathway.   
Treatment with VPA not only activates ERK pathway, but also increases BDNF in rat 
hippocampus. Treatments with VPA (400 mg/dg/day) increase the DNA binding activity 
of transcription factor polyomavirus enhancer-binding protein (PEBP) and robustly 
increased the levels of bcl-2 which is transcriptionally regulated by PEBP2 in frontal 
cortex (Chen et al., 1999). In addition, treatment with VPA (20 gm/kg containing rodent 
chow for 9 days or 28 days) increases the activation of phospho-ERK44/42. 
Phosphorylation of ERK44 at Thr202/Tyr204 and ERK42 at Thr183/Tyr185 by 
MAP/ERK kinase (MEK) corresponds to ERK activation. VPA also increases the level 
of activation of phospho-ribosomal protein S6 kinase-1 (RSK1) which is activated by 
phosphorylation of phospho-ERKs. Phospho-RSKs phosphorylate Bcl-2 antagonist of 
cell death (BAD) at Ser112, and cAMP response element-binding protein (CREB) at Ser 
133, increasing CREB transcriptional activity (Einat et al., 2003). 
 
It has been shown that VPA enhances cellular functions induced by ERK activation, 
such as neurogenesis, neurite growth and neuronal survival. VPA (20 gm/kg containing 
rodent chow) enhances ERK pathway-dependent cortical neuronal growth and promotes 
neural stem cell proliferation-maturation (neurogenesis), and hugely increased the 
number of BrdU-positive cells in the dentate gyrus (Hao et al., 2004). Using a 
biomedical model system Dictyostelium discoideum, VPA caused a transient increase in 
the activation of the MAPK signalling pathway, as shown by ERK2 phosphorylation. In 
Dictyostelium, the enhancement of intracellular cAMP by binding to cAR1 modulates 
ERK2 phosphorylation. Activation of PKA via stimulation by cAMP reduced ERK2 
phosphorylation. PKA blocks upstream (MEKK)-dependent ERK2 phosphorylation. 
Increased pERK2 levels are also present following VPA (1mM) treatment, suggesting a  
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role for VPA in the up-regulation of MEKK activity through the inhibition of the PKA 
signalling pathway. Therefore, it has been suggested that the rise in pERK2 level result 
from VPA attenuation of cAMP-dependent signalling (Figure 1.6) (Boeckeler et al., 
2006). Other evidence showed that VPA (1mM)-induced activation of ERK was blocked 
by the mitogen-activated protein kinase/ERK kinase inhibitor PD098059. VPA 
increased the expression of genes regulated by the ERK pathway, such as growth cone-
associated protein 43 and Bcl-2, promoted neurite growth and cell survival, and 
enhanced norepinephrine uptake and release (Yuan et al., 2001). 
 
1.9.1.4 VPA’s effect on PKA-cAMP can also influence the AMPA receptor 
There is also evidence that VPA can interfere with AMPA receptor trafficking. 
Modification of the levels of synaptic AMPA receptors by receptor subunit trafficking, 
insertion, and internalization, is important for regulating postsynaptic responses, 
learning, and various forms of neural and behavioural plasticity (Malinow and Malenka, 
2002;Rumpel et al., 2005;Hayashi et al., 2000;Jeon et al., 2006). 
 
AMPA receptor subunit GluR1 trafficking is regulated by protein kinase A (PKA), 
Ca
2+/calmodulin-dependent protein kinase II (CaMKII), and protein kinase C (PKC) via 
phosphorylation of specific sites on GluR1 (Lee et al., 1998;Malinow and Malenka, 
2002;Esteban et al., 2003;Blackstone et al., 1994;Roche et al., 1996;Mammen et al., 
1997;Glade-McCulloh et al., 1993). Phosphorylation of the receptor subunits regulation 
is important for intrinsic channel properties of the receptor and the interaction of the 
receptor with associated proteins, modulating the membrane trafficking and synaptic 
targeting of the receptors (Malinow and Malenka, 2002).   
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Chronic treatment with VPA (1mM) reduced surface expression of GluR1 and GluR2. 
Phosphorylation of GluR1 at the PKA (cAMP-dependent protein kinase) site (s845) 
which is critical for AMPA receptor insertion is reduced in VPA-treated neurons. In 
addition, GluR1 phosphorylation was attenuated in hippocampus VPA-treated animals 
in vivo. These results suggest that VPA down-regulates GluR1/2 by inhibiting 
phosphorylation of GluR1 at its PKA site as a drug-specific "chronic mechanism".   
(Vandenberghe et al., 2005;Du et al., 2008;Du et al., 2006;Du et al., 2004).   
 
1.9.2 The side effect of VPA 
Even though, VPA is widely used in clinical as treatment in epilepsy (complex partial 
and absence seizures) schizoaffective disorders (Puzyn'ski and Kłosiewicz, 1984), 
mania (Freeman et al., 1992) and migraine prophylaxis (Yurekli et al., 2008), using VPA 
has potentially serious side effects. VPA is a potent teratogen that most notably induces 
neural tube defects (NTDs) in human, mouse, and other vertebrate embryos. Exposure 
of the human embryo to VPA is also associated with risk of autism which is a brain 
development disorder characterized by impaired social interaction and communication, 
and by restricted and repetitive behaviour (Arndt et al., 2005) and at risk for 
significantly lower IQs (Meador et al., 2009). The other serious side effect of VPA 
therapy is hepatotoxicity (Powell-Jackson et al., 1984) and blood dyscrasia resulting in 
thrombocytopenia, and prolonged coagulation times. VPA may also cause acute 
hematological toxicities, especially in children, including rare reports of myelodysplasia 
and acute leukemia-like syndrome (Williams et al., 2008;Coyle et al., 2005). Long-term 
treatment with VPA cause cognitive and motor dysfunction, for example Parkinsonian 
symptoms (Armon et al., 1996), and even pseudoatrophic brain changes which is 
reversible shrinkage of the brain (McLachlan, 1987)  
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1. 10 Summary 
VPA exerts a powerful neuroprotective effect in a variety of animal models including in 
vivo status epilepticus models (Bolanos et al., 1998;Brandt et al., 2003).One mechanism 
underlying VPA’s neuroprotective effect has been suggested to be attenuation of protein 
kinase A (PKA) activity, which results in an increase in an increase in the activated 
(phosphorylated) form of ERK2 (Boeckeler et al., 2006). It is, however, unclear whether 
VPA directly affects Protein kinase A or indirectly by inhibiting the formation (or 
increasing the breakdown) of cyclic adenosine monophosphate (cAMP) (Chen et al., 
1996;Gallagher et al., 2004). In support of this, an in vivo microdialysis study 
demonstrated that increases in cAMP levels in the prefrontal cortex of freely moving 
animals induced by an infusion of the adenylyl cyclase activator forskolin were 
attenuated by treatment with VPA (Montezinho et al., 2006;Montezinho et al., 2007)   
 
Modulation of the cAMP-PKA pathway by VPA has other implications. VPA’s 
antimanic effect has been suggested to be secondary to attenuation of the surface and 
synaptic expression of AMPA receptors through a decrease in AMPA receptor subunit 
GluR1 phosphorylation at a specific PKA site (Du et al., 2004). Moreover, the cAMP-
PKA pathway is critical for the expression of NMDA receptor-independent long term 
potentiation (LTP) at the mossy fibre to CA3 pyramidal cell synapse in the hippocampus 
(Huang et al., 1994;Weisskopf et al., 1994;Nicoll and Malenka, 1995), and has been 
suggested to be involved in Schaffer collateral-CA1 LTP. Therefore inhibition of this 
pathway could impact upon LTP at these synapses. Moreover this pathway has also been 
proposed to play an important role in hyperexcitability and epileptogenesis. PKA 
activity increases in the neocortex and hippocampus of rats during epileptogenesis 
(Yechikhov et al., 2001). Activation of the cAMP-PKA pathway increases excitability 
and enhances epileptiform activity in rat hippocampal slices and human dentate gyrus  
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cells (Boulton et al., 1993;Higashima et al., 2002;Chen and Roper, 2003), and, in vivo, 
results in a potentiation of epileptic activity and status epilepticus (Üre and Altrup, 
2006). Therefore, the question was asked whether VPA through an action on PKA 
activity can modify synaptic plasticity and whether such a mechanism of action can 
explain its antiepileptic effect.   
 
Although VPA is used extensively for treating various kinds of epilepsy, the use of VPA 
is, however, limited by severe adverse effects. Its efficacy in epilepsy treatment and 
serious side effects associated with its therapy, provide an excellent incentive for 
developing a second-generation VPA which would possess broad-spectrum antiepileptic 
activity, better potency than VPA, and would lack side effects such as the teratogenicity 
and hepatotoxicity. 4-Methyloctanoic acid is, similar to valproate, a branch chain fatty 
acid, but in contrast to valproate it lacks any teratrogenic effect in animal models 
(Ambroso et al., 1999;Narotsky et al., 1994) and has a long safety histroy as a 
flavouring in foods. We therefore tested this compound in in vitro and in vivo animal 
models. If it is in efffective, the plan was to test further similarly structurered 
compounds. 
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Figure 1.6: VPA regulates the mitogen-activated protein kinase pathway which may be 
through modulation of cAMP/PKA signalling. Activation of PKA via increase of cAMP 
leads to inhibit the activation of ERK1/2 which contributes to neuroprotective effect. 
VPA, however, increase the activities form pERK 1/2, and this may be through the 
inhibition the activity of PKA. 
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1.11 Aims 
1.  To test the effect of VPA on PKA dependent long-term potentiation at the mossy     
    fibre  to  CA3  synapse.  
 
2.  To test whether VPA has a direct effect on PKA activity or an indirect effect       
    through  cAMP  modulation. 
 
3.  To test whether the effect of VPA on PKA/cAMP signalling system can explain the   
    anticonvulsant  effect  of  VPA. 
 
4.  To test whether the effect of VPA differs between epileptic and non-epileptic   
    a n i m a l s .   
 
5.  To determine whether a VPA analogue that has less teratogenic effect has a similar   
    physiological  and  anticonvulsant  profile  to  VPA 
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Chapter 2: General materials and methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
79 
 
2.1 Introduction 
In this thesis, various epilepsy models were used. The choice of the appropriate model, 
either in vitro model or in vivo model, depends on the question being asked. Using in 
vitro models allows greater control of the physiological environment, drug 
concentrations, and minimizes contamination by other drug such as anesthetic drugs 
that are necessary in an anesthetized in vivo preparation. Further, it is possible to 
selectively block specific pathways in a controlled fashion, enabling a better dissection 
of mechanisms of action. In vitro models are designed to generate fast, initial and 
reproducible data that will give general insight as to the action of drug that may be 
expected in in vivo. However, in vitro models lack the complexity of the in vivo models 
and by definition can only reproduce epileptiform activity not seizures (which are 
clinically discernible events). Acute in vivo seizure models have provided the evidence 
of efficacy for most of our presently used antiepileptic drugs (White, 1997). Using in 
vivo animal models allow for studying the progress of disease and collecting more 
clinically relevant data that is able to provide greater insight into the human disease. 
Acute models, are advantageous in that it is possible to induce a seizure and so know 
when the seizure will occur (this is of benefit when testing drug effects). However, it 
does not reproduce faithfully the human condition in which spontaneous seizures occur; 
for this chronic epilepsy models are required. For chronic models of epilepsy with 
pathological findings similar to human such as neuronal loss, glial activation and gliosis 
in epileptic tissue, and mossy fiber sprouting, it is useful to study the development of 
epilepsy from the initial insult to the brain to the occurrence of spontaneous seizures. 
(Löscher, 2002;Cole and Dichter, 2002). In addition, chronic epilepsy animal models 
are useful for identifying and characterizing the cellular and molecular mechanisms of 
the progressive consequences of epilepsy, which may present targets for therapeutic 
interventions (Cole and Dichter, 2002).  
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2.2 In vivo experiments 
2.2.1 Animals 
Male Sprague–Dawley rats, weighing between 250 g to 330 g, were used. Rats were 
kept under controlled environmental conditions (24–25 °C; 50–60% humidity; 12 h 
light/dark cycle) with free access to food and tap water. All experiments followed the 
Home Office regulations under the Animal (Scientific Procedures) Act, 1986. 
 
2.2.2 Anesthesia   
Male Sprague–Dawley rats were placed in a plastic chamber with 4% isoflurance in O2 
(isoflurance was purchased from Merial Animal Health Ltd. Harlow, Essex, UK). The 
rats were moved from the chamber to the stereotaxic frame (David Kopf stereotaxic 
frame) after a surgical plane of anaesthesia was achieved, which was determined by lack 
of movement and withdrawal to foot or tail pinch. The plane of anaesthesia was 
maintained with 2% isoflurance in O2 (at a flow rate of 2 litres /minutes) during surgery. 
 
2.2.3 Use of stereotaxic frame for rats 
Once anaesthetised, the hair on the rat’s head was clipped and the rats were then moved 
to a stereotaxic frame. The rat’s incisors were placed over a tooth bar and the non-
traumatic ear bars were placed such that the head was fixed and did not move with 
gentle downwards pressure. The height of the tooth bar was then adjusted so that the top 
of the skull was horizontal.   
 
2.2.4 The electrical stimulation model 
2.2.4.4 Electrode preparation 
The recording electrodes were prepared from intracranial Electrode (25 mm, Plastics 
One E363/1) by stripping the end insulation for < 0.5 mm using scalpel blade.    
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The stimulation electrodes were constructed by twisting 2 intracranial Electrode (25 mm, 
Plastics One E363/2). The 2 stainless wires were separated vertically by 0.5 mm. and 
the insulation was removed at the electrode tips by using a scalpel blade. 
 
A silver wire (about 4 cm), soldered to a female socket contact (Plastics One E363/0) 
was used as reference and earth electrode. 
 
2.2.4.2  Electrode  implantation                                                       
Three scull screws (plastics one) were placed in scull before implantation in order to 
anchor the headset, two anterior to bregma and one posterior to bregma (Figure 2.1). 
The skull screws were also used for securing the silver wire served as earth electrode 
which was wound around skull screws for approximately 2 cm, and was placed 
subcutaneously. The earth was additionally used as the indifferent reference electrode. 
 
The recording electrode was stereotaxically implanted into the dentate gyrus 
(coordinates: lateral 2.5 mm from midline, antero-posterior -4 mm from bregma, dorso-
ventral -3 mm from brain surface). Bipolar stimulation electrodes were implanted in the 
perforant pathway (coordinates: lateral 4.4 mm from midline, antero-posterior -8.1 mm 
from bregma, dorso-ventral -4 mm from brain surface) (Figure 2.1). These stereotaxic 
coordinates relative to bregma were based on the atlas of Paxinos and Watson (1998).   
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Figure 2.1: Schematic diagram of the skull with position of recording electrode, 
stimulation electrode and anchor screws. The recording electrode (blue) was 
stereotaxically implanted into the dentate gyrus (coordinates: lateral 2.5 mm from 
midline, antero-posterior -4 mm from bregma, dorso-ventral -3 mm from brain surface). 
Bipolar stimulation electrodes (Green) were implanted in the perforant pathway 
(coordinates: lateral 4.4 mm from midline, antero-posterior -8.1 mm from bregma, 
dorso-ventral -4 mm from brain surface). The three scull screws ( ) were placed in 
scull before implantation in order to anchor the headset, two anterior to bregma (red) 
and one posterior to bregma. 
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Test stimulations were delivered every 10 second with 4-5 mV, 50 μs monopolar pulses 
via a Neurolog stimulator. The depth of electrodes was adjusted to find the maximal 
population spike amplitude of the field potential (in the range 5-10mV)     
 
 
Figure 2.2: Stimulation of the perforant pathway. (A) The bipolar stimulation was place 
in perforant pathway and the recording electrode was placed into the dentate gyrus. (B) 
The population spike in DG was elicited by stimulation in perforant pathway.   
 
 
 
Once electrode positions were optimized, the entire headset was fixed and anchored 
using dental acrylic cement (Kemdent, Swindon, UK). The animals were allowed to 
recover for a period of 7 days after surgery  
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2.2.4.3 Electrical induction of self-sustained  status  epilepticus  (SSSE)                      
Seven days after electrode implantation, the rats were electrically stimulated via the 
perforant pathway with 4-5 mA, 50 μs monopolar pluses at 20 Hz for 2 hours to induce 
SSSE (figure 2.3). For the stimulation, the trains was generated by a pulse generator 
(NL310, Digitimer, Herts) and delivered via stimulus isolator (NL800 Digitimer; Herts). 
During the experiment, the EEG was recorded during stimulation and for up to 3 hours 
afterwards, using a neurolog system (Digitimer; Herts), consisting of a NL101 
headstage connected to a NL104 amplifier and a NL125 filter unit (for settings see 
figure 2.4), the signal was digitalized using CED micro1410 (Cambridge Electronic 
design, UK) and stored using “Spike 2”. The electrophysiological data were saved on a 
laptop computer for post-hoc analysis.   
 
 
 
 
 
Figure 2.3: Summary of the procedure - electrical induction of self-sustained status 
epilepticus. Rats were electrically stimulated via the perforant pathway with 4-5 mA, 50 
μs monopolar pluses at 20 Hz for 2 hours to induce self-sustained-status epilepticus 
(SSSE) seven days after electrode implantation. Three hours after the induction of the 
SSSE, the rats were given diazepam (10 mg/kg) by intraperitoneal injection to terminate 
the seizure activity. Two months after induction of status epilepticus in rat, the brain was 
moved and the histopathological examination was performed  
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Figure 2.4: Summary of the settings for electrical induction of self-sustained status 
epilepticus. During experiment, the stimulation was generated by a pulse generator 
(NL310, Digitimer, Herts) and delivered via stimulus isolator (NL800 Digitimer; Herts). 
The electroencephalography (EEG) was recorded using a neurolog system (Digitimer; 
Herts). The signal was digitalized using CED micro1410 (Cambridge Electronic design, 
UK) and stored using “Spike 2”. The electrophysiological data were saved on a laptop 
computer. 
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Behavioural seizures were monitored every 10 minutes and classified using the Racine 
scale (Racine, 1972) (Table 2.1) 
 
Table 2.1: Behavioural rating of induction of a self-sustained status epilepticus based 
on Racine scale (1972) 
stage 1  Mouth and facial movements 
stage 2  Head nodding and more serve facial and mouth movements (jaw-opening)
stage 3  Forelimb clonus 
stage 4  Rearing and bilateral forelimb clonuses 
stage 5  Rearing and falling, with loss of postural control, full motor seizure. 
 
 
Three hours after the induction of the SSSE, the rats were given diazepam (10 mg/kg) 
(Hameln Pharmaceuticals Ltd. Gloucester, UK) by intraperitoneal injection to terminate 
the seizure activity. If necessary, this dose of diazepam was repeated until motor and 
EEG seizure activity ceased in all rats. Rats developed SSSE after stimulating perforant 
pathway. Two months after induction of status epilepticus in rats, the brain was moved 
and was analysed histologically, in order to verify the location of the recording and 
stimulation electrodes, and to perform histopathological examination for the effect of 
drugs (VPA and 4-methyloctanoic acid) on neurodegeneration caused by status 
epilepticus.     
 
2.2.5 Pilocarpine model 
Sustained seizures were induced in experimental animals by the administration of 
pilocarpine (320 mg/kg, ip) (Sigma), a muscarinic cholinergic agonist. Twenty minutes 
before and after pilocarpine administration, animals were injected with a low dose of  
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the cholinergic antagonist Scopolamine methyl nitrate (1 mg/kg, ip) (Sigma) to reduce 
peripheral muscarinic effect and lower mortality rate. Diazepam (10 mg/kg, ip) was 
administered to the animals 90 minutes after the administration of pilocarpine to 
terminate behavioural seizures. 
 
After the pilocarpine injection, all animals were assessed for severity of behavioural 
seizures. Excessive salvation and seizures were classified based on Racine scale (see 
Table 2.1). Only the occurrence of behavioural seizures reaching at least Racine stage 3 
was considered as successful induction of SE. After SE, all animals were injected with 
1-2 ml normal saline subcutaneously and given rodent food soaked with water for 24 
hours. The animals experienced SE were kept for two weeks, prior to in vitro 
electrophysiological experiments (Figure 2.5). 
 
Figure: 2.5: Summary of the procedure of the pilocarpine model. Application of 
pilocarpine (320 mg/kg) induces sustained seizures in experimental animals. Twenty 
minutes before and after pilocarpine administration, animals were injected with 
scopolamine methyl nitrate (1 mg/kg) to reduce peripheral muscarinic effect and lower 
mortality rate. Diazepam (10 mg/kg) was administered to the animals 90 minutes after 
the administration of pilocarpine to terminate behavioural seizures. The in vitro 
electrophysiological experiment was carried out 2 weeks after induction of status 
epilepticus.  
  
88 
 
2.2.6 Brain Histology 
2.2.6.1 Brain fixation 
Rats were killed with an overdose pentobarbital sodium (500mg/kg, ip) (Fort dodge 
Animal Health, Southampton, UK). After injection, the skull was opened and the brain 
removed by severing it from the upper cervical cord. The brain was immediately 
immersed in 4% paraformaldehyde (Sigma) in 0.1 M phosphate buffer (pH 7.4) (Sigma) 
for over 24 hours, prior to transfer to phosphate buffer solution with 30% sucrose in 0.1 
M phosphate buffer (pH 7.4) as a post-fixation solution.   
 
2.2.6.2 Sliced preparation: 
Brain sections (40-μm thick thickness) were cut using a vibroslicer (Leica VT 1000S 
Microsystems, Wetzlar, Germany). The far rostral and caudal regions of brain were 
removed. The caudal side was glued on to the centre of the rotating specimen holder 
(figure 2.7). An agar block (4% or 7% agar, Sigma) was glued adjacent to the brain, to 
support the brain tissue during slicing. The brain and holder were transferred to a tray 
filled with phosphate buffer. A slow speed and high frequency (0.12 mm/s and 90 Hz, 
respectively) for the blade were used to obtain brain slices. Tissue sections were 
carefully transferred to a tray filled with phosphate buffer. They were further transferred 
onto microscope slides (SuperForst®Plus, VWR international).   
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Figure 2.6: The preparation of brain slices. Whole brain was glued to the centre of the 
rotating specimen holder. An agar block is fixed adjacent to the brain to support for the 
tissue during slicing. 
 
 
 
 
2.2.6.3 Nissl stain 
Nissl stain was use for checking the position of electrodes and examining the degree of 
neurodegeneration after inducing status epilepticus by electrical stimulation. First, 
sections were hydrated in xylene, 100% alcohol, and 95% alcohol, 70% alcohol and 
rinsed in water. The sections then were stained in warmed cresyl violet solution (37-50 
ºC) in order to improve penetration and enhance even staining. These were rinsed 
quickly in distilled water. The sections were dehydrated in 70 % alcohol, 95% alcohol, 
and 100% alcohol and washed with xylene. Finally, they were mounted with permanent 
mounting medium (DPX mountant, VWR International) (procedure see table 2.2). Nissl 
stain stains nuclei blue and the nissl bodies violet; the background is colourless under 
microscope (Alcohol was purchased from Merck, Xylene was purchased from VWR 
internal, and Cresyl violet was purchased from Sigma).     
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Table 2.2: Procedure for nissl stains 
procedure  Time (minutes) 
Xylene 5 
Xylene 5 
100% alcohol  5 
100% alcohol  5 
95% alcohol  5 
95% alcohol  5 
70% alcohol  5 
Water Drip 
Cresyl violet solution  15-30 
Water 3-5 
70% alcohol  3-5 
95% alcohol  3-5 
100% alcohol  3-5 
100% alcohol  3-5 
Xylene 5 
Xylene 5 
DPX moountant  mounted 
 
 
2.3 In Vitro experiments 
2.3.1 Slice preparation 
2.3.1.1 Procedure 
1. Brain preparation 
Rats were decapitated after killing by intraperitoneal injection with an overdose of 
pentobarbitone (500 mg/kg). The whole brain was removed immediately after the skull 
was opened, and placed in oxygenated ice-cold sucrose solution (NaCl 87 mM, KCl 2.5 
mM, MgCl2 7 mM, CaCl2 0.5 mM, NaH2PO4 1.25 mM, sucrose 75mM and glucose 3 
mM) (All compounds required for ice-cold sucrose solution were purchased from 
Sigma). 
 
2. Separating the brain/hippocampus:     
Isolated-hippocampus preparation: Isolated-hippocampus preparation: The 
cerebellum and hindbrain were removed from the whole brain. The cortex was then  
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separated from the hippocampi. The hippocampi were each straightened and placed 
length-wise into grooves of a previously prepared agar block. The agar block with two 
hippocampi was glued to the centre of the rotating specimen holder (As figure 2.8). This 
was then rapidly transferred into the buffer tray filled with oxygenated ice-cold sucrose 
solution (In mM: NaCl 87, KCl 2.5, MgCl2 7, CaCl2 0.5, NaH2PO4 1.25, sucrose 75, 
glucose 3). 
 
hippocampus
agar
 
            
 
 
Figure 2.7: The preparation of isolated-hippocampus. The cortex was separated from 
the hippocampi after cerebellum and hindbrain were removed from the whole brain. The 
hippocampi were each straightened and placed length-wise into grooves of agar block. 
The agar block with two hippocampi was glued to the centre of the rotating specimen 
holder. 
 
 
Combined horizontal entorhinal cortex-hippocampus slices: For this preparation, the 
whole brain was sectioned as in figure 2.9 and glued to the centre of the rotating 
specimen holder. An agar block (4% or 7%) is fixed adjacent to the brain. This provided 
support for the tissue during slicing.      
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Figure 2.8: The preparation of combined horizontal entorhinal cortex-hippocampus 
slices. Whole brain was sectioned in order to remove cerebellum and hindbrain and 
glued to the centre of the rotating specimen holder. An agar block is fixed adjacent to 
the brain to support the tissue during slicing. 
 
 
 
3. Slicing 
During slicing, a slow speed and high frequency was used. The frequency was set 
between 0.12 to 0.16 mm/sec speed and the frequency of blade oscillation from 60 to 90 
Hz. 350-400 μm slices were cut depending on experiment. Cut slices were transferred to 
a Petri dish filled with oxygenated ice-cold sucrose solution. 
 
4. Storage hippocampal slices 
Slices, then, were collected and placed in an interface chamber contained aCSF (In mM: 
NaCl 119, KCl 2.5, MgSO4 1.3, CaCl2 5, NaH2PO4 1, glucose 16.6) (All compounds 
required for aCSF were purchased from Sigma) over one hour before transfer to 
submersion recording chamber (Figure 2.10). The aCSF solution was gassed with 95% 
O2 mixed with 5% CO2.   
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Figure 2.9: The illustration of types of chamber used in in vitro experiment. (A) The 
interface chamber was used for storage hippocampus slices. (B) The submersion 
recording chamber was used during recording.       
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2.3.1.2 Electrophysiology 
Extracellular recordings give information about the synchronous activity of a population 
of neurons (field potentials) which reveal the activity of many neurons at the same time 
(Suter et al., 1999). The typical field excitatory postsynaptic potentials (fEPSPs) 
waveform includes stimulus artifact, fibre volley which represents the action potentials 
firing in presynaptic fibres and the summation of post-synaptic potentials (Figure 2.10) 
 
Field excitatory postsynaptic potentials (fEPSPs) were recorded with an axonpatch-1D 
amplifier connected to a Hum Bug Eliminator (Digitimer), which effectively eliminates 
50/60Hz noise and harmonics without altering the frequency characteristics of the input 
signal. The output was connected via a National Instruments A/D board to a computer 
running Labview software and stored for offline analysis. For stimulation I used a 
Digitimer constant current isolated stimulator (model DS3) connected to the National 
Instrument board output. (For settings see Figure 2.11). 
  
To record fEPSPs, a hippocampal slice was placed into a submersion recording chamber 
(Figure 2.10). The slice was gently immobilised by a platinum wire with attached nylon 
thread. Fresh carbogenated aCSF was perfused through the submersion recording 
chamber at > 2ml/min. 
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Figure 2.10: Illustration of typical field excitatory postsynaptic potentials (fEPSPs) 
recorded in mossy fiber synapse into CA3 region. The waveform includes stimulus 
artifact, fibre volley which represents the action potentials firing in presynaptic fibres 
and fEPSP 
 
 
  
96 
 
Isolated 
Stimulator Patch clamp 
(axon instructions)
mode I=0
gain 100
-3dB freq=500
National instrument
Stimulation 
electrode Recorder
C
o
m
p
u
t
e
r
Microscope
submersion recording chamber
Hum bug
 
Figure 2.11: The settings for electrophysiological experiment. To record Field excitatory 
postsynaptic potentials (fEPSPs), a hippocampal slice was placed into a submersion 
recording chamber. fEPSPs were recorded with an axonpatch-1D amplifier connected to 
a Hum Bug Eliminator (Digitimer). The output was connected via a National 
Instruments A/D board to a computer running Labview software and stored for offline 
analysis. Digitimer constant current isolated stimulator (model DS3) which is 
connected to the National Instrument board was used to deliverer stimulation.  
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2.4 PKA assay method 
This assay is designed to measure the phosphotransferase activity of PKA (cAMP-
dependent Protein Kinase) by phosphorylation of a specific substrate (kemptide) using 
the transfer of the γ-phosphate of adenosine-5'-[
32P] triphosphate ([γ-
32P]  ATP).   
 
 
 
The phosphorylated substrate is separated from the residual [γ-
32P] ATP using P81 
phosphocellulose paper and quantitated by using a scintillation counter. 
Phosphocellulose paper is able to bind phosphorylate and phosphorylated peptide 
quantitatively, whereas untreated [γ-
32P] ATP and free [
32] P phosphate are washed away 
by dilute phosphoric acid. 
 
In brief, the assay solution consisted of 20 mM 3-(N-morpholino) propanesulfonic acid 
(MOPS), pH 7.2, 25 mM β-glycerophosphate, 5 mM ethylene glycol tetraacetic acid 
(EGTA), 1 mM sodium orthovanadate and 1 mM dithiothreitol, cAMP, Kemptide (Leu-
Arg-Arg-Ala-Ser-Leu-Gly), ATP-mix (1 part of gamma -
32P ATP with 9 parts of cold 
ATP) and Bovine heart PKA (The PKA analysis kit, including emptide, cAMP, 
PKC/CaMK inhibitor cocktail, PKA inhibitor Peptide, assay dilution buffer, 
magnesium/ATP cocktail, and P81 phosphocellulose paper, was purchased from Upstate, 
Millipore; gamma-
 32P ATP was purchased from PerkinElmer). 
 
The whole experiment is divided into seven different groups with different treatments. 1)  
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The enzyme background, calculated from parallel reactions which did not contain 
kemptide, was subtracted from all groups. 2) The control group. 3) The PKA inhibition 
group, PKA inhibitor peptide was added to the assay solution. This acted as a positive 
control group. 4) The four treatment groups with different concentrations of VPA (VPA 
50 μM, VPA 100 μM, VPA 500 μM, and 1000 μM). The VPA pre-prepared from 1 M 
stock solution. During the experiment, the VPA was diluted to desired concentrations 
using assay dilution buffer.   
 
Reactions were carried out at 30 °C for 10 min (water bath). Aliquots were spotted onto 
P-81 phosphocellulose square paper and the radio labelled substrate was allowed to bind 
to P-81 paper for 30 seconds. The papers were washed in 0.75 % H3PO4 three times in a 
beaker with a stirrer under a small sieve. The papers were rinsed in acetone. The assay 
squares were transferred to a scintillation vial (PerkinElmer) and 2ml scintillation 
cocktail (PerkinElmer), which is a solution of a beta particle emitter. This is then 
analysed in an organic solvent along with a fluor emitting a scintillation of light, which 
was read by a scintillation counter (Beckman Coulter, LA6500) (Figure 2.12).   
 
The data were calculated as the percentage of PKA activity. Enzyme background data 
were subtracted from the raw CPM data and all the data were normalised by dividing by 
the data from control treatment. 
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Figure 2.12: The protocol of measurement the PKA activity. Reactions were carried out 
at 30 °C for 10 min (water bath). Aliquots were spotted onto P-81 phosphocellulose 
square paper and the radio labelled substrate was allowed to bind to P-81 paper for 30 
seconds. The papers were washed in 0.75 % H3PO4 three times in a beaker with a 
stirrer under a small sieve. The papers were rinsed in acetone. The assay squares were 
transferred to a scintillation vial and 2ml scintillation cocktail, which is a solution of a 
beta particle emitter. This is then analysed in an organic solvent along with a fluor 
emitting a scintillation of light, which was read by a scintillation counter.     
 
 
2.5 cAMP Assays 
This assay principle is based on enzyme fragment complementation (EFC). This assay 
takes advantage of a genetically engineered E. coli β-galactosidase (β-gal) enzyme. The 
β-gal enzyme consists of two fragments, a large protein fragment as an enzyme acceptor 
(EA) and a small peptide fragment as an enzyme donor (ED). The enzyme lacks activity 
when the two fragments are separated. In the working solution, the two fragments tend 
to recombine spontaneously by a complementation process to form active enzyme.  
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Once the β-gal recombines, it hydrolyzes luminescent or fluorescent substrates and 
produces a signal.     
 
The ED fragment is not only able to reassociate with EA to form active enzyme, but 
also recognized by anti-cAMP antibody. In this assay, cAMP from cell lysates and ED-
labelled cAMP (ED-cAMP) compete for antibody binding sites. Unbound ED-cAMP is 
free to complement EA to form active enzyme, which subsequently hydrolyzes 
fluorescent substrate for EFC detection by a microplate reader. Based on this principle, 
the competing intracellular cAMP and the impact of enzyme, such as adenylyl cyclise, 
can be measured (Figure 2.13).   
 
2.5.1 Preparation   
The cAMP hithunter was purchased from GE Healthcare and stored in fridge -20 °C. 
Kit Components : (1) cAMP Lysis Buffer; (2) cAMP EA Reagent; (3 ) cAMP ED 
Reagent; (4) cAMP Antibody; (5) cAMP Standard; (6) FL Substrate Reagent and FL 
Substrate Diluent; (7) BKG buffer.   
 
Standard solution: cAMP Standard stock (0.25mM) series diluted 9 fold in eppendorf 
tubes (The range of cAMP concentration of standard is from 62.5 to 9.54 x 10
-3 mM) by 
using Lysis Buffer/Ab Working Solution (1 part of cAMP plus 3 parts of Lysis 
Buffer/Ab Working Solution) 
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  β-galactosidase enzyme complementation 
FL Substrate
hydrolysis
Signal
  Inhibition β-galactosidase enzyme complementation with antibody 
Enzyme 
donor
(ED)
enzyme 
acceptor
 (EA)
Active enzyme
ED-cAMP
conjugate
Anti-cAMP
antibody
Enzyme
 inactivate
  Inhibition β-galactosidase enzyme complementation released by cAMP
FL 
Substrate
Signal
Active enzyme ED+unbound cAMP
 
Figure 2.13: The principle of cAMP assays-hithunter cAMP assay. Two fragments of E. 
coli β-galactosidase (β-gal): a large protein fragment (enzyme acceptor, EA) and a 
small peptide fragment (enzyme donor, ED). Separately, these fragments are inactive. 
The recombining of EA and ED actives enzyme, which is able to hydrolyze substrate to 
produce a fluorescent signal. In this assay, cAMP from cell lysates and ED-labelled 
cAMP (ED-cAMP) compete for antibody binding sites. Unbound ED-cAMP is free to 
bind to EA to form active enzyme, which is able to produce a fluorescent signal. The 
amount of signal produced is proportional to the amount of cAMP in the cell lysate. 
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2.5.2 Procedure 
Cell preparation: The hippocampus acquired from newborn rat (P0) was dissected out 
from heads of fetuses and placed in ice cold CMF-HBSS (Invitrogen). 2.5% trypsin 
(Invitrogen) was added in order to dissociate dissected cells. Once the cells were 
dissociated, the cell density was determined by cell counting, and cell viability was 
determined by the trypan blue exclusion method (Tolnai, 1975). During cell counting, 
cell suspension was diluted 1:5 in 0.4% trypan blue solution (Sigma). After being 
stained with trypan blue, the cells should be counted within 3 minutes. Stained cell 
suspension (20 μl) was placed onto hemacytometer (Hawksely, BS748), which was 
placed under a microscope for cell counting. Then, 150 μL(hippocampal cell number is 
30,000) /tube of cells in medium with Neurobasal A (Invitrogen) was dispensed in 1.5 
ml in eppendorf tubes. The media was gently aspirated after spinning down at 10,000 
rpm and dispensed in 120 μL/tube of Hanks’ Buffer (Invitrogen). These were incubated 
for 10 minutes at room temperature. 40 μL of cells were dispensed into a 384-well 
microtiter plate (10,000 cells/well). Then, hippocampal cells were treated with forskolin 
(50 μM) with different concentrations of VPA (10 μM, 100 μM, and 1 mM). The 
reaction was allowed to continue for 30 minutes, and the supernatant was removed. The 
cAMP extracted from the hippocampal cells was mixed with cAMP antibody and lysis 
solution, and incubated at room temperature for 60 minutes. The fluorescent substrate 
and the enzyme donor were mixed together and incubated for 60 minutes at room 
temperature. The enzyme acceptor was added and incubated for 60 minutes at room 
temperature. The relative fluorescent units were determined using a fluorescent reader 
(Molecular Devices, Model: GEMINI XS). Samples were excited at 530 nm, and an 
emission spectrum was collected from 540 nm to 640 nm (Table 2.3). 
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Table 2.3: The procedure of cAMP assays with different treatment by using cAMP hit 
hunter kit. The treatment including, BKG- back ground contro1 , standard-cAMP 
standard solution ranged from 62.5 to 9.54 x 10-3 mM, cell-experiment group(10,000 
cells/well) with forskolin (50 μM) and different VPA concentration(10 μM, 100 μM and 
1 mM)), and zero-experimental control(10,000 cells/well) with only forskolin (50 μM) . 
Condition BKG  Standard  Cells    Zero 
(control) 
Step 1: 
Forskolin/PBS 
  10  μL agonist (or 
drug) 
10 μL PBS 
  Incubate at 37°C for 30 minutes 
Step 2: 
Std/Lysis/Ab 
or 
Lysis Ab 
 
20 μL 
Lysis/Ab 
 
20 μL 
STD/Lysis/Ab 
 
20 μL 
Lysis/Ab 
 
20 μL 
Lysis/Ab 
60 minutes incubation at room temperature 
Step 3: 
ED/substrate/ 
BKG 
 
13 μL 
BKG/substrate 
 
13 μL ED/FL 
substrate 
 
13 μL ED/FL 
substrate 
 
13 μL ED/FL 
substrate 
60 minutes incubation at room temperature 
Step 4: EA  10 μL EA 
60 minutes incubation at room temperature 
Read on a fluorescent reader 
Excitation λ = 530 nM ± 25 nm, Emission λ = 610 nM ± 20 nm 
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Chapter 3: The effect of VPA on mossy fibre long-
term potentiation 
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3.1 Introduction 
VPA, di-n-propylacetic acid, is an eight-carbon branched-chain fatty acid. It is widely 
used clinically as an AED and a mood-stabilizing drug in bipolar disorder. It is also used 
to treat migraine headaches and schizophrenia.   
 
VPA exerts a powerful neuroprotective effect in a variety of models including in vivo 
epilepsy models. Chronic treatment with VPA prevents the deficits in learning and 
prevents SE-induced hippocampal damage. Following kainic acid-induced SE, animals 
treated with VPA did not have deficits in learning in Morris water maze test, and had 
fewer histological lesions in the hippocampus (Brandt et al., 2003a). Treatment with 
VPA after SE induced by electrical stimulation of the basolateral amygdala prevented 
hyperexcitability and locomotor hyperactivity. Furthermore, treatment with VPA 
decreased hippocampal damage including the dentate hilus, and prevented some of the 
behavioural alterations (Brandt et al., 2006). 
 
Previous studies suggest that the neuroprotective effect of VPA may involve the mitogen 
–activated protein pathway, through modulation of protein kinase A signalling pathway 
(Boeckeler et al., 2006). VPA activates extracellular signal-regulated kinase (ERK) 
which is known to be important for neuronal survival and long term neuronal plasticity. 
Furthermore, VPA increased the expression of genes regulated by the ERK pathway, and 
promotes neuronal survive (Yuan et al., 2001). Furthermore, an in vivo microdialysis 
study demonstrated that increases in cAMP levels in the prefrontal cortex of freely 
moving animals induced by an infusion of the adenylyl cyclase activator forskolin were 
attenuated by treatment with VPA (Montezinho et al., 2006;Montezinho et al., 2007). 
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Modulation of the cAMP/PKA pathway by VPA could have other implications. The 
cAMP/PKA pathway is critical for the expression of NMDA receptor independent LTP 
at the mossy fibre- CA3 synapse in the hippocampus (Huang et al., 1994;Nicoll and 
Malenka, 1995;Tzounopoulos et al., 1998;Weisskopf et al., 1994), and has been 
suggested also to be involved at Schaffer collateral-CA1 LTP. At this latter synapse, 
cAMP-mediated gene expression and synthesis of new protein, resulting in the growth 
of new synaptic connections, are required for LTP expression (Montarolo et al., 
1986;Glanzman et al., 1990). Therefore inhibition of the cAMP pathway could impact 
upon long-term potentiation at these synapses. Moreover these pathways have also been 
proposed to play an important role in hyperexcitability and epileptogenesis.   
 
Therefore, it has been hypothesized that the impact of VPA on cAMP/PKA signalling 
which contribute to VPA’s neuroprotective effect would affect mossy fibre LTP (Figure 
3.1).  
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Figure 3.1: Activation of adenylyl cyclase (ACA) catalyzes the transformation of ATP to 
cAMP, and further activates protein kinase A (PKA). PKA phosphorylates other proteins, 
altering their function such as decrease the activation of extracellular signal-regulated 
kinases 1 and 2 (ERK1/2) which is widely believed that contributes neuroprotective in 
epileptic condition. PKA also contributes to the enhancement of mossy fibre responses 
which may be related to neuroprotective effect. VPA, however, may inhibit the activation 
of PKA and provides the neuroprotective effect (Red Cross indicates the inhibition of the 
activity).   
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3.2 Methods 
3.2.1 Electrophysiology 
Isolated hippocampus slices were used in thesis experiment. Field excitatory 
postsynaptic potentials (fEPSP) were recorded using glass microelectrodes 
(approximately 2MΩ resistance) filled with aCSF solution positioned in stratum 
lucidum in CA3, the mossy fibre termination zone. Bipolar stainless steel stimulating 
electrodes were positioned in the dentate granule cell layer, and 0.6 mA pulses (400 µs 
duration) were applied with constant current stimulators (Figure 3.2). The electrode 
positions and stimulus intensities were adjusted until mossy fibre fEPSPs of maximal 
amplitude were recorded. Mossy fibres were identified by marked frequency facilitation 
which is a marked increase in the amplitude of the responses with an increase in the 
frequency of stimulation (> 2 fold increase in amplitude on increasing stimulation 
frequency from 0.05 Hz to 1 Hz).  
 
 
 
 
 
 
 
 
Figure 3.2: The trace recording of mossy fibre responses stimulated with 0.05 Hz and 1 
Hz. The waveform of this recording includes stimulus artifact, fibre volley, and the 
amplitude of fEPSP increase twice bigger once the frequency of stimulation increases 
from 0.05 Hz to 1 Hz. The black trace recording shows the baseline recording of mossy 
fibre response which is stimulated with 0.05 Hz; the red trace recording shows that 
mossy fibre response which was stimulated with 1Hz.  
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All the drugs were applied by bath perfusion. Valproate (1 mM) (Sigma), pentenoic acid 
(1 mM) (Sigma), APV-5 (50 µM)(Ascent), NBOX sodium (25 µM) (Sigma) and H89 
(10 µM) (Sigma) dissolved in distilled water, and forskolin (50 µM) (Sigma) dissolved 
in dimethyl sulfoxide (DMSO) (Sigma) were prepared as 1000 times stocks and stored 
at -20°C. All drugs were directly dissolved in aCSF to achieve their final concentrations 
during experiments and applied by gravity. All experiments were carried out at room 
temperature.  
 
3.2.2 High-frequency stimulation induced enhancement of mossy fibre responses 
In order to induce maximal mossy fibre synapse to CA3 LTP, three 1 second trains of 
high frequency stimuli (100 Hz) every 10 seconds was applied in the presence of the 
NMDA receptor antagonist APV (50µM). 
 
Recording was then continued for 100 minutes after the induction protocol. VPA (1 
mM) was applied before the LTP induction protocol and throughout the experiment. At 
the end of the experiment AMPA/kainate receptors were blocked with NBQX (25 µM). 
Although definitions of the timing of LTP and short term potentiation differ, for these 
studies LTP was considered to be a potentiation lasting greater than 30 minutes. 
Therefore, to assess LTP, the magnitude of potentiaion was calculated after 30 minutes 
after stimulation and the VPA and control slices were compared using a Student’s t test. 
 
3.2.3 Forskolin- induced enhancement of mossy fibre responses 
For the purpose of this experiment, fEPSP potentiation was elicited by application of the 
adenylyl cyclase activator forskolin (50 µM). Forskolin is commonly used to raise 
levels of cyclic AMP (cAMP) by activating the enzyme adenylyl cyclase. Application of  
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forskolin at mossy fibre–CA3 synapses induces LTP by increasing presynaptic adenylyl 
cyclase and so activating cAMP-dependent protein kinase (PKA). There were four 
different treatment groups: control, VPA (1mM), pentenoic acid (1 mM) (a straight 
chain fatty acid with no anticonvulsant activity) and H89 (10 µM) (a PKA inhibitor). 
 
3.2.4 Data analysis 
Because mossy fibre fEPSPs have a complex fibre volley that can contaminate the 
recording, the fibre volley (response after blocking AMPA/kainate receptors) was 
subtracted from all fEPSPs. The fEPSPs were then normalized to baseline (prior to LTP 
induction or application of forskolin). Data are shown as mean ± SEM. The mean 
fEPSP amplitudes were compared between groups using either Student’s Test or one 
way ANOVA with Tukey test as post hoc test. P < 0.05 was considered as significant. 
 
 
 
The equation of normalization of fEPSP: 
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Figure 3.3: The arrangement of recording in mossy fibre field. A recording electrode is 
placed in stratum lucidum. A bipolar stimulating electrode is placed in dentate granule 
cell layer.     
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3.3 Results 
3.3.1 VPA and pentenoic acid did not interfere with the short-term potentiation 
and baseline neurotransmission in mossy fibres synapse CA3.   
The effect of VPA (1 mM) and pentenoic acid (1mM), a short- straight chain fatty acid 
(see Table 3.1), on short-term potentiation and baseline neurotransmission in the mossy 
fibre synapse CA3 was first determined. The advantage of a specific feature of mossy 
fibres is their identity- marked frequency facilitation (Schmitz et al., 2001). So once a 
candidate mossy fibre fEPSP was found, the stimulus frequency was increased from 
0.05 Hz to 1 Hz and at least a two fold increase in fEPSP amplitude was used to confirm 
that the response was indeed a mossy fibre response.   
 
After baseline recording, in half the experiments VPA was added to the perfusate. The 
frequency facilitation was repeated in slices with and without VPA. There is no 
significant effect of VPA on fEPSP amplitude or short-term plasticity (Before VPA 
1mM: 313.56±23.64% of baseline, after VPA 1mM: 293.46±35.47% of baseline) 
(Figure 3.4).   
 
Similarly, there is no significant effect on the enhancement of mossy fibre after 
stimulation with 0.05 Hz and 1 Hz in pentenoic acid treated group (Before pentenoic 
acid 1mM: 313.56±23.64%, after pentenoic acid 1mM: 293.46±35.47%). Furthermore, 
application with VPA or pentenoic acid didn’t affect baseline neurotransmission in 
mossy fibres synapse CA3 (Figure 3.5). 
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Figure 3.4: The effect of VPA on STP at the mossy fibre synapse to CA3 region in 
hippocampus. (A) Trace of average EPSCs stimulated in dentate granule cell layer with 
frequency 0.05 Hz and 1 Hz present with/without VPA. (B) Example of the change of 
fEPSP amplitude in mossy with different stimulation frequency (0.05 Hz and 1 Hz). 
fEPSP amplitudes recordings plotted against stimulation number. fEPSP amplitudes 
normalized to the baseline; baseline values were set at 100%. (C) Comparison of the 
mean amplitude of fEPSP in control condition and present with VPA. Graphs show 
means ± SEM. There is no significant difference in control condition and VPA-treated 
condition with either 0.5 Hz or 1 Hz stimulation. 
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Figure 3.5: The effect of pentenoic acid on STP at the mossy fibre synapse to CA3 
region in hippocampus. (A) Trace of average EPSCs stimulated in dentate granule cell 
layer with frequency 0.05 Hz and 1 Hz present with/without pentenoic acid. (B) 
Example of the change of fEPSP amplitude in mossy with different stimulation 
frequency (0.05 Hz and 1 Hz). fEPSP amplitudes recordings plotted against stimulation 
number. fEPSP amplitudes normalized to the baseline; baseline values were set at 100%. 
(C) Comparison of the mean amplitude of fEPSP in control condition and present with 
pentenoic acid. Graphs show means ± SEM. There is no significant difference between 
control condition and pentenoic acid-treated condition.   
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3.3.2 VPA decreases the enhancement of mossy fibre responses induced by high-
frequency stimulation 
Activation of cAMP-dependent protein is required to induce mossy fibre LTP which is 
also known as a NMDA-independent LTP. The question whether there is an effect of 
VPA on NMDA receptor independent, PKA dependent LTP at mossy fibre to CA3 
pyramidal cell synapses was asked. The experiments were performed in isolated 
hippocampal slices; a bipolar stimulating electrode was placed in dentate granule cell 
layer; a recording electrode was placed in stratum lucidum (mossy fibre termination 
zone).   
 
Once the mossy fibre response was confirmed by the identification of short-term 
frequency-dependent facilitation, mossy fibre fEPSPs were recorded for 30 minutes as 
baseline with or without VPA 1mM. LTP was then induced as detailed above (Figure 
3.6). To prevent NMDA receptor mediated LTP, the experiments were carried out in the 
presence of APV-5 (50 μM) to block NMDA-mediated responses.     
 
The NBQX, AMPA/kainate receptor antagonist, was applied at the end of each 
experiment. The NBQX blocked the EPSCs, leaving the fibre volley which is subtracted 
from all traces (Figure 3.7).   
 
In the control group, the LTP protocol results in rapid short term potentiation and then 
the amplitude decreases over 10 minutes or so to reveal LTP. In the VPA treated group, 
the initial short-term potentiation was unaffected, arguing against an effect of VPA on 
the induction protocol. However, LTP was significantly reduced (Figure 3.8). 
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Figure 3.6: Marked facilitation following LTP induction. High frequency stimulation 
(three times 100 Hz/ second for every 10 seconds) enhances mossy fibre response. This 
enhancement of mossy fibre can last for hours (A) The mossy fibre response recorded 
before stimulation. (B) The mossy fibre response recorded during Stimulation (C) the 
mossy fibre response recorded immediately after high frequency stimulation. 
 
 
 
 
 
Figure 3.7: The identification of mossy fibre response. The black trace shows the 
baseline recording of mossy fibre response; The red trace shows that mossy fibre 
response was increase as twice bigger as baseline while stimulus intensity was 
increased from 0.05 Hz to 1 Hz; The blue trace shows the complex fibre volley following 
block of ionotropic glutamate receptors.      
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Figure 3.8: The effect of VPA on LTP at the mossy fibre synapse to CA3 region in 
hippocampus after high frequency stimulation. (A) Trace of average fEPSCs before and 
after tetanus in control condition and VPA-treated condition respectively. (B) Summary 
the data for mossy fibre LTP induced by tetanus. fEPSC amplitudes recordings plotted 
against time. fEPSC amplitudes normalized to the baseline values. 
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To compare VPA and control group, the amplitude of LTP after high frequency 
stimulation over 30 minutes was averaged. The mean amplitude of mossy fibre LTP was 
significantly suppressed in the group treated with VPA (148 ± 20 %), compared to 
control group (231 ± 22% n=6) (p=0.02 by Student’s t test) (Figure 3.9) 
 
 
 
 
 
 
Figure 3.9: Comparison of the mean fEPSP of amplitude after tetanus stimulation in 
control group and VPA-treated group. Each column shows the mean value of the fEPSPs 
expressed as a percentage of the baseline value (during the 10 min before tetanus). 
Graphs show means ± SEM. Statistical analysis was performed by Student’s t-test. * 
Indicates a significant difference between the two groups (P<0.05). The magnitude of 
the LTP in VPA-treated group is significant smaller than in the control group. 
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3.3.3 VPA decreases the enhancement of mossy fibre responses induced by 
application of forskolin 
To further evaluate whether the effect of VPA on mossy fibre LTP is mediated by 
cAMP/PKA signalling system, mossy fibre LTP was elicited by application of the 
adenylyl cyclase activator, forskolin (50 µM) (Figure 3.10). 
 
 
 
 
 
 
Figure 3.10: The trace recording of enhancement of mossy fibre responses by treatment 
with forskolin (50 µM). The black trace shows the baseline recording of mossy fibre 
response; the red trace shows that mossy fibre response following application of 
forskolin. 
 
 
 
 
 
 
As in the previous experiment, APV-5 was applied throughout. The mossy fibre 
excitatory postsynaptic potentials (EPSPs) elicited by this method were identified by 
marked frequency facilitation and sensitivity to the group II metabotropic glutamate 
agonist (2S, 1’R, 2’R, 3’R)-2-(2,3-dicarboxylcyclopropyl)-glycine (DCG-4) (1 µM) at 
the end of the experiment. The group II metabotropic glutamate receptor (mGluR2) 
suppresses synaptic transmission and reduces the synaptic excitation at the hippocampal 
mossy fibre-CA3 synapse by presynaptic mechanisms.(Yoshino et al., 1996;Kamiya and 
Yamamoto, 1997).    
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In control conditions, 30 minutes after application of forskolin, the fEPSP was reach a 
maximum and entered a steady state (mean amplitude of fEPSPs after application of 
forskolin was 458.56±53.33% of baseline, n=8) (Figure 3.11). In order to confirm that 
the enhancement of mossy fibre responses is mediated by activation of PKA, a PKA 
inhibitor H89 (10 µM) was added. There was a significant effect on the enhancement by 
forskolin (458.56 ± 53.33% of baseline, n=8) (Figure 3.11). Post-hoc analysis indicated 
that forskolin-induced enhancement of transmission was significantly attenuated in the 
presence of H89 (281.65 ±37.60% of baseline, n = 5, p < 0.05) 
 
Forskolin (50 µM) were added in the presence of VPA (1mM), or a straight chain fatty 
acid pentenoic acid (1 mM) as a further control (Figure 3.12). As has been previously 
observed, forskolin enhanced the fEPSP amplitude (458.56 ± 53.33% of baseline, n=8). 
There was a significant effect of treatment on the enhancement by forskolin (p =0.014, 
single factor ANOVA) (Table 3.2). Post-hoc analysis indicated that this enhancement 
was significantly attenuated in the presence of VPA (259.49 ± 25.99% of baseline, n = 7, 
p < 0.05), but not in the presence of pentenoic acid (470.86 ± 76.69 % of baseline, n=6) 
(Table 3.3).   
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Figure 3.11: PKA contributes to LTP at the mossy fibre synapse to CA3 region in 
hippocampus after application of forskolin (50 μM), adenylyl cyclase activator. (A) 
Summary data for mossy fibre LTP induced by treatment with forskolin. fEPSP 
amplitudes recordings plotted against time. EPSC amplitudes normalized to the 
baseline (during 10 minutes before treatment with forskolin) were set at 100% for each 
individual experiment). (B) Trace of average EPSCs before, during, and after 
application of forskolin.   
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Figure 3.12: VPA suppressed LTP at the mossy fibre synapse to CA3 region in 
hippocampus after application of forskolin (50 μM), adenylyl cyclase activator. (A) 
Summary the data for mossy fibre LTP induced by treatment with forskolin. fEPSP 
amplitudes recordings plotted against time. EPSC amplitudes normalized to the 
baseline (during 10 minutes before treatment with forskolin) were set at 100% for each 
individual experiment). (B) Trace of average EPSCs before, during, and after 
application with forskolin. (C) Comparison of the mean fEPSP of amplitude after 
treatment with forskolin. Each column shows the average value of the fEPSPs expressed 
as a percentage of the baseline value. Graphs show means ± SEM. Statistical analysis 
was performed by post hoc test-tukey test, following by ANOVA. * Indicates a 
significant difference between the two groups (P<0.05).   
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Table 3.1: The result of ANOVA test of groups with different treatments (control, H89, 
VPA, and pentenoic acid) 
  
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups 
24.167  3  8.056  6.504  0.003 
Within Groups 
27.247  22  1.238       
Total 
51.414  25          
* Sum of Squares: The estimate of variance corresponds to the numerator of the 
variance ratio. 
Df: Degrees of freedom for each estimate of variance. The degrees of freedom 
associated with the sources of variance 
Mean Square: Each mean square is calculated by dividing the sum of square by its 
degrees of freedom. 
F: F ratio is calculated by dividing mean square between-groups by mean square 
within groups (F = Mean square Between-groups / Mean square Within-groups) 
Sig.: Sig. gives the significance of the F ratio. This is the p value. If the p value is less 
than or equal α level, then you can reject H0 that all the means are equal. That is, 
there is insufficient evidence to claim that some of the means may be different from 
each other. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
124 
 
Table 3.2: Post-hoc comparison of multiple comparisons of treatments (Control, H89, 
VPA, and pentenoic acid) by Tukey test 
95% Confidence Interval 
 Comparisons  of  groups 
Mean 
Difference 
(Between 
groups) 
 
Std. Error 
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
Control VS VPA 
2.01372(*)  .59486  0.013  0.3619  3.6655 
Control VS Pentenoic acid 
0.18872  .61915  0.990  -1.5306  1.9080 
Control VS H89 
2.00717(*)  .61915  0.018  0.2879  3.7264 
VPA VS Pentenoic acid 
-1.82501(*)  .61915  0.035  -3.5443  -0.1057 
VPA VS H89 
-0.00655  .61915  1.000  -1.7258  1.7127 
Pentenoic acid VS H89 
1.81845(*)  .64252  0.045  0.0343  3.6026 
* Mean Difference: difference between the means 
Std. Error: standard error of the mean these are the standard errors associated with 
the  coefficients.   
Sig.: p value for the multiple comparisons used in testing whether a given coefficient 
is significantly different. P<0.05 consider as significant difference consider: 
95% Confidence interval for Lower Bound and Upper Bound: gives an estimated 
range of values, usually calculated as percentage 95% confidence intervals for the 
coefficients. The upper and lower bounds of a 95% confidence interval are the 95% 
confidence limits. The confidence intervals are related to the p-values such that the 
coefficient will not be statistically significant if the confidence interval includes 0 
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3.4 Discussion 
These results demonstrate that application of VPA had no effect on single fEPSPs or on 
short-term potentiation. However, VPA markedly impaired mossy fibre LTP induced by 
high frequency stimulation or through application of forskolin.   
 
Activation-dependent synaptic potentiation can be divided into several distinct temporal 
phase, including short-term potentiation (STP) and long-term potentiation (LTP). STP 
plays a fundamental role in information processing and rapid regulation of presynaptic 
input. STP enhancement reflects an increase in the probability of release of available 
quanta, or an increase in the number of release sites which are capable of releasing a 
quantum (Zucker and Regehr, 2002). Unlike associational/commissural synapses which 
are relatively insensitive to frequency of stimulation, marked frequency facilitation at 
low stimulation frequencies is a characteristic of mossy fibre to CA3 pyramidal cell 
synapses (Salin et al., 1996). VPA had no effect on single fEPSPs or on short-term 
potentiation indicates that VPA does not have any effect on neurotransmitter release 
probability. 
 
A further characteristic of mossy fibres is a robust NMDA receptor independent LTP. 
This LTP is dependent on the activation of protein kinase A via cAMP. NMDA receptor-
independent LTP in the mossy fibre pathway is blocked by inhibitors of PKA or genetic 
manipulation of PKA (Weisskopf et al. 1994; Huang et al. 1994; Huang et al. 1995; 
Huang, 1996). In addition, application of adenylyl cyclase activator, forskolin, or 
membrane-permanent analogous of cAMP causes a long lasting presynaptic 
enhancement of mossy fibre responses (Huang et al., 1994; Nicoll and Malenka, 1995; 
Tzounopoulos et al., 1998; Weisskopf et al., 1994).   
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In this study, the effect to VPA on mossy fibre LTP by High-frequency stimulation 
(HFS) was first verified. HFS also induced a large PTP (post-tetanic potentiation)/STP 
that declined to a stable value in approximate 10-20 minutes. However, STP and LTP 
are expressed via different mechanisms, occluding LTP does not occlude STP 
expression, occluding STP does not occlude LTP expression (Schulz and Fitzgibbons, 
1997). Therefore, in order to eliminate contamination of PTP/STP, LTP data were 
obtained more than 30 min after HFS. Application of VPA impaired induction of LTP in 
mossy fibre synapse to CA3 which is similar to application of PKA antagonist, H89, 
indicating that VPA may impair the formation of LTP in mossy fibre by inhibiting the 
activity of PKA. Inhibition of mossy fibre LTP and forskolin enhancement of 
transmission is consistent with an action of VPA on the cAMP/PKA pathway but it does 
not distinguish between an effect on cAMP accumulation or a direct action on PKA (this 
will be investigated in subsequent chapters). Furthermore, VPA could be acting 
downstream of PKA.   
 
In these experiments, the pentenoic acid was used as an experimental control. Pentenoic 
acid, a short straight chain fatty acid (an analogue of VPA), has little or no 
anticonvulsant properties. As application of pentenoic acid lacked an effect on the 
enhancement of mossy fibre responses induced by forskolin, then this raises the 
question whether an action of VPA on the cAMP/PKA pathway may be involved in its 
antiepileptic effect (This question will be addressed in subsequent chapters). 
 
In contrast to its effect on LTP, VPA had no significant effect on baseline transmission 
or short term plasticity. What is the possible physiological consequence of VPA’s effect 
on LTP? LTP has been proposed to be the cellular basis of memory formation in the  
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CNS, and so an action on inhibiting mossy fibre LTP may be relevant to the cognitive 
impact of high dose VPA (Lamberty et al., 2000). Further, the inhibition of long term 
enhancement of excitatory transmission may play a part in the antiepileptogenic effect 
of VPA (Silver et al., 1991).    
 
Are the concentrations used here relevant to human use? The concentrations used in 
these studies were 1 mM. The therapeutic plasma level of VPA in human is 50 mg/L-
150 mg/L (Covanis et al., 1982). The ratio of total and unbound plasma VPA 
concentrations is around 10 % (Cloyd et al., 2003), indicating the pharmacologically 
active concentration is relatively low. However, the concentration range of VPA 
necessary to have an antiepileptic effect in animals is orders of magnitude higher than in 
humans (about 200-500 mg/L) (Nau et al., 1981;Chapman et al., 1982), and the reason 
for this remains unclear. The VPA concentration in rat brain tissue that mediates an 
antiepileptic effect is about 150-200 µg/g (Chapman et al., 1982; Löscher et al., 1989), 
and these concentrations are consistent with a molar concentration of VPA of 1 mM. 
Therefore, the concentration here is directly relevant to the therapeutic concentration of 
VPA in rat brain. 
 
 
 
 
 
 
 
  
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: The effect of VPA on cAMP/PKA 
signalling system 
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4.1 Introduction 
In chapter 3, it has showed that the VPA decreased the enhancement of mossy fibre 
responses either induced by high frequency stimulation or by application of forskolin. 
These results strongly suggest a mechanism of VPA action may involve modulation of 
the cAMP/PKA signalling system. 
 
cAMP is derived from adenosine triphosphate (ATP) and is used for intracellular signal 
transduction. cAMP is involved in the regulation of several signalling pathways such as 
extracellular signal-regulated kinases 1 and 2 (ERK1/2) (Hafner et al., 1994;Enserink et 
al., 2002;de Rooij et al., 1998a;Kawasaki et al., 1998). The cAMP signalling pathway is 
also important in many biological processes, ranging from growth, differentiation, and 
gene expression to secretion and neurotransmission. It acts to stimulate protein kinases, 
such as protein kinase A (PKA) and it is rapidly broken down in cells by 
phosphodiesterases to terminate the signal. 
 
cAMP binds to regulatory units of protein kinase A, and causes dissociation between the 
regulatory and catalytic subunits. Activation of catalytic units results in the 
phosphorylation of substrate proteins. The activation of PKA catalyzes the transfer of 
phosphate from ATP to specific serine or threonine residues of protein substrates. This 
may activate or inhibit protein activity. For example, PKA phosphorylation has a direct 
action on regulating synaptic AMPA receptors in the rat hippocampus (Esteban et al., 
2003;de Rooij et al., 1998b;Roche et al., 1996;Carvalho et al., 1999) which may 
contribute to synaptic plasticity. PKA can also phosphorylate specific proteins that bind 
to promoter regions of DNA, resulting in increased expression of specific genes. 
Abnormal cAMP signalling system has been suggested to contribute to the increased 
excitability of neurons in epileptic animals (Tehrani and Barnes, 1995b;Yechikhov et  
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al., 2001). 
 
It is not clear from previous studies from chapter 3, whether VPA has a direct effect on 
PKA or an indirect effect by decreasing cAMP accumulation. In order to set out to 
distinguish these two possibilities in this chapter, biochemical assays were used.     
 
4.2 Method 
4.2.1 cAMP assay 
The hit hunter cAMP assay kit used in this experiment was purchased from GE 
Healthcare, UK. HitHunter cAMP Assays are based on using β-galactosidase (β-gal) 
enzyme consisting of two fragments, enzyme acceptor (EA) and enzyme donor (ED). 
These fragments are inactive separately, but in solution they rapidly complement to 
form active ß-gal enzyme which can hydrolyze substrate to produce fluorescent signal. 
For competing antibody binding sites by cAMP from cell lysates and ED-labelled 
cAMP (ED-cAMP), unbound ED-cAMP is free to bind to EA to form active enzyme. 
The amount of signal produced is proportional to the amount of cAMP in the cell lysate 
(for detail, see chapter 2 general methods). 
 
For these experiments, hippocampal cells (10,000 cells/ well) were acquired from 
newborn rats (P0) and stored in medium neurobasal, containing 2% B27 and 25 µM 
glutamine. Then the hippocampal cells were transferred into black 384-well microtiter 
plates (PerkinElmer). After removal of the medium, cells were stimulated with 50 µl of 
forskolin (50 µM) or forskolin plus VPA at different concentrations (10 µM, 100 µM, or 
1 mM) in HBSS buffer for 30 minutes. Once the supernatant media was removed, 20 µl 
of anti-cAMP antibody in lysis buffer was added. After an incubation time of 60 
minutes at room temperature, 10 µl of ED-cAMP (with substrate) was added. After  
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incubation at room temperature for 60 minutes, 10 µl EA was added and incubated for a 
further 60 minutes at room temperature, prior to reading the value of fluorescence, using 
software “SOFTmax pro”. 
 
4.2.2 PKA assay 
An alternative explanation for the action of VPA illustrated in chapter 3 is a direct effect 
on protein kinase A. To test this, an in vitro assay of PKA activity by measuring PKA 
phosphorylation of Kemptide substrate (see general methods) was used. In brief, the 
assay for PKA activity was carried out in a 30 µl reaction volume containing kemptide 
substrate, PKA, magnesium/ATP cocktail containing [γ-
32P]ATP and without/ with 
different concentrations of VPA (50 µM, 100 µM, 500 µM, and 1 mM). Then, the 
reaction solution was incubated at 30 °C for 10 min. A 20 µl aliquot of the reaction 
solution was spotted on P81 phosphocellulose paper, washed with 0.75% phosphoric 
acid. The P81 paper (millpore) was washed with acetone, left to dry, followed by adding 
scintillation cocktail solution and counting in a scintillation counter. 
 
4.2.3 Data analysis 
For cAMP assay, the fluorescence value was normalized to the control treatment. For 
the PKA assay, the CPM value from the scintillation counter was normalized to control 
treatment. Data are shown as mean ± SEM. The mean values in groups were compared 
by one way ANOVA and tukey test as post hoc test. P < 0.05 was considered as 
significant. 
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4.3 Results 
4.3.1 The effect of VPA on cAMP accumulation after stimulation with forskolin   
In this experimental paradigm, an assay is first performed with various concentrations 
of standard solution. The standard cAMP solution (0.25 mM) was serially diluted 9 
times (concentration range was 62.5 to 9.54 x 10-3 mM). cAMP standard detection 
reagents were added according to the assay protocols and fluorescence was read one 
hour after the addition of the EA reagent. These data are used to make the standard 
curve by using four-parameter logistic model, plotting concentration on the X axis, and 
assay measurement on the Y axis displayed a pronounced sigmoidal or S shape (Figure 
4.1). The values obtained from experimental groups were accepted when the values 
were located between the extremes of the standard curve.   
 
 
 
Figure 4.1: Example of a plotted standard curve 
 
 
 
Forskolin, 50 μM, was added without/with different concentrations of VPA. The 
fluorescence in the presence of different concentrations of VPA were compared with 
vehicle-control group and expressed as percent responses over cAMP level in vehicle-
control group. The hippocampal cells treated with cAMP analogue, forskolin, elicited a  
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robust activation of cAMP production (139.28 ±5.79%, n=13). This was significantly 
different from the vehicle-control group (P < 0.01; n = 14). VPA 1 mM suppressed the 
forskolin-mediated activation to 120.38±3.43%, n=15, P=0.012, compared to forskolin 
treated group) (Table 4.1 and Table 4.2). This effect was dose dependent with a low 
concentration of VPA (10 µM) having no discernible effect on cAMP production 
(Figure 4.2). This result suggests that the effect of VPA on mossy fibre LTP may 
through an action on cAMP accumulation. 
 
 
 
 
Figure 4.2: The effect of VPA on cAMP accumulation induced by forskolin (50 μM) in 
hippocampal cells. Application with forskolin significantly increased the cAMP 
accumulation. The high concentration of VPA (1mM) significantly suppressed the cAMP 
accumulation mediated by forskolin. The low concentration of VPA (10 μM) shows a 
lack of effect on suppression of cAMP accumulation induced by forskolin. Graphs show 
means ± SEM. Statistical analysis was performed by post hoc test-tukey test, following 
by ANOVA. * Indicates a significant difference between the two groups (P<0.05), and 
** Indicates a significant difference between the two groups (P<0.01). 
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Table 4.1: The ANOVA test result of cAMP accumulation with different treatment 
(Control, forskolin 50μM, VPA 10 μM, VPA 100 μM, and VPA 1mM) 
  
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups 
0.418  3  0.139  5.781  0.002 
Within Groups 
1.229  51  0.024       
Total 
1.647  54          
 
 
 
 
 
 
 
Table 4.2: Post-hoc comparison of cAMP accumulation with different treatment by 
Tukey Test (Control, forskolin 50 μM, VPA 10 μM, VPA 100 μM, and VPA 1mM) 
95% Confidence 
Interval 
  
Mean 
Difference  
  
Std. 
Error 
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
Forskolin (50 μM) -VPA (1mM) 
0.18900(*)  0.05882 0.012  0.0328  0.3452 
Forskolin (50 μM) - VPA (100 μM) 
0.14064  0.05882 0.092  -0.0156  0.2969 
Forskolin (50 μM) - VPA (10 μM) 
-0.01312  0.06214 0.997  -0.1782  0.1519 
VPA (1mM) - VPA (100 μM) 
-0.04835  0.05668 0.829  -0.1989  0.1022 
VPA (1mM) - VPA (10 μM) 
-0.20212(*)  0.06012 0.008  -0.3618  -0.0424 
VPA (100 μM) - VPA (10 μM) 
-0.15376  0.06012 0.063  -0.3134  0.0059 
* The mean difference is significant at the .05 level. 
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4.3.2 The effect of VPA on PKA activity 
For this assay, kemptide phosphorylation (see methods) was measured. Adding the PKA 
inhibitor peptide (1mM) significantly inhibited the activity of PKA (44.32±5.35% of 
control group n=8, p<0.01, compared to control group) (Table 4.3 and Table 4.4). VPA, 
on the other hand, had no or little effect on the inhibition of PKA activity, even at high 
concentrations (Figure 4.3). These data indicate that there is no direct inhibitory effect 
of VPA on PKA phosphotransferase activity.  
 
 
 
 
 
 
Figure 4.3: The effect of VPA on PKA activity. In this experiment, the effect of VPA on 
PKA activity was measured by using kemptide, a selective substrate for PKA. Effect of 
VPA at different concentrations (VPA 50 µM, VPA 100 µM, VPA 500 µM and VPA 1mM) 
on PKA activation in PKA assay is compared with control condition. The result shows 
that VPA does not significantly suppress PKA activity, even at high concentrations (1 
mM). Graphs show means ± SEM. Statistical analysis was performed by post hoc test-
Tukey test, following by ANOVA. * Indicates a significant difference between the two 
groups (P<0.05). 
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Table 4.3: The AVOVA test result of PKA activity with different treatment 
(Control, PKA inhibit peptide, VPA 50 μM, VPA 100 μM, VPA 500 μM and VPA 1mM) 
  
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups 
1.886  5  0.377  24.291  0.000 
Within Groups 
0.652  42  0.016       
Total 
2.538  47          
 
 
 
 
Table 4.4: Post-hoc comparison of PKA activity with different treatment by using Tukey 
test (Control, PKA inhibit peptide 50 μM, VPA 10 μM, VPA 100 μM, and VPA 1mM) 
Comparison 
 
Mean 
Difference 
Std. 
Error  Sig. 
95% Confidence 
Interval 
Control - PKA inhibit peptide  0.55684(*) 0.06231  0.000 0.3708  0.7428 
Control - VPA (50 μM)  0.03558 0.06231  0.992  -0.1504  0.2216 
Control - VPA (100 μM)  0.06758 0.06231  0.885  -0.1184  0.2536 
Control - VPA (500 μM)  0.01271 0.06231  1.000  -0.1733  0.1987 
Control - VPA (1 mM)  0.02398 0.06231  0.999  -0.1620  0.2100 
PKA inhibit peptide - VPA (50 μM)  -0.52127(*) 0.06231 0.000  -0.7073  -0.3353 
PKA inhibit peptide - VPA (100 μM)  -0.48927(*) 0.06231 0.000  -0.6753  -0.3033 
PKA inhibit peptide - VPA (500 μM)  -0.54413(*) 0.06231 0.000  -0.7301  -0.3581 
PKA inhibit peptide - VPA (1 mM)  -0.53287(*) 0.06231 0.000  -0.7189  -0.3469 
VPA (50 μM) - VPA (100 μM)  0.03200 0.06231  0.995  -0.1540  0.2180 
VPA (50 μM) - VPA (500 μM)  -0.02287 0.06231  0.999  -0.2089  0.1631 
VPA (50 μM) - VPA (1 mM)  -0.01160 0.06231  1.000  -0.1976  0.1744 
VPA (100 μM) - VPA (500 μM)  -0.05487 0.06231  0.949  -0.2409  0.1311 
VPA (100 μM) - VPA (1 mM)  -0.04360 0.06231  0.981  -0.2296  0.1424 
VPA (500 μM) - VPA (1 mM)  0.01127 0.06231  1.000  -0.1747  0.1973 
* The mean difference is significant at the .05 level. 
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4.4 Discussion 
By using biochemical methods to test whether VPA affects the production of cAMP or 
the activity of PKA, the result showed that VPA decreased the cAMP level in a high 
concentration whereas there is a lack effect of VPA on PKA activity in lower 
concentration (10 μM and 100 μM). Besides, there is a lack of an inhibitory effect of 
VPA on PKA phosphotransferase activity, even at high concentration (VPA 1 mM). This 
result is consistent with previous work on VPA on PKA activity at lower VPA 
concentrations (VPA range from 1 to 200 μM) by using kemptide (100 mM) as the 
substrate for PKA. 2-ene-VPA (2-ene-valproate, 2-propyl-2-pentenoic acid), which is 
the major VPA metabolite in humans, has a lack of an inhibitory effect on PKA 
phosphotransferase activity at concentrations ranging from 100 to 400 μM (Mirnikjoo et 
al., 2001). These results suggest that the mechanism of VPA involves modulation of 
cAMP accumulation induced by application with forskolin, but there is no direct effect 
on PKA. The effect on cAMP could be secondary to an effect on phosphodiesterases or 
adenylyl cyclase (my experiments do not distinguish these possibilities).   
 
In the experiment of using the cAMP assay, the hippocampal cells were acquired from 
newborn rat by using primary hippocampal cell culturing methods. Primary 
hippocampal cell culturing, a well developed method, is used by neuroscientists to 
examine the activity and properties of neurons at the individual cell and single synapse 
level. The hippocampus may be isolated from each newborn animal in as short as 2 to 3 
minutes, and the cultures can be maintained for up to two weeks. One possible 
confounder is that the data acquired from hippocampal cells from newborn rats may be 
different from adult hippocampus. Indeed, it has been shown that adenylyl cyclase 
system in the rat brain is more susceptible to aging processes. For example, [3H] 
forskolin binding shows a conspicuous reduction in various brain areas in 18-month-old  
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rats, compared to adult animals. In 24-month-old rats, the reduction of [3H]forskolin 
binding was observed in the cerebral cortex, hippocampal CA3 pyramidal cell layer, 
dentate gyrus, thalamus and molecular layer of cerebellum (Araki et al., 1995). This 
may partly provide an explanation that the enhancement of cAMP accumulation by 
application of forskolin is 139.28 ±5.79% of control, whereas the enhancement of 
mossy fibre response induced by application of forskolin is 458.56±53.33%. This may 
also be explained by a non-linear relationship between cAMP concentration and 
neurotransmitter release. Despite differences in absolute enzyme activity between 
immature brain and adult brain, this assay still provides a qualitative insight into the 
action of VPA on modulation of cAMP accumulation. 
 
Recent studies in the rat prefrontal cortex have shown that 48 hours of VPA treatment 
reduced β-adrenergic receptor activation of cAMP production and direct adenylyl 
cyclase stimulation via forskolin (Montezinho et al., 2006;Montezinho et al., 2007).   
However, it was not clear from these experiments if this occurred through 
transcriptional regulation, or if this effect was adenylyl cyclase isoenzyme specific. One 
recent report has suggested that VPA works through elevated phosphodiesterase activity 
in addition to reduced adenylyl cyclase activity, in C6 glioma cells (Gallagher et al., 
2004). In another study, chronic treatment of these cells with VPA for 6 days showed 
reduced basal, and forskolin-induced cAMP production, in both intact cells and cell 
membranes (Gallagher et al., 2004;Chen et al., 1996). The data shown here suggest, for 
the first time, an acute biochemical action of VPA in synaptic signalling. Due to the 
rapid timing of these effects, they are therefore independent of teratogenic 
(transcription-regulated) effects of VPA.   
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VPA shows a powerful neuroprotective effects in vitro and in vivo model of various 
degenerative disorders; however, the mechanism is still unclear. It has been suggested 
that VPA up-regulates the activation of ERK1/2 through an inhibitory effect on PKA 
pathways in Dictyostelium discoideum (Boeckeler et al., 2006). Other studies also 
provide evidence that VPA increases phosphorylation of ERK1/2 (Yuan et al., 
2001;Boeckeler et al., 2006). ERK1/2 is a member of mitogen activated protein kinases 
which can be activated by various growth factors and cAMP-signalling pathway 
(Vossler et al., 1997;Hetman and Gozdz, 2004). Therefore, VPA’s activity on the 
cAMP/PKA pathway may also contribute to its neuroprotective effect. 
 
This action of VPA on the cAMP/PKA signalling system may also contribute to other 
effects of VPA on receptors and cellular pathways. GABA(A) and GABA(B) receptors 
are modulated by PKA mediated phosphorylation (Moss et al., 1992;Couve et al., 2002). 
The cAMP/PKA signalling system also modulates Na
+ channel slow inactivation (Chen 
et al., 2006). Moreover, cAMP/PKA signalling can interact with other signalling 
pathways, such as the calmodulin-dependent protein kinase cascade (DeBernardi and 
Brooker, 1996) and the PI3K pathway (Namkoong et al., 2009), possibly contributing to 
the diverse pharmacological actions of VPA.   
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Chapter 5: The mechanisms of action of VPA 
related to cAMP/PKA signalling in in vitro 
epilepsy models 
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5.1 Introduction 
There is considerable evidence that cAMP/PKA activity has an impact on the 
development of seizure activity in both in vivo and in vitro models. 
 
The level of cAMP is significantly increased in epileptogenic cortical foci produced by 
freezing and application of penicillin (Walker et al., 1973; Krivánek and Mares, 1977). 
Repeated injections of subconvulsive doses of cAMP into rats’ amygdale produced 
progressive seizure development (Kihara et al., 1989). In in vitro seizure models (PTZ 
model and an electrical stimulation model) in cortical slices, cAMP accumulation is also 
observed (Lewin et al., 1976;Kakiuchi et al., 1969). Furthermore, activation of adenylyl 
cyclase with forskolin or inhibition of phosphodiesterase with rolipram enhanced the 
ictal-like afterdischarges (ADs) induced by high-frequency stimulation in rat 
hippocampal slices (Higashima et al., 2002). In epileptic patients, the cAMP 
concentration in the cerebrospinal fluid is also elevated after a seizure ( Myllylä et al., 
1975).  
 
PKA is one of the primary targets of cAMP. PKA has been proposed to contribute to the 
development of epilepsy. In rats which are prone to epilepsy, PKA activity increases in 
neocortex and hippocampus (Yechikhov et al., 2001). Activation of the cAMP/PKA 
signalling system increases excitability and enhances epileptiform activity in rat 
hippocampal slices and human dentate gyrus (Boulton et al., 1993;Higashima et al., 
2002;Chen and Roper, 2003). It has also been shown that application of forskolin can 
block endogenous antiepileptic processes; moreover, activation of PKA can prolong 
epileptic activity and induce status epilepticus ( Üre and Altrup, 2006).   
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In previous chapters, it has been demonstrated that VPA decreases the enhancement of 
mossy fibre response either induced by electrical stimulation, or through application of 
forskolin. Moreover, in hippocampal cells, VPA decreased cAMP accumulation after 
forskolin application. These experiments indicate that VPA can modulate cAMP/PKA 
signalling through decreasing cAMP accumulation. Does this explain or contribute to 
the anticonvulsant action of VPA? To address this, well-established in vitro seizure 
models were used: PTZ model and low magnesium model. The advantage of using these 
two in vitro acute seizure models is that they are both sensitive to VPA , but are induced 
by different methods (Armand et al., 1998). Efficacy in both, therefore, adds weight to 
the antiepileptic effects of a drug.   
 
PTZ-model: Exposure of hippocampal slices (in an interface chamber) to PTZ results in 
the appearance of spontaneous interictal-like discharges in CA1 and CA3 subfields 
(Piredda et al., 1985;Leweke et al., 1990). Similar results can be obtained with 
submerged slices treated with PTZ once extracellular K
+ concentration is increased 
(Heinemann et al., 1977). However, it has also been shown to increase voltage-gated 
potassium conductances, permitting rapid action potential firing (Madeja et al., 1996). 
In addition, PTZ induces calcium releases from calcium stores, and increases 
intracellular calcium, contributing to the generation of bursting activity (Sugaya and 
Onozuka, 1978).   
 
Low Mg
2+ model: application of low Mg
2+ aCSF generates rhythmic short recurrent 
discharges activity in CA1 and CA3 area in hippocampus in rats (Mody et al., 1987). It 
has been suggested that low-Mg
2+-induced seizure-like events originate from the 
entorhinal cortex and propagate towards the temporal neocortex and the hippocampal  
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formation (Buchheim et al., 2000). This may be due to enhancement of NMDA receptor 
currents by releasing the NMDA receptor from the inhibitory action of Mg
2+ (Mody et 
al., 1987;Senatorov et al., 1995).   
 
Indeed there are limitations of using in vitro slice models of acute seizure activity, such 
as the massive loss intrinsic and extrinsic connections; furthermore the main problem of 
using in vitro slice models is interpretation of the result obtained in epileptogenic 
condition in intact system. However, slice models can provides useful information about 
seizure activity modification by application of drugs. 
 
In this study, the aims are to investigate whether cAMP/PKA signalling is involved in 
epileptiform activity, and whether the effect of VPA on modulation of cAMP/PKA 
signalling contributes to the anticonvulsant action of VPA. In order to distinguish the 
role of cAMP and PKA in epileptiform activity, H89 (an inhibitor of protein kinase A) 
and SQ22536 (a cell-permeable adenylyl cyclase inhibitor) were used during the 
experiments. Further, in order to elucidate whether the anticonvulsant action of VPA 
may be via modulation of cAMP/PKA signalling system, pentenoic acid, a VPA analogy 
lacking anticonvulsant effect, was used as an experimental control. 
 
5.2 Methods 
Combined horizontal entorhinal cortex-hippocampus slices from male Sprague-Dawley 
rats were used in these in vitro epilepsy models. The method of induction of 
epileptiform discharges was modified from previously described protocols (Heinemann 
1994, 1998). During the experiment, the slices were transferred from an interface 
chamber to a submersion recording chamber and continuously perfused with prewarmed  
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(about 33 °C) oxygenated (95% O2, 5% CO2) aCSF for one hour prior to the start of 
recording. fEPSP recording was made by placing a glass microelectrode filled with 
aCSF solution in stratum radiatum of CA1. A bipolar stimulating electrode was 
positioned in the Schaffer collateral/commissural fibre pathway in stratum radiatum to 
confirm slice viability. Following stimulation of Schaffer collateral/commissural 
pathway, a clear field response at the pyramidal cell layer was observed. This field 
response consisted of positive waves, the population excitatory post-synaptic potential 
(pEPSP), and a brief negative wave, the population spikes (PS) (Figure 5.1). 
 
 
 
 
 
Figure 5.1: The arrangement of electrodes in hippocampus slices for in vitro epilepsy 
model. Left, the position of electrodes for recording was placed in CA1 pyramidal cell, 
and stimulation electrode was placed in Schaffer collateral/commissural fibre pathway 
in combined horizontal entorhinal cortex-hippocampus slices. Right, the fEPSP 
response in CA1 was evoked by stimulation Schaffer collateral/commissural fibre 
pathway. This waveform of a recording from the stratum pyramidale is initially a 
positive-going fEPSP that at times displayed a downward population spike.   
 
 
 
 
 
 
 
  
145 
 
Pentylenetetrazole model: PTZ (2 mM) (sigma) was added to the perfusate and K
+ was 
increased to 6 mM in order to induce epileptiform activity. Drugs were applied once the 
frequency and amplitude of the epileptiform discharges were stable for at least 10 
minutes. Anticonvulsant effects were evaluated by measuring the variation of frequency 
of the discharges every minute. 
 
Low-Mg
2+ Model: Low Mg
2+-induced epileptiform activity was elicited by using Mg
2+-
free aCSF. After the short discharges in hippocampal area CA1 were stable for at least 
10 minutes, drugs were applied for 40 minutes. Discharge frequency was measured 
every minute. 
All the drugs were applied by bath perfusion. VPA (1mM) (sigma), pentenoic acid 
(1mM) (sigma), H89 (10 µM) (sigma) were dissolved in distilled water, and SQ 22536 
(100 µM) (sigma) was dissolved in DMSO. All the drugs were prepared as 1000 times 
stocks and stored at -20°C. All drugs were directly dissolved in aCSF to achieve their 
final concentrations during experiments. The concentration of SQ22536 (100 μM) and 
H89 (10 μM) were chosen to have a maximal but specific effect in the hippocampus 
(Otmakhova and Lisman, 1998;Komagiri and Kitamura, 2003;Alle et al., 2001;Huang et 
al., 2002). 
 
The baseline consisted of the average discharge frequency over 10 minutes prior to drug 
application. The discharge frequency was then averaged every 5 minutes during the 
experiment and normalised to baseline. All data were expressed as mean±SEM. The 
mean discharge frequencies were compared by one way ANOVA and tukey test as post 
hoc test. Differences were considered as significant at P < 0.05.  
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5.3 Results 
5.3.1 The role of cAMP/PKA signalling system and the effect of VPA in PTZ model 
PTZ-induced positive field potentials appeared 10-30 minutes after application of PTZ 
plus increase of [K
+] (to 6 mM) (Figure 5.2). The epileptiform discharge consisted of a 
positive field potentials on which population spikes were superimposed. At steady state, 
the mean frequency of recurrent bust was 14.92± 0.84 per minute, n=25.   
 
 
 
 
 
Figure 5.2: Examples of CA1 pyramidal cell layer responses following PTZ application. 
Lower panel illustrates the trace on an expanded time scale. 
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Application of VPA (1 mM) significantly suppressed the frequency of burst discharges 
in this PTZ model to 75.06±1.68 % of control in CA1 region at 30-40 minutes after 
application (P<0.01) (Figure 5.3 and Figure 5.5). In contrast, application of pentenoic 
acid (1 mM), a straight chain analogue of VPA, only had a slight effect on the frequency 
of burst discharges (90.28± 2.01% of baseline) (Table 5.1 and Table 5.2) 
 
 
 
 
Figure 5.3: Summary of the change in the frequency of PTZ-induced burst discharges 
following application of VPA and pentenoic acid. The frequency of PTZ-induced burst 
discharges plotted against time. Drugs were applied between 0-40 minutes. Examples of 
trace recordings of PTZ-induced burst discharges are in right panels. Top-the trace 
recordings obtained in control condition; the middle-trace recordings obtained before, 
during and after application of VPA (1 mM); the lower- trace recordings obtained 
before, during and after application of pentenoic acid (1mM). 
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In order to address the question of whether cAMP/PKA signalling can directly influence 
the burst discharges in PTZ model, H89 (10 μM), a specific PKA inhibitor, was applied.   
Application of H89 had a non-significant effect on the frequency of epileptiform 
activity (88.47± 4.25% of baseline) (Figure 5.4 and Figure 5.5). Surprisingly, 
application of SQ 22536 (100 μM), an adenylyl cyclase inhibitor, significantly increased 
the frequency of burst activity to 127.39± 3.45 %, n=5, in 30-40 minutes after 
application in this PTZ model (P<0.01, compared to control group) (Table 5.1 and Table 
5.2). These effects were reversible after wash out (Figure 5.4). 
 
  
 
 
 
Figure 5.4: Summary of the changes in the frequency of PTZ-induced burst discharges 
following application of H89 and SQ22536. The frequency of PTZ-induced burst 
discharges plotted against time. Drugs were applied between 0-40 minutes. Example 
traces are illustrated in the right-hand panels. Top-the trace recordings obtained in 
control condition; the middle-trace recordings obtained before, during and after 
application of H89 (10 μM); the lower- trace recordings obtained before, during and 
after treatment with SQ22536 (100 μM). 
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Figure 5.5: Comparison of the mean frequency of PTZ-induced burst discharges with 
different treatments. Each column shows the mean value of the frequency of PTZ-
induced burst discharges expressed as a percentage of the baseline value. Graphs show 
means ± SEM. Statistical analysis was performed by post hoc test-Tukey test, following 
by ANOVA. * Indicates a significant difference (P<0.05), compared to control group.   
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Table 5.1: The result of ANOVA analysis with different treatment group (Control 
condition, VPA 1mM, pentenoic acid 1mM, SQ22536 100 μM, H89 10 μM) the main 
factor in PTZ model.    
 
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups  0.762 4 0.190 40.664  0.000 
Within Groups  0.094 20 0.005    
Total  0.855 24    
 
 
 
 
 
 
 
Table 5.2: Post-hoc comparison of different treatments in PTZ model by Tukey test  
95% Confidence 
Interval 
 
Mean 
Difference  
  
Std. 
Error 
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
Control VS. VPA (1 mM) 
0.24121(*) 0.04328 0.000  0.1117  0.3707
Control VS. Pentenoic acid (1 mM) 
0.08912 0.04328 0.276  -0.0404  0.2186
Control VS. H89 (10 μM) 
0.10725 0.04328 0.136  -0.0223  0.2368
Control VS. SQ22536 (100 μM) 
-0.28203(*) 0.04328 0.000  -0.4115  -0.1525
VPA (1 mM) VS. Pentenoic acid (1 mM) 
-0.15209(*) 0.04328 0.017  -0.2816  -0.0226
VPA (1 mM) VS. H89 (10 μM) 
-0.13396(*) 0.04328 0.040  -0.2635  -0.0045
VPA (1 mM) VS. SQ22536 (100 μM) 
-0.52324(*) 0.04328 0.000  -0.6527  -0.3937
Pentenoic acid (1 mM) VS. H89 (10 μM) 
0.01813 0.04328 0.993  -0.1114  0.1476
Pentenoic acid (1 mM) VS. SQ22536 (100 
μM)  -0.37114(*) 0.04328 0.000  -0.5006  -0.2416
H89 (10 μM) VS. SQ22536 (100 μM) 
-0.38927(*) 0.04328 0.000  -0.5188  -0.2598
* The mean difference is significant at the .05 level. 
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Although non-significant, there may be a small effect of H89, to address whether the 
effect of VPA on PKA system contributes to the efficacy of VPA in this model, the 
efficacy of VPA in the presence of H89 (10 μM) was tested. As shown in Figure 5.6, 
VPA (1mM) suppressed the frequency of bursts to75.24±3.89% of baseline, n=6, p<0.01 
compared to baseline by paired-sample t test). However, the effect of VPA on 
suppression of frequency of burst activity was unaffected by the presence of H89 
(without H89: 75.06±1.68 % n=5; with H89: 75.24±3.89%, n=6), indicating that the 
anticonvulsant effect of VPA is not through inhibition of PKA activity. 
 
 
 
 
Figure 5.6: Summary data for the effect of VPA (1 mM) on frequency of PTZ-induced 
burst discharges in area CA1 recorded from the stratum pyramidale without or without 
H89 (10 μM). The frequency of PTZ-induced burst discharges plotted against time. 
Drugs were applied between 0-40 minutes. Comparison of the mean frequency of PTZ-
induced burst discharges showed on the right panel. There is no significant difference 
on the effect of VPA in the frequency of PTZ-induced burst discharges in the present 
without or without H89. 
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5.3.2 The role of cAMP/PKA signalling system and the effect of VPA in low Mg
2+ 
model  
The anticonvulsant action of VPA and modulation of the cAMP/PKA signalling system 
was further tested in a separate in vitro epilepsy model induced by Mg
2+ free aCSF in 
combined entorhinal- hippocampal slices. 
 
Omission of Mg
2+ from the perfusate induced epileptiform recurrent short discharges in 
CA1 area after 20-40 minutes. After about one hour, the epileptiform discharges 
attained a stable rate of 3.16±0.29 per minutes, n=25. Each discharge comprised 2 to 5 
population spikes on a positive filed potential (Figure 5.7).     
 
 
 
 
Figure 5.7: Examples of pyramidal cell layer responses evoked by low-Mg
2+ aCSF 
application. Application of low-Mg
2+ aCSF induced epileptiform activity- recurrent 
short discharges. Lower panel illustrates expanded time scale. The epileptiform activity 
evoked by low-Mg
2+ aCSF application is comprised of population spikes   
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VPA (1 mM) suppressed the frequency of recurrent short discharges to 72.65±3.59 % of 
baseline, n=5 at 30-40 minutes after application (p=0.033, compared to control) (Table 
5.3 and Table 5.4) and this effect is reversible after wash out. Application of pentenoic 
acid, in contrast, has no significant effect on the frequency of recurrent short discharges 
in 30-40 minutes after application (92.51± 6.49 % of baseline, respectively, n=5) 
(Figure 5.8 and Figure 5.10).   
 
 
 
 
Figure 5.8: Summary of the change of frequency of low Mg
2+-induced epileptiform 
discharges in area CA1 recorded by application with VAP and pentenoic acid. Right 
panel shows the frequency of epileptiform activity induced by low Mg
2+ aCSF plotted 
against time. Drugs were applied between 0-40 minutes. Right panel shows the example 
of the trace recording of low Mg
2+-induced epileptiform discharges in area CA1. Top-
the trace recordings obtained in control condition; the middle-trace recordings obtained 
before, during and after application of VPA (1 mM); the lower- trace recordings 
obtained before, during and after application of pentenoic acid (1 mM).   
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Similar to the PTZ model, application of H89 has no significant effect on the frequency 
of burst discharges (100.38± 4.38 %, n=5). Application of SQ22536 significantly 
increased the frequency of epileptiform discharges repetition in 30-40 minutes after 
treatment (149.99±8.60% of baseline, n=5, p<0.01 compared to control) (Table 5.3 and 
Table 5.4). The effect of SQ22536 on epileptiform activity was reversible after washout 
(Figure 5.9 and Figure 5.10).   
 
 
 
 
Figure 5.9: Effect of cAMP/PKA signalling system on epileptiform activity induced by 
low Mg
2+ aCSF in combined rat entorhinal cortex-hippocampus slices. (A) Summary 
the data for the change of frequency of low Mg
2+-induced epileptiform discharges in 
area CA1 recorded from. The frequency of epileptiform activity induced by low Mg
2+ 
aCSF plotted against time. Drugs were applied between 0-40 minutes. (B) Sample trace 
recordings of low Mg
2+-induced epileptiform discharges. Top-the trace recordings 
obtained in control condition; the middle-trace recordings obtained before, during and 
after application of H89 (10 μM); the lower- trace recordings obtained before, during 
and after application of SQ22536 (100 μM). 
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Figure 5.10: Comparison of the mean frequency of epileptiform activity with different 
treatments. Each column shows the mean value of the frequency of epileptiform- activity 
expressed as a percentage of the baseline value. N =5 for each drug. Graphs show 
means ± SEM. Statistical analysis was performed by post hoc test-Tukey test, following 
by ANOVA. * Indicates a significant difference (P<0.05).   
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Table 5.3 The ANOVA result in for effect of treatment (Control condition, VPA 1mM, 
pentenoic acid 1mM, SQ22536 100 μM, H89 10 μM) in low Mg
2+ model.     
   Sum of  df  Mean Square  F  Sig. 
Between Groups  1.627 4 0.407 21.851  0.000 
Within Groups  0.372 20 0.019    
Total  2.000 24    
 
 
Table 5.4: Multiple comparisons of treatments in low Mg
2+ model by Tukey-test.   
95% 
 
Mean 
Difference 
Std. 
Error 
Sig. 
   Lower  Upper 
Control VS. VPA (1mM)  0.27517(*) 0.08630  0.033  0.0169 0.5334
Control VS. Pentenoic acid (1mM)  0.07658 0.08630  0.898  -0.1817 0.3348
Control VS. H89 (10 μM)  -0.00218 0.08630  1.000  -0.2604 0.2560
Control VS. SQ22536 (100 μM)  -.49828(*) 0.08630  0.000  -0.7565 -0.2400
VPA (1mM) VS. Pentenoic acid (1mM)  -0.19859 0.08630  0.186  -0.4568 0.0596
VPA (1mM) VS. H89 (10 μM)  -0.27735(*) 0.08630  0.032  -0.5356 -0.0191
VPA (1mM) VS. SQ22536 (100 μM)  0-.77345(*) 0.08630  0.000  -1.0317 -0.5152
Pentenoic acid (1mM) VS. H89 (10 μM)  -0.07876 0.08630  0.889  -0.3370 0.1795
Pentenoic acid (1mM) VS. SQ22536 (100 μM)  -0.57486(*) 0.08630  0.000  -0.8331 -0.3166
H89 (10 μM) VS. SQ22536 (100 μM)  -0.49610(*) 0.08630  0.000  -0.7543 -0.2379
*    The mean difference is significant at the .05 level. 
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5.4 Discussion 
In this study, the question whether the effect of VPA on modulation of cAMP/PKA 
signalling system could explain the antiepileptic effect of VPA was asked. I took 
advantage of two acute in vitro seizure models, PTZ model and low Mg
2+ model, in 
which VPA has previously been shown to be effective (Armand et al., 1998;Sokolova et 
al., 1998). By using these two well-established models, it showed that VPA has a 
significant depressive effect on epileptiform activities, whereas pentenoic acid lacks 
effect. Furthermore, the effect of VPA on depression of frequency of burst spikes is not 
directly through modulation PKA. In these experiments, it shows that application of 
SQ22536 significantly increased the frequency of bursts in these two models, whereas 
H89, a PKA inhibitor, had no significant effect, and could not occlude the effects of 
VPA. 
 
These experiment, combined hippocampal-entorhinal-cortex slice was used, instead of 
isolated hippocampal slices. Unlike isolated hippocampal slices, hippocampal- 
entorhinal cortex slices preserve the connectivity between the entorhinal cortex and 
hippocampus. The entorhinal cortex is the major source of afferents to the hippocampus 
via the perforant path. The hippocampal-entorhinal cortex slice therefore enables 
recurrent excitation between the hippocampus and entorhinal cortex and so is better able 
to maintain epileptiform activity. 
 
Alterations in neuronal metabolism plays an important role in epileptogenesis 
(Arabadzisz et al., 2005;Raza et al., 2004) and protein phosphorylation has been 
reported to increase in status epilepticus (Funke et al., 1998;Moussa et al., 2001). There  
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is also considerable evidence that potentiating the production of cAMP increases 
epileptic activity (Higashima et al., 2002; Üre and Altrup, 2006), and that cAMP 
production increases with seizure activity (Hattori et al., 1987;Hattori et al., 1993). This 
and the persistent increase in the expression level of type II adenylyl cyclase mRNA 
after generalized seizure (Iwasa et al., 2000) has led to the proposal that increases in 
cAMP and/or activation of PKA have a proepileptic effect. Since a robust action of VPA 
on cAMP/PKA signalling and a lack of effect of pentenoic acid a compound that has no 
antiepileptic activity in vivo was observed (Chapman et al., 1983;Keane et al., 1983), 
the question whether this could explain the antiepileptic effect of VPA was asked. The 
advantage of two acute in vitro seizure models in which VPA has previously been 
shown to be effective were taken (Armand et al., 1998;Sokolova et al., 1998). 
  
Consistent with previous studies, the result was observed an antiepileptic effect of VPA; 
importantly, pentenoic acid had no effect in these models, consistent with the 
hypothesis. To further test this hypothesis, the effects of decreasing cAMP production 
through inhibition of adenylyl cyclase with SQ22536 or inhibition of PKA activity with 
H89 were tested. Inhibition of PKA activity had no effect on seizure activity and did not 
occlude the effects of VPA, indicating that VPA was reducing epileptiform activity 
through a different mechanism. The results do not imply that the action of VPA on 
adenylyl cyclase/PKA has no antiepileptic effect, but that this action cannot explain 
VPA’s efficacy in these slice models 
 
Surprisingly, inhibition of adenylyl cyclase with SQ22536 increased the epileptiform 
activity. One possible explanation, which was hypothesised by Ferrendelli et al. (1980),  
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is that accumulation of cAMP may be involved in mechanisms of inhibiting the spread 
and/or duration of seizure discharges but not in seizure induction. Pre-treatment with 
drugs decreasing accumulation of cAMP resulted in augmented seizure severity (Gross 
and Ferrendelli, 1979). The role of cAMP is further confounded by the observation that 
under some circumstances cAMP analogues can have an antiepileptic effect (Apland et 
al., 1997). This suggests a biphasic effect in which increases in cAMP (such as 
following administration of forskolin), and marked reductions in cAMP levels can both 
promote seizure activity. 
 
. 
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Chapter 6: The effect of VPA on mossy fibre 
response in status epilepticus rat 
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6.1 Introduction 
As detailed in chapter 1, there are numerous mechanisms that contribute to the 
development of epilepsy. In addition to the development of epilepsy, there are changes 
that occur in synaptic plasticity, in particular the occurrence of metaplasticity- a change 
in the ability of the system to undergo synaptic plasticity (Goussakov et al., 2000). This 
has been observed at the mossy fibre to CA3 synapse; the ability to elicit mossy fibre 
LTP is compromised in post status epilepticus rats (Goussakov et al., 2000). This is 
associated with a decrease in paired-pulse facilitation lasting at least several weeks after 
SE; this implies that release probability at this synapse is increased during 
epileptogenesis so that LTP cannot occur (Goussakov et al., 2000). One possible 
explanation is that the cAMP/PKA signalling system is overstimulated during 
epileptogenesis, so occluding mossy fibre LTP. If this is the case, then VPA should have 
an effect on baseline transmission at the mossy fibre-CA3 synapse in epileptic rats. In 
this chapter, this hypothesis is set up to be tested. 
 
The pilocarpine model of epilepsy was used to address this hypothesis. There are a 
number of advantages of using the pilocarpine model of epilepsy to address the effect of 
VPA on the mossy fibre -CA3 response following SE. Unlike the electrical stimulation 
model in which electrodes are implanted into brain, the pilocarpine model of epilepsy 
does not require implantation or prior anaesthesia, reducing both animal suffering and 
experimental time. More importantly, the pilocarpine model is a well characterised 
chronic epilepsy model which shares many of the clinical and pathophysiological 
characteristics of partial-complex or temporal-lobe epilepsy in humans (Babb et al., 
1991;Houser, 1990;Strowbridge et al., 1992;Sutula et al., 1989), such as hippocampal 
sclerosis, mossy fibre sprouting (Mello et al., 1993), neuronal hyperexcitability 
(Isokawa and Mello, 1991), altered GABA(A) receptor function (Rice et al., 1996), and  
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interictal spike patterns on EEG (Leite et al., 1990).   
 
Administration of pilocarpine to rats results in progressive worsening seizures, leading 
to long-lasting SE (Turski et al., 1989). The behavioural and EEG alterations, which are 
induced by administration pilocarpine in rats, are similar to those observed in human 
temporal lobe epilepsy (Cavalheiro et al., 1996;Cavalheiro, 1995;Curia et al., 2008). 
After onset of SE, pilocarpine-treated animals enter seizure-free period, which is known 
as the latent period. During the latent period, pilocarpine-treated animals generally show 
normal behaviour and EEG activity. Recurrent spontaneous seizure occurs after latent 
period. 
  
In this model, days to weeks following SE, animals begin having spontaneous recurrent 
seizures (SRSs) and continue to have seizures for the lifetime of the animal (Mello et 
al., 1993;Priel et al., 1996). Thus, the pilocarpine model with its similarities to human 
epilepsy provides a relevant model to investigate the molecular mechanisms underlying 
the transition from a normal to an epileptic brain following a brain insult such as SE. 
 
Using the pilocarpine model, the question whether the effect of VPA on the mossy fibre 
-CA3 response was altered following SE was asked. 
 
6.2 Methods 
6.2.1 Seizure induction 
Details of the experimental procedure are described in general methods chapter. In brief, 
adult male Sprague–Dawley rats were administrated scopolamine methyl nitrate (1 
mg/kg, ip), 20 min before and after induction of SE by injection of pilocarpine (320  
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mg/kg). Seizures were monitored behaviourally. Seizures were terminated with 
diazepam (10 mg/kg, ip) 90 min after the injection of pilocarpine, and diazepam dosing 
was repeated as necessary to prevent recurrence of seizure behaviour. Following 
termination of seizures, all animals were kept hydrated with subcutaneous saline. Only 
animals that displayed continuous convulsive seizure activity reached stage three were 
used in the experimental ‘‘seizure’’ group. 
 
This protocol results in animals progressing on to spontaneous recurrent seizures (Mello 
et al., 1993) (Figure 6.1). and optimises the number of animals developing epilepsy 
against mortality from SE (Curia et al., 2008). 
 
 
 
 
 
 
Figure 6.1: The progress of developing epilepsy in pilocarpine model. 
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6.2.2 Electrophysiology 
Two weeks after induction of epilepsy by administration of pilocarpine, the rats were 
decapitated after killing by injection with an overdose of pentobarbitone (500 mg/kg, ip). 
Brains were removed and preserved in oxygenated ice-cold sucrose solution. Transverse 
slices (350 μm) were prepared and were then stored in an interface chamber containing 
artificial cerebrospinal fluid solution (aCSF) (detail see general methods). The slices 
were stored for over one hour before being transferred to a submersion recording 
chamber continually perfused with aCSF for recording. 
 
fEPSP were recorded using glass microelectrodes (approximately 2MΩ resistance) 
filled with aCSF solution positioned in the stratum lucidum in CA3, the mossy fibre 
termination zone. Bipolar stainless steel stimulating electrodes were positioned in the 
dentate granule cell layer, and 0.6 mA pulses (400 µs duration) were applied with 
constant current stimulators. The electrode positions and stimulus intensities were 
adjusted until mossy fibre fEPSPs of maximal amplitude were recorded. 
 
6.2.3 Data analysis 
As in chapter 3, NBQX 25 μM (sigma), AMPA/kainate receptor antagonist, was applied 
at the end of each mossy fiber experiment to assess the amplitude of the fiber volleys, 
and was subtracted from fEPSP responses. The amplitude of the fiber volleys were 
normalised to baseline. Data are shown as mean ± SEM. The mean fEPSP amplitudes in 
groups were compared by paired T-test. Differences were considered as significant at P 
< 0.05. 
 
  
165 
 
6.3 Results 
6.3.1 Behavioural alterations after administration of pilocarpine 
The pilocarpine model is a well documented animal model to investigate the 
development of epilepsy. After pilocarpine administration (320 mg/kg, ip), rats 
demonstrate consistent behavioural changes. These began with akinesia, ataxia, 
lurching, peripheral cholinergic signs (such as piloerection, bloody tears, and diarrhoea), 
stereotyped movements (continuous sniffing, paw licking, rearing), clonic movements 
of forelimbs, head bobbing and tremors and finally evolved to the general motor seizure 
which are classified as stage 5 by the Racine scale (Racine, 1972). In this study, 80 % of 
rats developed stage 3 seizures following administration of pilocarpine. Only these rats 
were used in subsequent experiments (Figure 6.2).   
 
 
 
 
 
Figure 6.2: The percentage of the rats treated with pilocarpine developing stage three 
seizures during status epilepticus. 
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The time for rats to develop stage 3 seizures are varied. The mean time for rats to 
develop seizure reach stage 3 is 23±4.56 minutes. A box-whisker plot which is helpful 
to understand the distribution of the time needed for rats to develop different stage 
seizures were used (Figure 6.3). The line in the middle of the box indicates the median 
values which is 29 minutes. The value of right and left lines of each “box” (25th and 
75th percentiles) are 29 minutes and 35 minutes, respectively. The “whiskers” (lines 
extending right and left the box) show the extent minimum value and maximum value 
which are 15 minutes and 56 minutes, respectively. Because of the whisker to the right 
of the box is much longer than the one to the left indicates that the distribution is 
positively skewed. 
 
 
 
 
Figure 6.3: Box-and-whiskers plot showing that the time developing to stage 3 seizures, 
following intraperitoneal injection with pilocarpine (320 mg/kg). The box 
Represents ± 25% percentile and the whiskers represent full range.   
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6.3.2 The alteration of effect of VPA on short-term potentiation in mossy fibres 
synapse CA3 in rat with status epilepticus 
Rats following SE were killed two weeks after SE at a time when metaplasticity of 
mossy fibre responses has been previously described. Slices form these animals were 
compared against those from control (non-SE) animals from chapter 3. The effects of 
VPA (1 mM) on baseline neurotransmission and on short-term potentiation in the mossy 
fibre synapse CA3 (previously in chapter 3) were first tested. The result showed that in 
control animals VPA had no effect on these). The experiments were performed in 
isolated hippocampal slices, a bipolar stimulating electrode were placed in dentate 
granule cell layer; a recording electrode was placed in stratum lucidum (as previously 
described). Once a candidate mossy fibre fEPSP was found, the stimulus frequency was 
increased from 0.05 Hz to 1 Hz. (See chapter 3).   
  
After baseline recording with 0.05 Hz and 1 Hz electrical stimulation, VPA was added 
to the perfusate and the frequency facilitation was repeated. Similar to chapter 3, there 
was no effect of VPA on fEPSP amplitude during stimulation at 0.05 Hz (after VPA 
1mM: 87.35±8.06 % of baseline) (Table 6.1). However, VPA altered short-term 
plasticity. Frequency facilitation was significantly decreased (Before VPA 1mM: 
349.32±47.08% of baseline, after VPA 1mM: 255.96±30.69% of baseline, p=0.03 paired 
t test) (Figure 6.4 and Table 6.2).    
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Figure 6.4: The effect of VPA on STP at the mossy fibre synapse to CA3 region in 
hippocampi acquired from post status epilepticus rats. The hippocampal slices were 
acquired from the rats 2 weeks after induction of status epilepticus. (A) Example 
fEPSPs at 0.05 Hz and 1 HZ without and with VPA. (B) Example experiment of fEPSP 
amplitude at different stimulation frequency (0.05 Hz and 1 Hz) before and then after 
addition of VPA. (C) Comparison of the mean amplitude of fEPSP before and after 
administration with VPA (1mM) at two stimulation frequencies. Graphs show means ± 
SEM. * Indicates a significant difference between the two groups (P<0.05). 
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Table 6.1 Paired Samples T-Test of the baseline transmission before and after treated 
VPA in mossy fibre synapse to CA3 in hippocampus acquired from status epilepticus 
rats. 
 
Paired Differences 
95% Confidence 
Interval of the 
Difference    
  
Mean 
  
Std. 
Deviati
on 
  
Std. 
Error 
Mean 
   Lower  Upper 
t 
  
  
df 
  
  
Sig. (2-
tailed) 
  
  
Rat in control 
condition 
(Before VPA 
Vs After VPA 
0.12651  0.18018 0.08058 -0.09721 0.35024 1.570  4  0.191
 
 
 
 
Table 6.2 Paired Samples T-Test of STP before and after treated VPA in mossy fibre 
synapse to CA3 in hippocampus acquired from status epilepticus rats.   
Paired Differences
95% Confidence 
Interval of the 
Difference
  
  
  
Mean 
  
Std. 
Deviati
on 
  
Std. 
Error 
Mean 
   Lower  Upper 
 
t 
  
  
 
df 
  
  
 
Sig. (2-
tailed) 
  
  
status 
epilepticus 
(Before VPA 
Vs After VPA) 
0.93364  0.63872 0.28565 0.14056 1.72672 3.269  4  0.031
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6.4 Discussion 
In this experiment, a post-status epilepticus epilepsy model, the “Pilocarpine model”, 
was used to investigate whether VPA could reverse the mossy fibre metaplasticity 
observed with epileptogenesis. Unexpectedly, VPA had no effect on baseline 
transmission but decreased short term potentiation in epileptic animals.   
 
It is suggested that the cAMP/PKA signalling system as mossy fibres during 
epileptogenesis may be “over activated”. Genetically altered animals which display 
spontaneous seizure activity show an abnormal elevation of protein kinase A activity 
(Tehrani and Barnes, 1995a;Yechikhov et al., 2001). If this were the case VPA would be 
expected to reduce baseline transmission in the epileptic animals through inhibition of 
cAMP accumulation. However, no such change was observed. Instead, VPA decreased 
short term potentiation (STP) at the mossy fibre synapse. This contrasts with the effects 
of VPA in slices from healthy animals (chapter 3) where VPA had no effect on STP. 
What is the mechanism of this? Normally STP is the result of increasing presynaptic 
calcium accumulation and is partly dependent on the activation of pre-synaptic kainate 
receptors (Contractor et al., 2001). The absence of an effect of VPA on mossy fibre STP 
in naive animals suggests that VPA does not act on these mechanisms. Also it suggests 
that VPA is not causing a use dependent block of sodium channels at the low frequency 
(1 Hz) necessary to induce STP at this synapse. That VPA having an effect in epileptic 
animals results in two new hypotheses: 1) the mechanism underlying STP at mossy 
fibres has changed in epileptogenesis, and 2) this new mechanism is sensitive to 
inhibition by VPA. Indeed, it has been previously established that SE can lead to a long-
lasting modification of release probability in mossy fibre synapses. Paired-pulse 
facilitation and augmentation in mossy fibres are potently reduced several weeks after 
SE (Goussakov et al., 2000). Mossy fibre LTP is also severely diminished. In addition,  
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potentiation of transmission by activation of either adenylyl cyclase or protein kinase A 
is abolished in SE animals (Goussakov et al., 2000).   
 
Further testing of these hypotheses was beyond the scope of this thesis. Nevertheless, 
the effect of VPA on STP in only epileptic animals indicates that such a mechanism may 
selectively decrease higher frequency transmission specifically in epileptic tissue and 
could contribute to the antiepileptic effect of VPA. 
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Chapter 7: The effect of 4-methyloctanoic acid, 
an analogue of VPA, in animal models of epilepsy   
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7.1 Introduction 
Although valproic acid (VPA) is used extensively for treating various kinds of epilepsy, 
its use has been hampered by its teratogenic potential. It may result in multiple birth 
defects, dysmorphic facies, developmental delay, learning difficulties and/or 
behavioural problems in humans (Kini, 2006), and in animals (Narotsky et al., 
1994;Menegola et al., 1998). In addition, therapeutic use of the VPA has been associated 
with severe and often fatal hepatotoxicity. Patients usually present with lethargy, 
anorexia, and vomiting with rapid progression to coma (Stephens and Levy, 1992). 
Therefore, it would be advantageous to develop a more potent and safer drug. 
 
There have been previous studies of the efficacy of branched chain fatty acids in sound 
induced epilepsy mice (Chapman et al., 1983). Previous studies have indicated that 
branched chain fatty acids have activity against seizure induced by pentylenetetrazole, 
whereas straight chain fatty acids have limited effect on the suppression of seizure 
activity. Furthermore, branched chain fatty acids increase brain GABA levels, whereas 
straight chain fatty acids do not (Keane et al., 1983).   
 
4-methyloctanoic acid, an analogue of VPA, is a branched short-chain fatty acid (Figure 
7.1). It is responsible for the sweaty/sour flavour in mutton (Brennand and Lindsay, 
1992). During cooking, 4-methyloctanoic is released from lamb and mutton (Brennand 
et al., 1989). Even though, milk fat of cows only contain low concentrations of 4-
methyloctanoic acid, milk fat of sheep and goat contains significant amounts of 4-
methyloctanoic, which contributes to mutton-like and goat-like flavours. In addition, 4-
methyloctanoic acid from goat and sheep milks provides distinguishing flavours to 
various cheese (Ha and Lindsay, 1991). Importantly, fatty acids with a methyl side chain 
have been shown to lack teratogenic effects (Narotsky et al., 1994).  
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In this chapter, the potency of VPA and 4-methyloctanoic acid, a branched-chain 
analogue of VPA was first tested, for their anti-acute seizure activity in in vitro PTZ and 
low Mg
2+ model. Further, VPA and 4-methyloctanoic were tested for their 
anticonvulsant activity in a SE in vivo model (the perforant pathway stimulation model). 
Two months later, the neuroprotective effect of VPA and 4-methyloctanoic acid were 
evaluated by histological method. Finally, in order to understand whether 4-
methyloctanoic shares similar mechanisms with VPA on the modulation of cAMP, the 
effect of 4-methyloctanoic on the enhancement of mossy fibre responses induced by 
application with forskolin was also tested.   
 
 
 
  
 
Figure 7.1: Comparison of the structures of VPA and 4-methyloctanoic acid 
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7.2 Methods 
7.2.1 In vitro seizure models 
Hippocampus slides preparation 
Horizontal combined entorhinal cortex-hippocampus slices (350-µm) were prepared 
from SD rat and storage in an interface chamber contained artificial cerebrospinal fluid 
solution (aCSF) gassed with 95% O2 / 5% CO2 (See general method).   
 
PTZ model 
Pentelenetetrazole (PTZ) (2 mM) was added to the perfusate and [K
+] was increased to 
6 mM in order to induce epileptiform activity.   
 
Low Mg
2+ model 
Application with Mg
2+ free aCSF generated a rhythmic short recurrent discharges 
activity in CA1 and CA3 area in hippocampus in rats.   
(For more detail methods see general method and chapter) 
 
 
7.2.2 In vivo experiments   
In vivo status epilepticus: This method has been described in detail in in vivo status 
epilepticus. 
 
The depths of the electrodes were adjusted to maximize the slope of the dentate granule 
cell field potential. During surgery, the location of recording electrode can be 
recognized by the patterns of field potential responses (Figure 7.2). When the recording 
electrode entered CA1 region, the field potential shows a negative wave superimpose a 
positive wave. When recording electrode close to the dentate gyrus, the pattern of field 
potential changed, the latency was decreased and the positive wave was deceased. When  
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the electrode entered molecular layer of the dentate gyrus, it started to show population 
spikes. The optimist positions of recording electrode (especially regarding depth) is the 
amplitude of maximum population spike reached 4-5 mV. 
 
The electrodes were held in place with dental acrylic and skull screws. The animals 
were allowed to recover from anaesthesia. Seven days later, the perforant path was 
electrically stimulated with 4-5 mA 50 µsec monopolar pulses at 20 Hz for 2 hr; this 
induced self-sustaining SE. After 10 min of self-sustaining SE, compounds (VPA or 4-
methyloctanoic acid) or vehicle were administered and the behavioural seizures and 
EEG were monitored for 3 hours. At this point diazepam (10 mg/kg) was administered 
to all animals to stop the status epilepticus. Groups were compared by ANOVA followed 
by post-hoc testing using Tukey test.   
 
 
 
Figure 7.2: Histological localization and of chronically implanted electrodes. (A)The 
field potential recording in CA1 shows a negative wave superimposes a positive wave. 
(B)The latency was decreased and the positive wave was deceased when electrode 
recording close to dentate gyrus. (C)The field potential recording in molecular layer of 
the dentate gyrus shows population spikes. (D) The photo of hippocampal slices. The 
black dock is the location of recording electrode in dentate gyrus 
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7.3 Result 
7.3.1 The effect of 4-methyloctanoic acid on acute seizure in vitro model-PTZ 
model  
Application with branched chain fatty acid, 4-Methyloctanoic acid (1 mM), 
significantly suppressed the frequency of burst discharge induced by administration 
with PTZ (49.14±4.49 %) in the CA1 region 30-40 minutes after application (P<0.01, 
compared to control group). The effect of 4-methyloctanoic was greater than that of 
VPA (1mM) (VPA: 75.06±1.68 % of baseline, n=5, p<0.01 compared to 4-
Methyloctanoic acid) (Figure 7.3, Table 7.1, and Table 7.2). 
 
 
                                                                                
Figure7.3: The comparison of the effect of 4-methyloctanoic acid and VPA on the 
frequency of epileptiform activity induced by application of PTZ in combined entorhinal 
cortex-hippocampus. (A) Summary of the frequency of PTZ-induced burst discharges 
following application of 4-methyloctanoic acid or VPA. The frequency of epileptiform 
activity induced by PTZ plotted against time. The drugs were application from time=0 
to 40 minutes. (B) Comparison of the mean frequency of PTZ-induced burst discharges 
with different treatments. Graphs show means ± SEM. * Indicates a significant 
difference at P<0.05, ** Indicates a significant difference at P<0.01 
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Table 7.1: The ANOVA result of frequency of burst-discharge in different treatmenst 
(Control, 4-methyloctanoic acid 1mM, VPA 1mM) in in vitro model of epilepsy-PTZ 
model.  
  
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups  0.627 2 0.313 57.009  0.0000007 
Within Groups  0.066 12 0.005    
Total  0.693 14    
 
 
Table 7.2: Post-hoc comparison of frequency of burst-discharge with treatments 
(Control, 4- methyloctanoic acid 1mM, VPA 1mM) in in vitro PTZ model by Tukey test 
95% Confidence 
Interval 
 
Mean 
Difference 
  
Std. Error 
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
Control VS 4-methyloctanoic acid  0.50056(*) 0.04689 0.000 0.3755  0.6257
Control VS VPA  0.24121(*) 0.04689 0.001 0.1161  0.3663
4-Methyloctanoic acid VS VPA  -0.25935(*) 0.04689 0.000 -0.3844  -0.1343
*    The mean difference is significant at the .05 level. 
 
 
 
7.3.2 The effect of 4-methyloctanoic in vitro low Mg
2+ model 
In order to confirm the potency of 4-methyloctanoic, the effect in a different in vitro 
model induced by low-Mg
2+ in combined entorhinal-hippocampal slices was also tested. 
VPA (1 mM) suppressed the frequency of recurrent short discharges to 72.65±3.59 % of 
baseline, n=5 30-40 minutes after application and the effect of suppression is reversible 
after wash out. Application of 4-methyloctanoic acid almost abolished the frequency of 
recurrent short discharges30-40 minutes after application to (1.60± 3.12 % of baseline, 
n=5, p<0.01compared to control; P<0.01 compared to VPA) (Figure 7.4, Table 7.3, and 
Table 7.4).   
  
179 
 
 
Figure 7.4: The comparison of the effect of 4-methyloctanoic acid and VPA on the 
frequency of epileptiform activity induced by low Mg
2+ aCSF in combined entorhinal 
cortex-hippocampus. (A) Summary the change in the frequency of low Mg
2+ -induced 
burst discharges following application of 4-methyloctanoic acid or VPA. The frequency 
of epileptiform activity induced by Mg
2+-free aCSF plotted against time. The drugs were 
given from time = 0 to 40 minutes. (B) Comparison of the mean frequency of low Mg
2+ -
induced burst discharges with different treatments. Graphs show means ± SEM. * 
Indicates a significant difference P<0.05, ** Indicates a significant difference P<0.01 
 
 
 
 
Table 7.3: The ANOVA result of frequency of burst-discharge in different treatment 
groups (Control, 4-methyloctanoic acid 1mM, VPA 1mM) in in vitro low Mg
2+ model. 
  
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups  24898.944 2 12449.472 169.752  0.000 
Within Groups  880.070 12 73.339    
Total  25779.014 14    
 
 
 
 
Table 7.4: Post-hoc comparison of burst-discharge of different treatments (Control, 4-
methyloctanoic acid 1mM, VPA 1mM) in in vitro low Mg
2+ model by Tukey test 
95% Confidence Interval 
  
Mean 
Difference  
  
Std. Error
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
Control VS VPA  24.61214(*) 5.41624 0.002  10.1623  39.0619
Control VS 4-methyloctanoic acid  96.06384(*) 5.41624 0.000  81.6141  110.5136
VPA VS 4-methyloctanoic acid  71.45171(*) 5.41624 0.000  57.0019  85.9015
*    The mean difference is significant at the .05 level. 
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7.3.3 The effect of 4-methyloctanoic in in vivo electrical stimulation model of status 
epilepticus 
To further demonstrate efficacy in epilepsy with these compounds, 4-methyloctanoic 
acid in an in vivo model of status epilepticus induced by perforant pathway stimulation 
was tested. This model is resistant to a number of antiepileptic drugs and does not 
involve the application of an exogenous convulsant. 
 
First, the effective concentration of VPA in this in vivo model was tested. VPA is 
effective in this model at 600 mg/kg which abolished the seizure activity (not only the 
EEG activity but also behavioural seizures) in all animals. This contrasted with lower 
dose VPA (400 mg/kg) which was ineffective (Figure 7.5).   
 
 
 
Figure 7.5: Comparison of the effects of VPA in different concentration (400 mg/kg and 
600 mg/kg) on spontaneous spikes activity, including spike amplitude and spike 
frequency, induced by perforant path stimulation. Rats given saline were used as control 
group (n=5). (A) A summary of the change of amplitude after administration with VPA 
(n=5 at each dose) in SE rats. (B) A summary of the change of frequency after 
administration with VPA in SE rats. 
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The efficacy of 4-methyloctanoic acid (400 mg/kg) against VPA (400 mg/kg) and 
vehicle control (DMSO) group (Summary in Table 7.5 and Table 7.6) were compared. 
Administration of 4-methyloctanoic reduced the mean spike frequency to 39.33±11.28 
% in the first hour, 18.06±10.28% in the second hour, 26.85±12.31% in the third hour. 
4-methyloctanoic terminated status epileptius (defined as a spike frequency of less than 
1 Hz) in status epilepticus animals. Administration with VPA has less effective on spike 
frequency than administration with 4-methyloctanoic acid (75.16±9.23 % in the first 
hour, 61.05±8.33% in the second hour, 55.08±6.64% in the third hour). In VPA group, 
status epilepticus was not stopped in any of the animals investigated. In this experiment, 
the DMSO which is the solvent of 4-methyloctanoic acid was also tested; administration 
with DMSO shows no effect on the spike frequency (100.44±5.17 % in the first hour, 
103.32±9.79% in the second hour, 97.56±4.98% in the third hour) (Figure 7.6; Figure 
7.7) 
As result shown in Figure 7.6; Figure 7.8, 4-Methyloctanoic acid also shows a 
significant effect on suppression of the spikes amplitude (to 27.17±9.79 % in the first 
hour, 18.87±1.15% in the second hour, 44.45±17.13% in the third hour). Interestingly, 
administration with VPA suppressed spike amplitude which increased at later time 
points (40.06±7.74 % in the first hour, 49.02±15.59% in the second hour, and 
92.22±36.88% in the third hour) (Summary Table 7.7 and Table 7.8).   
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Figure 7.6: Illustrative trace samples of EEG from status epilepticus animal. 
Administration with VPA (400 mg/kg) or 4-methyloctanoic acid (400 mg/kg) shows 
attenuation of seizure activity by VPA and termination of seizure activity by 4-
methyloctanoic acid, whereas the DMSO has no effect on seizure activity. 
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Figure 7.7: Comparison of the effects of 4-methyloctanoic acid (400 mg/kg) and VPA 
(400 mg/kg) on the frequency of the spontaneous spikes activity, induced by perforant 
path stimulation. (A) Time course of the effects on spontaneous spike frequency 
following administration of DMSO (n=5), VPA (n=7) or 4-methyloctanoic acid (n=7) in 
10 minutes after stop perforant path stimulation. (B) Summary data for the effects of 
DMSO, VPA and 4-methyloctanoic acid in one, two and three hour after administration. 
. * Indicates a significant difference P<0.05, ** Indicates a significant difference 
P<0.01 and NS indicates non-significant. 
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Table7.5: The ANOVA result of spikes frequency in status epilepticus rats with different 
treatment (DMSO, 4-methyloctanoic acid 400 mg/kg, VPA 400 mg/kg.)   
ANOVA  The first hour  The second hour  The third hour 
F Values  9.607  18.472  13.387 
Sig. 0.002  0.00007  0.0004 
 
 
 
Table 7.6: The result of Post Hoc Tests-Tukey (Multiple Comparisons), compared the 
spike frequency in one hour, two hour and three hour after different treatment (DMSO, 
4-methyloctanoic acid 400 mg/kg, VPA 400 mg/kg) in status epilepticus rats 
95% Confidence Interval   
  One hours after administration 
drugs 
Mean 
Difference  
  
Std. Error
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
4-methyloctanoic acid VS DMSO  -0.61106(*) 0.14241 0.002  -0.9785  -0.2436
4-Methyloctanopic acid VS VPA  -0.35825(*) 0.13000 0.036  -0.6937  -0.0228
DMSO VS VPA  0.25280 0.14241 0.209  -0.1147  0.6203
*    The mean difference is significant at the .05 level. 
 
 
95% Confidence Interval 
Two hours after administration 
drugs 
Mean 
Difference  
  
Std. Error
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
4-Methyloctanoic acid VS DMSO  -0.85167(*) 0.14094 0.00005  -1.2153  -0.4880
4-Methyloctanoic acid VS VPA  -0.42999(*) 0.12866 0.011  -0.7620  -0.0980
DMSO VS VPA  0.42168(*) 0.14094 0.022  0.0580  0.7854
*    The mean difference is significant at the .05 level. 
 
 
95% Confidence Interval 
  Three hours after administration 
drugs 
Mean 
Difference  
  
Std. Error
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
4-Methyloctanoic acid VS DMSO  -0.70704(*) 0.13667 0.0003  -1.0597  -0.3544
4-Methyloctanoic acid VS VPA  -0.28228 0.12476 0.091  -0.6042  0.0397
DMSO VS VPA  0.42475(*) 0.13667 0.018  0.0721  0.7774
*    The mean difference is significant at the .05 level. 
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Figure 7.8: Comparison of the effects of 4-methyloctanoic acid (400 mg/kg) and VPA 
(400 mg/kg) on the amplitude of the spontaneous spikes activity, induced by perforant 
path stimulation. (A) Time course of the effects on spontaneous spike amplitude 
following administration of DMSO (n=5), VPA (n=7) or 4-methyloctanoic acid (n=7) in 
10 minutes after stop perforant path stimulation. (B) Summary data for the effects of 
DMSO, VPA and 4-methyloctanoic acid in one, two and three hour after administration. 
* Indicates a significant difference P<0.05, ** Indicates a significant difference P<0.01 
and NS indicates non-significant.     
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Table 7.7: ANOVA result of spikes amplitude in status epilepticus animals with different 
treatments (DMSO, 4-methyloctanoic acid 400 mg/kg, VPA 400 mg/kg) 
  The first hour  The second hour  The third hour 
F Values  13.119  4.601  0.912 
Sig. 0.0004  0.026 0.422 
 
Table 7.8: The result of Tukey (Multiple Comparisons), comparing the spike amplitude 
in one hour, two hour and three hour after different treatments (DMSO,   
4-methyloctanoic acid 400 mg/kg, and VPA 400 mg/kg) in status epilepticus animal. 
95% Confidence 
Interval 
  One hours after administration drugs 
Mean 
Difference 
  
Std. Error 
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
4-Methyloctanoic acid VS DMSO  -
0.59742(*) 0.12015 0.00039  -0.9074  -0.2874
4-Methyloctanoic acid VS VPA  -0.12886 0.10968 0.484  -0.4119  0.1541
DMSO-VPA  0.46856(*) 0.12015 0.003  0.1585  0.7786
*    The mean difference is significant at the .05 level. 
 
 
95% Confidence 
Interval 
  Two hours after administration drugs
Mean 
Difference 
  
Std. Error 
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
4-Methyloctanoic acid VS DMSO  -
0.55298(*) 0.18456 0.022  -1.0292  -0.0767
4-Methyloctanoic acid VS VPA  -0.30150 0.16848 0.205  -0.7362  0.1332
DMSO-VPA  0.25147 0.18456 0.383  -0.2248  0.7277
*    The mean difference is significant at the .05 level 
 
 
95% Confidence 
Interval 
Three hours after administration 
drugs 
Mean 
Difference 
  
Std. Error 
  
Sig. 
  
Lower 
Bound 
Upper 
Bound 
4-Methyloctanoic acid VS DMSO  -0.26464 0.38799 0.777  -1.2658  0.7365
4-Methyloctanoic acid VS VPA  -0.47764 0.35418 0.390  -1.3915  0.4363
DMSO-VPA  -0.21300 0.38799 0.848  -1.2141  0.7881
*    The mean difference is significant at the .05 level 
Effects on behavioural seizures 
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Continuous perforant path stimulation initially elicits a series of wet dog shakes and 
later increasingly severe seizures including tonic-clonic seizures. By the end of the 
stimulation, all animals had reached stage 5 seizures (full motor seizure, rearing and 
failing). After stimulation, behavioural seizures continued at Racine stage 2 to stage 5 in 
untreated animals. 
 
Following stimulation, the behavioural seizures was assessed in control, VPA and 4-
methyloctanoic animals (Table 7.9 and Figure 7.9). In the first hour both VPA and 4-
methyloctanoic acid significantly decreased seizure severity compared to control (P < 
0.05 and P < 0.01 respectively). By two hours, there was also a significant difference 
between VPA and 4-methyloctanoic acid groups (P < 0.05) but by three hours, there was 
no significant difference between groups. Impressively, by two hours 4-methyloctanoic 
acid has stopped behavioural seizures in all animals, over half of which did not have 
any behavioural seizure recurrence by 3 hours.     
 
 
 
Table 7.9: Numbers of animals with each behavioural seizure severity after status 
epilepticus induction (severity is given as maximum seizure severity in that time period) 
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Figure 7.9 Comparison of the severity of seizure activity in the group application of 4-
methyloctanoic acid (400 mg/kg) and VPA (400 mg/kg) induced by perforant path 
stimulation. Percentage of animals with each seizure severity. 
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7.3.4 Degeneration of the hippocampus following status epilepticus 
Figures (Figure 7.10; Figure 7.11; Figure 7.12) illustrate nissl stain sections of the 
hippocampal region, dentate hilus, CA3, CA1, of non-epileptic controls and the three 
groups of epileptic animal. All slices containing hippocampus (40 μM) were collected, 
and the neurodegeneration was evaluated in each slices. Even though, the degrees of 
neurodegernation in each treatment (DMSO, VPA, 4-methyloctanoic acid) were not 
quantified, qualitative histology was visually assessed and graded as mild, moderate or 
severe. Visual inspection of these sections indicates severe neuronal damage of dentate 
hilus and CA3 area, and milder loss in CA1 area in DMSO-treated epileptic rats. In 
VPA-treated epilepticus rats, there was a moderate cell loss in the hippocampus 
formation, including dentate hilus, CA1, CA3. The result indicates that VPA protected 
cell from neurodegeneration in hippocampus formation. In 4-methyloctanoic acid, 
however, there is a severe cell loss in the area of the hilus. The region CA1 and CA3 
show less extended cell damage, indicating that 4-methyloctanoic acid protects cell 
from neurodegeneration in area CA1 and CA3, but not in dentate hilus.     
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Figure 7.10: The example of representative nissl-stained horizontal sections of the 
dentate hilus in hippocampus. The animals were divided into non-SE animal as control 
animal, DMSO-treated SE animal, VPA-treated SE animal, and 4-methyloctanoic acid-
treated SE animal. The DMSO-and 4-methyloctanoic acid treated epileptic rat showed 
severe neuronal damage in dentate hilus in the hippocampal formation. In contrast, the 
VPA-treated epileptic rat shows a less extended cell loss. (Arrow indicates the 
neurodegeneration) 
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Figure 7.11: The example of representative nissl-stained horizontal sections of the CA3 
in hippocampus. The animals were divided into non-SE animal as control animal, 
DMSO-treated SE animal, VPA-treated SE animal, and 4-methyloctanoic acid-treated 
SE animal. The DMSO-and treated SE animal showed severe neuronal damage in CA3 
region in the hippocampus. In contrast, the VPA-treated and -4methyloctanoic acid-
treated SE animal shows moderated cell damage compared to non-epileptic rats. 
(Arrow indicates the neurodegeneration)   
 
  
192 
 
 
 
Figure 7.12: The example of representative nissl-stained horizontal sections of the CA1 
in hippocampus. The animals were divided into non-SE animal as control animal, 
DMSO-treated SE animal, VPA-treated SE animal, and 4-methyloctanoic acid-treated 
SE animal. The SE animal received administration with DMSO shows a mild neural loss 
in CA1. The animals received VPA and 4-methyloctanoic acid has no difference 
compared to control animal. (Arrow indicates the neurodegeneration) 
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7.3.5 The effect of 4-methyloctanoic acid on forskolin induced mossy fibre 
potentiation 
The question whether 4-methyloctanoic had similar effects to VPA on mossy fibre to 
CA3 transmission was asked. The effect of 4-methyloctanoic acid on short-term 
potentiation and baseline neurotransmission at the mossy fibre to CA3 synapse were 
tested in hippocampus slices acquired from normal rats. The normal brain slices were 
chosen for following reasons. First, in order to elucidate whether the action of 
mechanism of the 4-methyloctanoic shares the similar action of mechanism of VPA on 
mossy fibre LTP, the experiments were conduct in the same conduction as previous 
experiments (Chapter 3). Second, the network of hippocampus formation and the 
property of synapse may alter during epileptogenesis. The result shows that there is no 
effect of 4-methyloctanoic acid short-term potentiation (Before 4-methyloctanoic acid 
1mM: 268.41±18.05% of baseline, after 4-methyloctanoic acid 1mM: 263.78±31.68% 
of baseline) or baseline transmission (Before 4-methyloctanoic acid 1mM: 97.38±3.70% 
of baseline, after 4-methyloctanoic acid 1mM: 94.55±7.29% of baseline) (Figure 7.13) 
 
Then, the effect of administration of 4-methyloctanoic acid on enhancement of mossy 
fibre responses induced by forskolin was test. Thirty minutes after forskolin application, 
the fEPSP was 231.67 ± 53.56% of baseline in 4-methyloctanoic acid treated group (n = 
6). This was significantly less than control conditions (458.56±53.33% of baseline P = 
0.005). Using the values obtained with VPA in chapter 3, and comparing using ANOVA 
and post-hoc testing, it can be seen that the effect of 4-methyloctanoic acid is similar to 
that of VPA (Figure 7.14, Table 7.10, and Table 7.11).   
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Figure 7.13: Summary the effect of 4-methyloctanoic acid (1mM) on baseline 
transmission and short term potentiation at the mossy fibre synapse to CA3 region in 
hippocampus. (A) Example of average traces EPSCs stimulated in dentate granule cell 
layer with frequency 0.05 Hz and 1 HZ. (B) Example of the change of fEPSP amplitude 
in mossy fibre with different stimulation frequency (0.05 Hz and 1 Hz). fEPSP 
amplitudes recordings plotted against stimulation number. (C) Comparison of the mean 
amplitude of fEPSP before after administration 4-methyloctanoic acid. Graphs show 
means ± SEM. There is no significant difference in control conditions and 4-
methyloctanoic acid-treat condition at either 0.5 Hz or 1 Hz. 
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Figure 7.14: Summary the effect of 4-methyloctanoic acid (1 mM) on enhancement of 
mossy fibre responses induced by application of forskolin (50 μM). (A) Examples of 
average traces of mossy fibre responses recorded in control condition and application of 
4-methyloctanoic. (B) Summary the effect of 4-methyloctanoic on enhancement of mossy 
fibre responses induced by application of forskolin. (C) Comparison of the mean fEPSP 
amplitude after application of forskolin. Graphs show means ± SEM. Groups were 
compared using post-hoc Tukey test. * Indicates a significant difference between the two 
groups (P<0.05). ** Indicates a significant difference between the two groups (P<0.01)  
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Table 7.10: The ANOVA for the fEPSP amplitude after application of forskolin in 
different treatment groups (control, VPA, and 4-methyloctanoic acid). 
  
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups  21.981 2 10.990 8.171  0.003 
Within Groups  22.866 17 1.345    
Total  44.847 19    
     
 
 
 
 
Table 7.11: The result of Tukey test (Multiple Comparisons), for each treatment group 
95% Confidence Interval 
 
  
Mean 
Difference 
  
Std. Error 
  
Sig. 
  
Lower 
Bound  Upper Bound
Control VS VPA  2.01372(*) 0.61993 0.012 0.4234  3.6041
Control VS 4-MO  2.36856(*) 0.64524 0.005 0.7133  4.0238
VPA VS 4-MO  0.35484 0.64524 0.848 -1.3004  2.0101
*    The mean difference is significant at the .05 level. 
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7.4 Discussion 
Here it has shown that 4-methyloctanoic acid is more potent than VPA in two in vitro 
seizure models, and an in vivo model of SE. Furthermore, similar to VPA, application 
with 4-methyloctanoic acid suppressed the forskolin enhancement of in mossy fibre to 
CA3 synaptic transmission.     
 
The dose of VPA 400-600 mg/kg in vivo was used in this study. And the dose of 4-
methyloctanoic acid (400 mg/kg) was decided upon the effective dose of VPA in this in 
vivo model. VPA is effective in this model at 600 mg/kg which abolished the seizure 
activity in all animals wherease the lower dose VPA (400 mg/kg) which was ineffective. 
In order to compare the effect of 4-methyloctanoic acid and VPA, the lower dose of 400 
mg/kg in VPA and 4-methyloctanoic acid was used.   
 
It could be argued that the dose is much higher than the normal clinical dose, indicating 
that my results may not be clinically relevant. However, the “therapeutic range” of VPA 
in animal models of seizure states is much higher than in humans (Nau et al., 
1981;Chapman et al., 1982) (Table 9.1). The minimum VPA dose which has an 
anticonvulsant effect in experimental animal models in vivo is 100-700 mg/kg P.O. (40-
400 mg/kg ip.) (Chapman et al., 1982). The result indicates that the doses of VPA 
necessary for antiepileptic activity in human are about ten times lower than those 
necessary in rodent. The reasons for this are unclear; however, high plasma protein 
binding and active outward transport of VPA at the blood-brain barrier may be involved. 
The pharmacokinetic parameters of VPA in the human are drastically different from 
those in animals. Due to the high metabolic rates of VPA in rodents, VPA has a very 
short half life and a high plasma clearance rate (Nau et al., 1981;Nau and Löscher, 
1984). In animal models, steady state concentrations are difficult to maintain for a  
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period of time, because of the very high metabolic rate (Nau et al., 1981).   
 
4-methyloctanoic acid, an analogue of VPA, is a natural substance existence in daily 
food product such as cheese and lamb (Brennand and Lindsay, 1992), indicating that it 
may be safer than VPA, even though its toxicity has not been determined, including oral 
toxicity , dermal toxicity , and inhalation toxicity. The concentration in subcutaneous 
adipose is much greater than its flavour threshold (Brennand et al., 1989). Similarly, the 
cheeses made from goat milk and sheep milk contain significant amounts of 4-
methyloctanoic acid (from 0.09 μg/g to 9.70 µg/g) (Ha and Lindsay, 1991). These 
findings suggest that 4-methyloctanoic acid is likely to be safe in humans at low doses. 
 
4-methyloctanoic acid has not been investigated extensively. The anticonvulsant effect 
of 4-methyloctanoic acid had not yet been studied and described before.   
The teratogenic effects of VPA have been proposed to be secondary to its effect as a 
histone deacetylation inhibitor (Gurvich et al., 2005;Eikel et al., 2006;Phiel et al., 2001). 
Fatty acid with methyl side chains lack this activity and so are likely to have a much 
lesser teratogenic effect (Narotsky et al., 1994). 4-methyloctanoic acid has great effect 
on suppression of epileptiform activity in two vitro model (PTZ model and Mg
2+ model) 
and on decreasing spontaneous spike activity and behavioural seizures in vivo (perforant 
path stimulation model). Furhter, 4-methyloctanoic acid also provides neuroprotective 
effect in hippocampus after SE. These preliminary data presented here suggest that 4-
methyloctanoic acid may be more potent than VPA in treating seizures and therefore 
may represent an alternative. Its putative action on the cAMP/PKA signalling pathway 
predicts that 4-methyloctanoic acid may have neuroprotective and antiepileptic effects. 
There was some evidence of neuroprotection in the animal SE model. This effect may  
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also mean that it shares with VPA some of the cognitive side-effects. Further testing of 
this drug is, however, warranted. 
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Chapter 8: General discussion   
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8.1 Results summary 
Chapter 3: VPA inhibits PKA-dependent, long-lasting enhancement of synaptic 
transmission elicited by high-frequency stimulation or application of forskolin at mossy 
fibre to CA3 pyramidal cell synapses.   
 
Chapter 4: VPA has no direct effect on PKA phosphotransferase activity, even at high 
concentrations (VPA 1 mM). However, VPA decreases forskolin-induced cAMP 
accumulation in a high concentration (1mM). 
 
Chapter 5: VPA’s anticonvulsant action in two in vitro models of epileptiform activity 
(PTZ model and low-Mg
2+ model) is not secondary to its effect on cAMP/PKA activity.   
Surprisingly, SQ22536, an adenylyl cyclase inhibitor, increases the frequency of 
epileptiform bursts in these two models. 
 
Chapter 6: Application of VPA significantly decreases mossy fibre frequency facilitation 
(short-term plasticity) in epileptic, but not control- rats. 
 
Chapter 7: 4-methyloctanoic acid, a VPA analogue, is more potent than VPA in two in 
vitro models of epileptiform activity, PTZ model and Mg
2+ model. Moreover, 4-
methyloctanoic acid was significantly more effective than VPA at reducing the spike 
frequency in an in vivo model of status epilepticus, the perforant path stimulation model. 
Similar to VPA, 4-methyloctanoic acid also inhibits mossy fibre LTP.     
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8.2 The effect of VPA on cAMP/PKA signalling may have an impact on learning 
and memory, but may prevent epileptogenesis. 
In this thesis, it has been showed that VPA has no effect on baseline transmission or on 
short term potentiation at the mossy fibre to CA3 pyramidal cell synapses but decreased 
forskolin mediated enhancement of mossy fibre responses. Consequently VPA inhibits 
NMDA receptor-independent, long-term potentiation at the mossy fibre to CA3 synapse.   
Furthermore, VPA impaired the enhancement of cAMP accumulation whereas there was 
no direct effect on PKA activity.   
 
The action of VPA on cAMP signalling system may also provide a possible explanation 
for the observation that VPA has been shown to act at many receptors and different 
cellular pathways such as glutamate receptors (Gean et al., 1994;Rinaldi et al., 2007), 
inositol metabolic pathway (Shaltiel et al., 2004;Williams et al., 2002;Tokuoka et al., 
2008), wnt signals (Hall et al., 2002), histone Deacetylation (Göttlicher et al., 
2001;Phiel et al., 2001;Li et al., 2008). cAMP is a second messenger important in many 
biological processes used for intracellular signal transduction, conveying the cAMP-
dependent pathway. GABA(A) and GABA(B) receptors are modulated by PKA 
mediated phosphorylation, suggesting that the intracellular cAMP levels may modulate 
the responses of neurons to GABA and consequently have profound effects on synaptic 
excitability (Moss et al., 1992;Couve et al., 2002). cAMP/PKA signalling system also 
modulates Na
+ channel slow inactivation contributing to cellular plasticity controlling 
the firing behaviour of central neurons (Chen et al., 2006). Furthermore, AMP/PKA 
signalling serves as a second messenger, and is able to crosstalk to other signalling 
pathways such as ERK pathway (Houslay and Adams D.R., 2003), calmodulin-
dependent protein kinase cascade (DeBernardi and Brooker, 1996), PI3K pathway 
(Namkoong et al., 2009), etc, resulting in diverse physiological effects.  
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The result further showed that this effect does not explain VPA’s antiepileptic action. 
One alternative possible mechanism of action of VPA is through modulation the inositol 
metabolic pathway. VPA has been suggested to reduce phospholipid signalling 
processes and cause a rapid attenuation of phosphatidylinositol (PI) turnover in 
Dictyostelium. Furthermore, PI turnover is not dependent upon inositol recycling, but is 
regulated through de novo inositol biosynthesis which is PI3K-dependent (Orabi et al., 
2010). This research also indicates that attenuation of PI signalling through inhibition of 
de novo inositol biosynthesis in Dictyostelium predicts seizure control activity in animal 
models of epilepsy (Orabi et al., 2010) 
 
Even though the effect of VPA on modulation of cAMP/PKA signalling system does not 
explain VPA’s antiepileptic action; it may, however, contribute to other actions of VPA, 
including effects on neuroprotection, epileptogenesis, and the impact of VPA on 
learning and memory. 
 
9.2.1 The effect of VPA on epileptogenesis through modulation cAMP/PKA 
signalling system 
There is increasing interesting in the effect of VPA in preventing epileptogenesis. 
However, the effect of VPA on epileptogenesis is still controversial. VPA has been 
suggested to be anti-epileptogenic in the kainic acid epilepsy model of TLE (Bolanos et 
al., 1998). In another epilepsy model, the kindling model, VPA profoundly inhibited 
kindling development. VPA inhibited the steady increase in after-discharge duration and 
behaviour seizure class, which were observed in the vehicle-treated animals, in a dose-
dependent manner during 9 days of its administration (Silver et al., 1991). However, 
VPA did not prevent epileptogenesis in rats with SE induced by prolonged electrical 
stimulation of the basal amygdale, but it did prevent hyperexcitability and locomotor  
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hyperactivity (Brandt et al., 2006). Disappointedly, VPA does not prevent post-traumatic 
epilepsy in patients with head trauma (Temkin et al., 1999). 
 
Even though the effect of VPA on epileptogenesis is uncertain, VPA exerts powerful 
neuroprotective effects in varied in vitro and in vivo models. Treatment with VPA after 
status epilepticus induced by electrical stimulation of the anterior basolateral amygdala 
prevented the loss of principal cells in the hippocampus formation, including the dentate 
hilus (Brandt et al., 2006). In the kainate model, treatment with VPA 24 h after SE onset 
protectedCA1 from damage and to a lesser degree CA3 (Bolanos et al., 1998). VPA has 
also been found to be neuro-protective in cultured cerebellar granule cells of rat against 
apoptosis induced by low K
+ concentration (Mora et al., 1999). Hippocampal slices 
prepared from rats chronically treated with VPA had a significant reduction in cell death 
in the presence of cytotoxic extracellular ATP (Wilot et al., 2007).   
 
It has been suggested that VPA’s neuroprotective effect involves its modulation of 
extracellular signal-regulated kinase (ERK). ERK regulates AP-1 function and is 
utilized by neurotrophins to mediate their diverse effects, including neuronal 
differentiation, neuronal survival, long term neuroplasticity, and potentially learning and 
memory. VPA can activate the MAPK/ERK signalling pathway by increased 
phosphorylation of ERK1 and ERK2 in rat hippocampus and frontal cortex (Einat et al., 
2003). VPA-induced activation of ERK was blocked by the mitogen-activated protein 
kinase/ERK kinase inhibitor PD098059 and dominant-negative Ras and Raf mutants but 
not by dominant-negative stress-activated protein kinase/ERK kinase and mitogen-
activated protein kinase 6 mutants. VPA also increased the expression of genes 
regulated by the ERK pathway, including growth cone-associated protein 43 and Bcl-2,  
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promoted neurite growth and cell survival, and enhanced norepinephrine uptake and 
release. These data demonstrate that VPA is an ERK pathway activator and produces 
neurotrophic effects (Yuan et al., 2001). 
 
Recent research has suggested that VPA can activate ERK via cAMP/PKA signalling 
system. Application with forskolin blocked ERK phosphorylation with an EC50 of less 
than 3 µM, and application with the PKA inhibitor H-89 enhanced ERK 
phosphorylation, implicating inhibition of PKA as the predominant pathway for ERK 
activation (Boeckeler et al., 2006). However, my data indicate that VPA acts not directly 
on PKA but by inhibiting the accumulation of cAMP. 
  
9.2.2 VPA and learning and memory 
LTP has been proposed to be the cellular basis of memory formation in the central 
nervous system. It has been demonstration that VPA induces cognitive impairments in 
Morris maze performance since the treated animals (VPA, 200-300 mg/kg, in normal 
rats and VPA, 100 mg/kg, in amygdala-kindled rats) required a longer time to find the 
hidden platform. Also, VPA (1mM) caused a decrease in posttetanic potentiation and 
LTP in CA1 area of rat hippocampal slices (Lamberty, 2000). Other studies also 
indicated that VPA (0.1 mg/ml) abolished the expression of NMDA receptor-dependent 
LTP, even though it did not inhibit NMDA receptor-independent LTP in hippocampal 
CA1 area (Lee, 1996). 
 
The cAMP/PKA signalling pathway is crucial for both the late phase of LTP in the 
hippocampus and in the late, de novo brain protein synthesis-dependent phase of 
memory formation (Tully, 1997;Scharf et al., 2002). PKA mutant mice show  
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impairments in CA1 Late-LTP elicited by spaced stimulation (Abel et al., 1997). Late 
LTP transforms newly learned information into a permanent and stable state. It depends 
on a crucial phase of gene expression and de novo protein synthesis in rodents that 
requires phosphorylation/activation by PKA and ERK/MAP of the transcription factor 
CREB (cAMP response element-binding protein)(Gonzalez and Montminy, 1989;Dash 
et al., 1991;Bernabeu et al., 1997;Scharf et al., 2002;Impey et al., 1998;Roberson et al., 
1999). VPA could therefore have an impact on memory and learning through its action 
on PKA. Is there evidence for such an action in humans? There is certainly growing 
evidence that children exposed in utero to VPA may have later learning difficulties 
(Meador et al., 2009). In adults, there are well recognised reports of cognitive 
impairment associated with VPA use. Patients receiving long-term VPA therapy can a 
syndrome of reversible Parkinsonism and cognitive impairment. The signs of 
parkinsonism includes the 4 to 7 Hz tremor, rigidity or cogwheeling, decreased alternate 
motion rates (extremities, tongue) or hypokinetic speech, abnormalities of posture or 
gait (instability, shuffling), and bradykinesis. Furthermore, long term using VPA can 
cause memory dysfunction and personality changes (Armon et al., 1996). Since the 
anticonvulsant effect of VPA does not depend upon its action on PKA, it may be 
possible to design drugs in future that are anticonvulsant but have a much improved 
cognitive profile. 
 
9.3 The effect of 4-methyloctanoic acids, an analogue of VPA on animal models of 
epilepsy 
4-methyloctanoic acids, also known as hircinoic acid, appears to contribute mutton and 
goat meat odour and responsible for the "billy-goat" flavour of goat milk cheese. The 
study of this compound is mainly in food industry and agriculture. The property of its 
anti-epileptic effect has not been previously explored and discussed.      
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Application of 4-methyloctanoic acid in an in vivo model of SE demonstrates efficacy in 
animal seizure models. SE was induced by stimulation of the perforant path in awake, 
freely moving rats. This model is resistant to a number of antiepileptic drugs and does 
not involve the application of an exogenous convulsant. The efficacy of 4-
methyloctanoic acid (400 mg/kg) against valproic acid (400 mg/kg) and vehicle (DMSO) 
was compared. 4-methyloctanoic acid was significantly more effective at reducing the 
spike frequency, spikes amplitude, and behavioural seizures. 4-methyloctanoic acid 
protected neurodegeneration in CA3 and CA1 in hippocampus after SE, suggesting that 
it may share the same mechanism with VPA on modulation of cAMP/PKA signalling 
system. Indeed administration with 4-Methyloctanoic acid suppressed the enhancement 
of mossy fibre responses, suggesting that this compound may act on modulation of 
cAMP signalling. These finding, therefore provide a novel insight into the effectiveness 
of this compound in the treatment of epilepsy, suggesting that this compound has a 
potential to develop as an anticonvulsant drug which is more efficient with less 
teratogenic potential. 
 
9.4 Using animal model to investigate Human disease- epilepsy 
In this thesis, varied animal models were used to study the epilepsy which is a human 
neurological disease. The ability to reproduce human diseases in animal models is a 
great advantage for modern experimental medicine. Animal models, such as genetically 
modified animals, and experimental animal model involving chemical or electrical 
stimulation can mimic the human condition, both pathophysioloigcally and 
pharmacologically. In vitro models involving manipulations conducted in organs, tissues, 
cells, and biomolecules in a controlled, artificial environment are useful tools to 
elucidate the disease pathology, the mechanism of pathology, and evaluate the effect of  
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drugs (Figure 8.1). Unfortunately it is rarely possible to reproduce all aspects of human 
disease in animals. Therefore, the relevance of animal models to human disease is not 
always clear cut. 
 
Indeed, the validity of animal epilepsy models has been challenged for the following 
reasons. (1) Many animal studies are carried out in “normal” rather than “epileptic” 
brains. (2) The behavioural expression of seizures in animals is different from that in 
humans. (3) There may be different anatomical and physiological substrates for seizures 
in animals (Sarkisian, 2001). Nevertheless, notwithstanding their limitations, animal 
models have given us considerable insight into the pathogenesis of human epilepsy, and 
have enabled drug development (Pitkänen al., 2007; Löscher, 2002). 
 
 
Figure 8.1: Research of animal models for human diseases. The animal models, such as 
genetic modified animals, experimental animal model, and in vitro model are useful tool 
to elucidate the disease pathology, the mechanism of pathology and evaluate the effect 
of drugs. Furthermore, the benefit of using animal’s model to study human disease is to 
develop the new technique or new therapy in order to prevent, treat and cure disease, 
such as epilepsy 
Genetic modified 
animals model 
Experimental 
animal model  
In vitro model 
   
Elucidation of 
pathological 
mechanism 
Elucidation of 
pathology 
 
Development new techniques in medical science, such as new drug, 
new therapy, in order to prevent, treat or cure a disease     
Evaluate the 
effect of drugs 
Application    
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9.6 Future work 
Many questions have been raised in my thesis. Does the effect of VPA on the 
cAMP/PKA signalling system translate to a neuroprotective and antiepileptogenic effect 
in vivo? To address this I would like to show that VPA attenuates PKA activation during 
SE and that specific targeting of the PKA signalling cascade can prevent neuronal death 
and epileptogenesis. Ideally, I would like to screen VPA analogues through a cAMP 
assay to identify putative antiepileptic compounds that lack this effect. The 
neuroprotective and anticonvulsant properties of those compounds (and also their 
impact on memory and learning) need to be further tested.   
 
In this thesis, a new putative antiepileptic drug has been identified. Much further work 
is required before this compound could be considered for human trials, including 
toxicity testing and testing in other animal epilepsy models (e.g. the NIH screening 
program). Lastly, we have now developed a wireless telemetry unit. This requires 
testing in larger numbers of animals over longer periods of time. If it lives up to its 
present promise, it may provide an ideal way to test the antiepileptogenic and 
antiepileptic affect of drugs in vivo both acutely and with more chronic administration.     
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Appendix: Method development Wireless 
transmitter  
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A.1 Introduction 
There is a growing need for long term continuous EEG recordings in animals in order to 
monitor seizure frequency and the process of epileptogenesis more accurately. Moreover, 
it is critical to have such a system in place to monitor the impact of treatments on both 
seizures and epileptogenesis. 
 
Conventionally, physiological data, such as EEG, heartbeat, blood pressure, gained from 
animals are recorded by a direct connection of animals to the recording apparatus. The 
EEG recording, for example, is through a cable which connects between EEG 
electrodes on the animal’s head and the EEG recording amplifier. There are a number of 
disadvantages to this: (1) tethering of an animal can cause a certain amount of distress 
(2) cables form the animal amplify any movement artefact (3) Cables from the animal 
act as an antenna and so can “pick up” extraneous electrical noise, in particular “mains 
hum”. Therefore, there are considerable advantages in developing wireless telemetric 
recording systems. 
 
In order to develop a useful and stable wireless transmitter which can be implanted into 
experimental animals, there are some aspects needed to be addressed. First of all, the 
wireless transmitter should be as small and light as possible in order to ensure that 
awake experimental animals are as comfortable as possible, to minimize the suffering of 
animals and to permit subcutaneous placement. Secondly, the wireless transmitter 
should be fully bio-stable and biocompatible in order to permit prolonged implantation 
(months). Thirdly, battery life should be compatible with continuous recording over 
weeks to months. Fourthly, it is important to have a switching system which can be 
operated from outside of the body. Furthermore, a high sampling frequency is necessary 
in order to be able to record fast activity associated with seizures, yet the energy  
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consumption of the implanted wireless transmitter should be as low as possible to 
preserve battery life. Finally, in order to increase flexibility, transmitter data should be 
able to be acquired by remote computer or laptop directly, or via the local area network.     
 
The object of this part of the thesis was the development of a telemetric system in order 
to test novel treatment strategies. The design and testing of the system was in 
collaboration with Open Source Instruments, MA, USA, who designed and built the 
electronic circuits. I implanted these wireless transmitters into rats and tested their 
ability to record EEG accurately and over prolonged periods of time in adult freely 
moving rats under normal conditions, during and following SE. 
 
A.2 Methods 
A.2.1 Overview 
This system consists of an implantable transmitter which amplifies and converts the 
recorded signal and communicates with an antenna via radio transmission over a 
distance ranged from 50-300 cm. The receiver antenna is connected to a data receiver 
via a cable connection. The data are displayed and saved by software developed by open 
instruments for this purpose through Long-Wire Data Acquisition (LWDAQ) hardware 
(Figure A.1). 
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Figure A.1: Schematic of the main components of the telemetric system. The recording 
electrodes are implanted on the cortical surface and the reference electrodes are place 
on the surface of skull. The electrodes are connected to a transmitter placed in the back 
area of the rat. The transmitter is switched ON/OFF by the magnet. The recorded signal 
is directly amplified and digitized by the transmitter, emitted in all directions and 
detected by the receiver at a distance of up to 300 cm. The data are transferred from the 
receiver to a computer via LWDAQ system. 
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A.2.2 Subcutaneous transmitter design 
A number of different encapsulating processes were tested. Silicone covering alone was 
penetrated by fluid within a week in five out of five animals. This led to the use of an 
initial epoxy coating to prevent water penetration. The Subcutaneous Transmitter 
(Figure A.2) was therefore encapsulated in epoxy and silicone, which proved to be 
water resistant in all animals tested up to 2 months. Further complicating factors were 
the wires from the transmitter to the electrodes. Coiled steel wire provided the only wire 
tested that was durable, yet strong enough to not break over such long recording periods 
(other wires tested were silver n = 3, copper n = 2 and uncoiled steel n = 5). The 
Subcutaneous Transmitter detects biometric signals with thin wires and transmits them 
with another wire acting as an antenna. The Subcutaneous Transmitter transmits signals 
from the body of a freely-moving rat to a receiving RF antenna at ranges of 50 cm to 
300 cm. (for summary of subcutaneous Transmitter see Table A.1) 
 
 
Figure A.2: The example of subcutaneous transmitter 
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Table A.1: Properties of the transmitter unit 
Property 
 
 Weight  5 g (with batteries and wires) 
 Dimensions  20 mm × 20 mm × 10 mm 
 Power supply  3-V 120 mA-hr Li 
 Switch    a magnet 
 Data Transmission Rate  400 samples per second 
 Data Format  16-bit digital with 24-bit ID   
 Life time battery  over 4 months 
 
In order to conserve the battery, the transmitter transmits information in short bursts at 
RF frequency (915 MHz). These bursts contain information about the transmitter 
(which number) and the EEG signal. In this way many transmitters can be recorded 
simultaneously by the same receiver (each transmitter transmits at different times for 
only a fraction of time). 
 
A.2.3 RF Antenna 
The RF Antenna is a loop of wire with diameter 328 mm and with impedance 102Ω 
which is optimised to record othe915-MHz signal. The RF antenna has to be positioned 
near to the cage and away from reflecting surfaces which result in “collisions” causing 
interference. A collision is the interaction of a signal with its reflection, resulting in 
corruption of the signal. 
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A.2.4 Data Receiver 
The data Receiver consists of a demodulating Receiver, saw oscillator, and data 
recorder with BNC connection for an RF Antenna. The demodulating receiver combines 
the RF input passes with the local oscillator input. The demodulated output is passed via 
an ethernet cable to LWDAQ. The receiver has a buffer, so that if the connection to the 
LWDAQ is broken data is still stored. 
 
A.2.5 LWDAQ hardware 
The LWDAQ is a TCPIP-based hardware which permits data transmission via a local 
network or the internet. 
 
The LWDAQ software has been developed by Open Source Instruments Inc (USA) is a 
combination of analysis routines written in Pascal and communication routines written 
in TclTk. The core of LWDAQ Software is a TclTk interpreter. This interpreter 
executes the TclTk scripts that control the LWDAQ over TCPIP and creates the 
graphical interface. It loads the analysis library “lwdaq” which is created for the 
LWDAQ software only, and it makes its routines available to the scripts as TclTk 
commands.  
 
A.2.6 Surgery 
All experiments were conducted in accordance with the Home Office regulations under 
the Animal (Scientific Procedures) Act, 1986. Male Sprague–Dawley rats weighed 
between 300 g to 400 g were used. The animals were housed individually in standard 
plastic cages (42 cm × 26 cm × 20 cm) under a 12 h light–dark cycle. The room 
temperature was maintained at 24–25 °C and relative humidity at 50–60%. Standard 
rodent food and tap water were provided.  
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The surgery was performed in deeply anaesthetised animals, maintained with 2% 
isoflurance in O2 (at a flow rate of 2 litres/minutes) on a stereotaxic frame with heating 
pad (David Kopf stereotaxic frame) 
 
The transmitter was placed subcutaneously on the back of the animal and secured with a 
suture. The wires from the transmitter were tunnelled under the skin to the exposed 
skull. One wire was connected to an exposed silver wire ground. The other wire was 
insulated with ~ 1 mm of wire exposed. This was held in place extradurally with a skull 
screw. The whole assembly was held in place with dental cement (Simplex Rapid, 
Acrylic Denture Polymer, UK) (Figure A.3).   
 
A.2.7Data recordings 
The recording started immediately after surgery. The rats were placed in a plastic cage. 
The subcutaneous transmitter was switched on with the magnet and the signal was 
observed in real-time on a computer's screen. The signal was recorded with LWDAQ 
software and saved on the hard-disk. Data were then replayed or further analysed. 
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Figure A.3: Implantation of wireless transmitter (A) Placement of the transmitter in the 
back, the leads were tunnelled under the skin from the back to the skull and holes were 
drilled in the skull to place the recording electrode, which were fixed to the skull with 
dental cement. (B) The reference electrodes were placed above the skull, and the 
recording electrode recording electrode was placed above the cortex (extradurally). 
 
 
 
A.2.8 Kainic acid induced Status epilepticus   
SE was induced with a single dose of 10 mg/kg of Kainic acid given intraperitoneally 
(ip) to Sprague-Dawley rats (300-400 g), which were then carefully observed to detect 
signs of seizures. One hour after the first Racine stage 5 seizure, 10 mg/kg of diazepam 
or 30 mg/kg pentobarbital was injected (ip) to stop the seizures. The wireless transmitter 
was used to continuously record EEG.  
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A.3 Result 
After implantation of the transmitter, rats were placed in standard plastic cages 
individually, and EEG was recorded continuously (Figure A.4). Continuous EEG 
recordings were achievable for over 1 month before battery failure. 
 
 
Figure A.4: Example of EEG recording from wireless transmitter in a control rat one 
week after transmitter implantation. Voltage versus time is on the left, 140 μV/div and 
800 ms/div. Spectrum versus frequency (fast Fourier analysis) is on the right, with 15 
μV/div and 10 Hz/div. 
 
 
 
A.3.1 The EEG record during status epilepticus induced by administration with 
Kainic acid 
In two animals, I have been able to undertake long term recordings following kainic 
acid injection. An example EEG recording during the kainic acid injection is given 
below. Injection of kainic acid (10 mg/kg, ip) induced convulsive SE. Pentobarbital (30 
mg/kg) was given to reduce the mortality, 1 hour after the first stage 5 seizure. 
 
Ten minutes after injection, spikes were apparent, even though the rat had no sign of 
behaviour seizure. The frequency of spikes ranges from 0-30 Hz. The spike amplitudes 
were 560-700 μV. As for spectrum analysis, the peak amplitude was about 22.5-30 μV 
between 5-10 Hz (Figure A.5).    
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Figure A.5: Example of EEG recording from wireless transmitter in rat 10 minutes after 
injected kainic acid. Voltage versus time is on the left, with 140 μV/div and 800 ms/div. 
Spectrum versus frequency is on the right, with 15 μV/div and 10 Hz/div. 
 
 
 
 
Twenty minutes after injection, the rat showed head nodding which is classified as a 
stage two seizure. Spike amplitudes ranged from 420-560 μV. The spectrum analysis 
demonstrated three sharp peaks, 22.5 μV at 2.5HZ, 37.5 μV at 7.5 HZ, and 30 μV at 
12.5 Hz. (Figure A.6). 
 
 
 
 
Figure A.6: Example of EEG recording from wireless transmitter in rat with stage two 
behavioural seizures induced by injected kainic acid. Voltage versus time is on the left, 
with 140 μV/div and 800 ms/div. Spectrum versus frequency is on the right, with 15 
μV/div and 10 Hz/div. 
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The behavioural seizure progressed to stage 3 one hour after injection. The amplitude of 
the spikes increased to 500 μV. There was a peak in the frequency spectrum at 15-16 Hz 
with amplitude 35-37.5 μV.  
 
The behavioural seizure progressed to stage 3 one hour after injection. The amplitude of 
the spikes increased to 500 μV. There was a peak in the frequency spectrum at 15-16 Hz 
with amplitude 35-37.5 μV. 
 
About 90 minutes after injection the seizure reached stage 5, with rearing and failing. 
The amplitude of the EEG spikes dramatically increased to 1400-1500 μV. In the 
frequency spectrum, there was a sharp peak at frequency 2.5-7.5 Hz with amplitude 
over 80-90 μV (Figure A.7).   
 
 
 
Figure A.7: Example of EEG recording from wireless transmitter in rat with stage 5 
behavioural seizure. Voltage versus time is on the left, with 140 μV/div and 800 ms/div. 
Spectrum versus frequency is on the right, with 15 μV/div and 10 Hz/div 
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A.4 Discussion 
In collaboration with Opensource Instruments we developed a long-term wireless EEG 
monitoring system that offers several advantages over currently available telemetric 
systems. The relatively small size and weight of our fully implantable device is very 
well accepted by adult rats which do not show any kind of behavioural impairments or 
sign of discomfort. Furthermore, the transmitter can be easily switched on and off from 
outside the body. The LDWAQ software is easy to use and can be used to analyse the 
signal. The system is inexpensive, portable and easy to use. Another advantage of this 
system is the transmitting data can be displayed and recorded via internet. 
 
The system has only so far undergone preliminary testing and a larger study is still 
required. Some problems still, however, need to be addressed. There are silent 
transmission areas such that when the rat gets into certain positions reception of the 
signal is poor, and in some animals the subcutaneous wires broke. 
 
Another problem is that the broad-band low power signals can easily be overwhelmed 
by ambient interference, such as mobile telephones. Besides, in the laboratory, there are 
many extraneous signals that can cause interference (Figure A.8).   
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Figure A.8: Spectrum analysis of environmental noise. Blue lines are 900 MHz, 915 
MHz, and 930 MHz. The horizontal lines mark relative power density in +10 dB 
increments. In the recording room, there is residual power in the Fixed Mobile band, 
942 MHz - 960 MHz. The peaks between 920MHz-930 MHz are another fixed mobile 
band. Below that we have several power peaks in the range 910 MHz to 925 MHz. 
 
 
In order to address these problems, we have started using Faraday cages to prevent 
interference. The faraday cages can also isolate transmitters from one to another, so that 
transmitters with the same channel number will not interfere with each other. By 
enclosing the transmitters and receiver in a faraday cage, we hope to decrease ambient 
interference and improve reception of the transmitter signals. 
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